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Routinely collected healthcare data are increasingly being used as a source for 
research into the effectiveness and safety of drugs. Although these data have 
great potential, they require preparation before they can be used in research, a 
process which, amongst a number of other tasks, typically involves quantifying 
patients’ exposure to the drug of interest. The aim of this thesis was to develop 
and validate a set of flexible, reusable functions for generating common drug 
exposure variables based on routinely collected prescribing data. 
Six main classes of method for quantifying drug exposure were identified through 
a review of pharmacoepidemiological research; ever use vs. never use, use at a 
specified time point, daily dose or duration, persistence and discontinuation, 
adherence, and population level measures. The information obtained on these 
methods, their applications and the potential variations within each class 
formed the basis for developing an R package, prescribeR, which contains a 
range of functions designed to simplify and standardise the generation of drug 
exposure variables, and to provide a structure for reporting how these variables 
were produced. 
The utility of the package was then demonstrated by applying it to two exemplar 
clinical studies, using a cohort of 5,571 patients with epilepsy constructed using 
linked data within the NHS Greater Glasgow and Clyde Safe Haven environment. 
In the first, prescribeR was used to quantify persistence to anti-epileptic drugs 
over the first 365 days of follow-up for cohort patients in order to assess 
differences in persistence across different drugs, as well as to compare 
persistence in new and existing users and patients prescribed monotherapy and 
combination therapy. All of the required persistence measurements for this 
study were generated using the prescribeR package, highlighting the relative 
ease of generating exposure data for a large cohort of patients and a number of 
different drugs. 
In the second, the package was used to examine the effects of adjusting drug 
exposure definition on the estimated number of patients exposed to various 
drugs, the estimated exposure durations. The association between levetiracetam 
exposure and all-cause mortality was estimated using a range of time-fixed and 
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time-varying exposure definitions, and a wide range of hazard ratios and 
significance levels were observed across the resulting models, highlighting that 
the selected definition of drug exposure can potentially have a large impact on 
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Drugs are one of the key forms of intervention available to physicians for the 
prevention and management of diseases.(1) Data from the 2014 European Health 
Survey found that 48.6% of participants across all of the EU member states 
reported having taken a prescribed medication in the two weeks prior to the 
survey – rates of medication consumption varied between the individual member 
states, ranging from 22.8% in Romania to 60.2% in Belgium.(2) The survey also 
reported that medication use was higher in older patients, with 21.9% of 
participants between 15 and 24 years old taking at least one prescribed 
medication compared to 87.1% of patients aged 75 years and over across all of 
the member nations. A study investigating the prevalence of use of medications 
amongst the elderly in the US reported similar results, showing that 88% of a 
group of 2,245 elderly patients with a mean age of 71 years were taking at least 
one prescribed medication.(3) In the United Kingdom (UK), prescribing is the 
most common patient-level intervention, and the second highest area of 
National Health Service (NHS) spending, below only staffing costs.(4) In 2016, 
the NHS in England dispensed 1.1 billion prescription items within a community 
setting, a 46.8% increase on the number of items dispensed in 2006.(5) These 
figures highlight the ever-increasing importance of drugs as a medical 
intervention, and therefore the importance of understanding the safety and 
effectiveness of these drugs. 
1.1 Randomised controlled trials 
Randomised controlled trials (RCTs) are considered to be the gold standard 
methodology for generating evidence on the efficacy and safety of 
medications.(6) The strength of RCTs as a source of evidence rests on the fact 
that they are carefully structured and controlled – a well-defined study 
population coupled with randomisation to treatment arms helps to minimise the 
effects of possible confounding and maximise internal validity, therefore 
theoretically providing an understanding of how effective the study medication 
is under ideal conditions. Large-scale RCTs are typically the final test of a drug’s 
efficacy and safety in the drug development process, and the evidence 
generated is used to determine whether or not a drug is approved for release 
onto the market. RCTs are not without their limitations - they are typically 
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extremely expensive to conduct, with one study reporting an average cost of 
between US$11.5 million and US$52.9 million to run a phase 3 clinical trial 
depending on therapeutic area.(7) The financial cost and organisational 
complexity of running large, multi-centre clinical trials limits the duration of 
follow-up, and therefore limits their ability to monitor long-term effectiveness 
and adverse effects of the medication being studied. The long timescales 
associated with planning, running and analysing RCTs also mean that they are 
not always able to keep pace with clinical advances, changes in public policy or 
urgent and emerging healthcare crises. Additionally, although the highly 
selective criteria used to select patients provides very strong internal validity of 
results, the use of restricted study populations coupled with the limited follow-
up duration of trials can limit the ability to identify rare or late adverse 
events.(8)  
Strong internal validity also typically comes at the cost of external validity and 
generalisability to the wider population. (8) A number of published studies have 
investigated the extent to which trial subjects reflect the wider population who 
would be prescribed the drug once it reaches the market. One study assessed 
the proportion of patients with a diagnosis of major depressive episode who met 
a standard set of exclusion criteria for anti-depressant medication efficacy 
trials.(9) The study found that out of 3,119 patients with a current diagnosis of 
major depressive episode, 75.8% were excluded by one or more of the eligibility 
criteria, with the presence of comorbid, non-depressive disorders and the 
duration of the depressive episode excluding the largest percentage of these 
individuals. A second study which assessed a cohort of 4,811 Scottish women 
with breast cancer using the eligibility criteria from twelve trials which have 
influenced national treatment guidelines found that while 73% of the women 
were eligible for at least one of the trials, the proportion of women from the 
cohort who were eligible for individual trials rarely exceeded 45%.(10) A review 
of 52 studies assessing the external validity of cardiology, mental health and 
oncology RCTs based on the representativeness of the study population showed 
that in 72% of the included studies the trial samples were not representative of 
the general population.(11) A number of the included studies found that RCT 
patient populations had a lower risk profile than real-world populations due to 
the exclusion of elderly patients and patients with comorbid conditions. These 
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results help to highlight limitations on how well the results of safety and efficacy 
testing under trial conditions reflect the safety and effectiveness of these drugs 
in patients who would be receiving them in ‘real-world’ treatment scenarios 
after they have been approved.  
A review of sources of evidence for decision making in healthcare discussed the 
fact that RCT results are often given additional weight when considering the 
available evidence, at the cost of other valuable data sources, and that the 
limitations discussed above mean that there is a need for other methodologies 
which can compensate for the limitations of RCTs, highlighting that no study 
design is flawless and that using complementary methods can help improve the 
quality of the overall evidence base.(12)  
1.2 Pharmacoepidemiology and pharmacovigilance 
Pharmacoepidemiology is the study of the use and effects of drugs in large, 
defined populations, adapting methodologies used for the study of disease in 
general epidemiology and applying them to aspects of clinical pharmacology.(13) 
Pharmacovigilance is the science related to the monitoring, understanding and 
prevention of adverse drug events with the aim of improving the understanding 
of medicines and patient safety.(14) The need for long-term studies of 
medications is highlighted by a number of cases where drugs have been 
approved for use and made available on the market, then have been 
subsequently recalled due to issues around safety that have only been 
discovered once they have been in general use. Perhaps the most well-known 
example of this is thalidomide, a drug which was prescribed to treat morning 
sickness during pregnancy in the late 1950s and early 1960s, and was 
subsequently found to cause a high rate of severe birth defects.(15) More recent 
examples include mibefradil, a drug used to treat hypertension and angina which 
the manufacturer withdrew a year after approval due to a range of possible drug 
interactions, some of which were potentially fatal,(16) and sibutramine, a 
weight loss drug which was removed from the market due to an increased risk of 
cardiovascular events and stroke in a subset of patients prescribed it.(17) A 
review examining patterns of post-marketing withdrawal worldwide identified 
462 products withdrawn from the market post-approval attributed to adverse 
reactions between 1953 and 2013.(18) 
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1.3 Routinely collected data 
As electronic systems have become more commonplace in the healthcare sector, 
an ever-increasingly large amount of data are being recorded about the care 
patients are receiving. As these data represent the process and outcome of 
healthcare provision in real-world practice, they have become a highly valuable 
resource for pharmacoepidemiology and pharmacovigilance. Routinely collected 
healthcare datasets can typically be classified as either administrative or clinical 
depending on the original purpose for which the data were collected.(19) 
Administrative data include databases containing information originally collected 
for the purposes of payment or reimbursement of healthcare services, as well as 
data recorded for service planning, and government registers of births, deaths, 
hospitalisations or disease.(19) Clinical databases, on the other hand, are 
typically records made during the provision of care by physicians or other 
members of medical staff containing data such as vital statistics, patient history, 
laboratory tests, diagnoses and procedures most often in the form of electronic 
hospital charts or general practitioner (GP) records.(20)  
Both types of data can be useful to researchers, with the type of data being used 
determining the types of research questions that can be answered. Typically, 
routinely collected administrative data have good coverage, but collect limited, 
generic information whereas clinical systems may not have full coverage and can 
vary between geographic sites but will contain more detailed, clinically relevant 
information. So, for example, medical records taken from a general practice or 
hospital may provide a record of all drugs prescribed to patients by the doctors 
at that site as well as diagnostic and demographic information which could be 
useful for pharmacoepidemiology and pharmacovigilance but may not provide 
the full picture if a patient has also been treated at other sites whose records 
are not available to researchers. Administrative records taken from a pharmacy 
or insurance provider on the other hand would contain information on all drugs 
dispensed to patients from a range of sites, which could be useful for studies on 
prescribing patterns and drug utilisation but may not contain the detailed 




The potential benefits of using routinely collected healthcare data for research 
include access to large, unselected populations with long-term follow-up, which 
can provide opportunities for greater power to investigate uncommon adverse 
events and to investigate the long-term effects of taking a medication.(21) As 
these data reflect how drugs are prescribed and consumed in ‘real-world’ 
settings as opposed to tightly controlled clinical trial conditions, there is also the 
potential to study interactions between different drugs being taken for comorbid 
conditions, and to study sub-groups of the population who are typically excluded 
from participating in clinical trials such as children, older people and pregnant 
women. The inclusion of these groups helps to improve the generalisability of 
the results of studies using routinely collected data to the whole population. 
1.3.1 Routinely collected data in Scotland 
The use of Scottish data for this type of research is of particular interest as 
Scotland has a comparatively non-mobile population, a single unified health 
provider responsible for delivering the majority of care (NHS Scotland) and a 
high incidence of a number of disease groups of interest including cardiovascular 
disease and a number of mental health conditions.(22) In Scotland, everyone 
who is registered with a GP is assigned a Community Health Index (CHI) number 
which is a unique identifier recorded during all of their encounters with NHS 
services.(23) The purpose of the CHI is to ensure that patients can be correctly 
identified at the point of care and that relevant information on the patients’ 
health is available to health services, but it also provides a method of linking 
routinely collected data covering hospital admissions, laboratory tests, births, 
deaths and prescribing with relative ease for use in research.(24) 
All medications prescribed, dispensed and reimbursed within the community 
setting by NHS Scotland services are recorded in the Prescribing Information 
System (PIS).(25) This includes prescriptions written by GPs, nurses, dentists, 
pharmacists and a number of non-medical prescribers. It does not include 
prescriptions dispensed within hospitals but does include those prescribed by 
hospitals but dispensed at pharmacies in the community. PIS contains aggregate 
information on over 1.6 billion prescriptions reimbursed in the community 
nationwide from April 1993 onwards. Incorporation of the CHI number into PIS 
records, with complete coverage from 2009 onwards, means that individual level 
23 
 
information is also available for over 507 million items prescribed and 344 
million items dispensed from 2009 onwards.(26) Around 100 million new data 
items are added to PIS annually.(25) PIS has great potential as a data source for 
use in pharmacoepidemiology and pharmacovigilance as it contains data which 
are representative of the full national population and through linkage to other 
nationally collected healthcare datasets, can provide information on patient 
characteristics and long-term clinical outcomes. 
1.3.2 Limitations of routinely collected data 
Although there are advantages to using routinely collected healthcare data for 
research, these data are not without their limitations. It is important to consider 
the completeness and accuracy of these datasets before using them. Data 
completeness refers to how much of the required or expected data are present 
within the dataset; this can be measured by assessing the quantity of missing 
data.(27) Data accuracy describes how well the data correctly represent the 
‘real-world’ events they describe.(28)  A number of the limitations within these 
datasets are related to the fact that they were not initially created and 
collected for research purposes. Datasets may not contain all of the variables of 
interest for a particular research question, there may be differences in the way 
that routine data are coded and the level of detail available when compared to 
primary research datasets, or there may be errors in the data due to improper 
data entry.(29) Additionally, individual datasets may not contain all of the 
records relating to the patients who appear in the data. For example, if a 
country has a mix of private and public healthcare, or a number of different 
healthcare providers then the records of one provider may not contain a full 
record of each patients’ medical history.(30) Some of these issues can be 
overcome by using data from a number of different sources, but this is not 
always straightforward. For example, different coding systems may be used 
across different sources, there may be difficulty in accurately linking subjects 
across datasets if common identifiers are not used, and there could be issues 
with combining the data on a technical level if the formats that data are stored 




A number of studies have been conducted aiming to validate the information 
held in databases such as pharmacy records and compare them to other sources 
such as home medication inventories and patient questionnaires. One study 
which assessed the level of agreement between Medicare claims data, self-
report and medication inventories for lipid-lowering drugs found that although 
there were instances where data did not match, there was generally a high level 
of agreement, with 86.5% overall agreement between medication inventory and 
Medicare claims data and 84.7% overall agreement between self-report and 
claims data.(31) A similar study which compared pharmacy data against self-
report for patients taking medication for osteoporosis concluded that there was 
good agreement between the two sources, but that care had to be taken when 
attempting to define current use based on pharmacy data.(32) Overall, there is 
evidence to support the validity of routinely collected healthcare data as a 
source of information on which drugs patients have available, but these studies 
still stress that care should be taken in the assumptions that are made when 
using the data. It is also important to note that, even if there are complete 
records showing that a physician has prescribed a medication and a pharmacy 
has dispensed it, we cannot be sure whether or not a patient has actually taken 
the medication, or if they have taken it according to the dosage instructions. 
1.4 Data preparation 
Understanding and accounting for these potential limitations is essential when 
using routinely collected data for research, as identifying and accounting for 
potential errors in the data are essential in minimising the risk of bias. Bias is a 
systematic (or non-random) deviation of study results from the truth resulting 
from errors in measurements, selection processes, inferences, statistical 
analysis, or other procedures.(33) As described above, the fact that these data 
are not originally collected for research purposes can result in systematic issues 
with completeness and accuracy which can lead to bias if the data are used as 
collected.  
Data preparation is an essential stage in any research project using these 
routinely collected data, as it provides an opportunity to address a variety of 
limitations of routinely collected data. It may not be possible to resolve all 
systematic issues within routinely collected data, but it is important that 
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researchers address the known issues as much as possible during data 
preparation and analysis to maximise the validity of the results obtained. The 
exact process of preparing data for analysis varies, but typically involves 
exploration, cleaning and enrichment of the raw data. Before making any 
changes, it is important to explore the data to understand the characteristics of 
the dataset and identify potential sources of error. This will often involve 
understanding the processes by which the data are collected and the way that 
records are generated, the generation of summary tables or plots, and manual, 
unstructured exploration of the data available to help familiarise the user with 
its content and structure. Data cleaning typically involves steps such as removing 
irrelevant or duplicated data, dealing with missing, incorrect and implausible 
values, standardising data types, formatting and syntax, and verifying the data 
after making these changes.(34) Once the data are cleaned, steps can be taken 
to further enrich the data through processes such as the merging or linking of 
datasets from different sources or the generation of additional variables based 
on existing data.  
Exposure to medication is usually the key exposure of interest in 
pharmacoepidemiological and pharmacovigilance research. Unlike in RCTs, 
however, detailed information on patient’s drug exposure status is not typically 
recorded in routinely collected datasets. Therefore, drug exposure variables 
must be generated based on data such as records of dispensed prescriptions, 
hospital or GP records or insurance claims. There is no gold standard 
methodology for defining drug exposure based on routinely collected data. 
Different methods of quantifying drug exposure will provide varying levels of 
detail on individual patients’ exposure status – for example, it is possible to split 
patients based on whether or not they have ever been prescribed a drug and 
compare them to those who have not or to assess changes in exposure status 
over the duration of a study period based on the quantity of a drug prescribed.  
When deciding how to quantify drug exposure in any study, there are a number 
of factors which must be considered to minimise the risk of introducing either 
time-related or measurement bias and maximise the validity and accuracy of 
both the exposure variable itself and any other results obtained based on this 
measurement of exposure. To that end, it is important to take into account 
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which exposure quantification methods are suitable for both the study design 
being used and the available data.  
Studies using exposure data can largely be split into descriptive studies, where 
exposure itself is amongst the main factors of interest, and studies trying to 
estimate a causal effect, where the focus is on the effects of exposure on an 
outcome of interest. In studies where the focus is on a causal link between 
exposure and an outcome care has to be taken to separate the time period in 
which exposure is measured from the follow-up period where the outcome can 
occur in order to avoid immortal time bias. Immortal time bias occurs when the 
start of the follow-up period is incorrectly defined and a period of immortal time 
where the study event cannot occur is included during the follow-up period. This 
immortal time can lead to over-estimating the effectiveness of the treatment of 
interest. Exposure misclassification is a form of measurement bias which occurs 
when the measurement of exposure to the drug of interest used in the study 
does not accurately affect the reality of the patient’s medication exposure. In 
order to minimise exposure misclassification in pharmacoepidemiology, 
researchers must select an exposure definition provides enough detail to answer 
the research question being investigated but can be accurately estimated based 
on the available data.  
1.5 Aims 
The primary aim of this thesis was to develop and validate a set of flexible, 
reusable functions for generating common drug exposure variables based on 
routinely collected prescribing data. This was split into three research 
objectives: 
• Identify common methods used to quantify drug exposure based on 
routinely collected data through a systematic review of the literature 
• Develop an R package containing functions for generating drug exposure 
variables based on the methods identified 
• Test the package and demonstrate its utility in two exemplar clinical 
studies using real-world prescribing data on a cohort of epilepsy patients – 
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one aiming to measure rates of persistence to anti-epileptic medications 
and a second investigating the impact of varying drug exposure definition 
on observed outcome-exposure associations and a second  
1.6 Thesis structure 
This thesis consists of six chapters. This chapter has provided a general 
introduction to the use of routinely collected healthcare data for research, the 
strengths and limitations of these data and the need for data preparation. 
Chapter 2 describes a systematic review of pharmacoepidemiology and 
pharmacovigilance research aimed at identifying and classifying common 
methods for quantifying drug exposure using routinely collected data. Chapter 3 
describes technical aspects of data preparation and exposure quantification, and 
provides documentation of the R package, prescribeR, which consists of a range 
of functions developed for generating drug exposure variables using the methods 
identified in the review. Chapter 4 discusses the data cleaning processes 
involved in the construction of a cohort of patients with epilepsy using linked 
data from NHS Greater Glasgow and Clyde and the use of the prescribeR package 
to examine rates of AED persistence amongst cohort patients during the first 
year of follow-up. Chapter 5 describes the use of this cohort to assess the impact 
that changing the definition of drug exposure has on the estimated number of 
patients exposed to a range of drugs and the rates of persistence to these drugs, 
as well as how using these different measures in statistical models impacts the 
association between levetiracetam exposure and all-cause mortality. Finally, 
Chapter 6 contains a summary of the findings of this thesis alongside a discussion 




2 Review of methods to quantify drug exposure 
using routinely collected healthcare data 
2.1 Aims 
As previously described, drug exposure is typically the key exposure variable in 
pharmacoepidemiological and pharmacovigilance research and can be defined in 
a number of different ways based on routinely collected data. The main aim 
when generating drug exposure variables is to accurately describe which patients 
were exposed to the drug of interest and when in order to minimise the 
potential for bias in the form of exposure misclassification and to therefore 
maximise the validity of the study results. The aim of this systematic review was 
to identify and classify methods previously used to quantify drug exposure based 
on a variety of different routinely collected healthcare data sources. 
2.2 Methods 
2.2.1 Search strategy 
The Ovid interface was used to search Medline and Embase to identify 
pharmacoepidemiological studies conducted using routinely collected health 
data. An initial basic search was performed using terms commonly found in key 
papers from the field. This was then expanded using synonyms and other terms 
found amongst the results of the basic search to give the complete list of search 
terms seen in Table 1, below. The search structure was reviewed by both a 
college librarian and PhD supervisors to ensure there were no key terms missing.  
2.2.2 Review process – inclusion and exclusion criteria 
Inclusion was limited to papers published in English between January 2012 and 
April 2017 (i.e., within the previous 5 years at the time of the initial search). 
Studies were considered eligible if their methodology included the use of at 
least one routinely collected healthcare data source to quantify subjects’ 
exposure to one or more drug(s) of interest, or if they discussed the 
development or validation of methods of quantifying drug exposure based on 
these data. Studies were excluded if they exclusively used primary data 
collected directly from patients, however studies which used both routinely 
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collected data and primary data for follow-up, comparison or validation were 
included. Conference abstracts and review articles were excluded.  
# Embase Medline 
1 pharmacoepidemiology/ Pharmacoepidemiology/ 
2 drug utilization/ Drug Utilization/ 
3 pharmacoepidemiology.tw. pharmacoepidemiology.tw. 
4 drug utili?ation.tw. drug utili?ation.tw. 
5 methodology.ab. methodology.ab. 
6 1 or 2 or 3 or 4 or 5 1 or 2 or 3 or 4 or 5 
7 prescription/ Drug prescriptions/ 
8 electronic prescribing/ Electronic Prescribing/ 
9 pharmacy data*.ab. Prescriptions/ 
10 prescri* data*.ab. pharmacy data*.ab. 
11 pharmacy records.ab. prescri* data*.ab. 
12 pharmacy claims.ab. pharmacy records.ab. 
13 electronic prescri*.ab. electronic prescri*.ab. 
14 administrative data*.ab. pharmacy claims.ab. 
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 administrative data*.ab. 
16 exposure.ab. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
or 15 
17 drug exposure.ab. Medication Adherence/ 
18 medication exposure.ab. exposure.ab. 
19 exposure period.ab. drug exposure.ab. 
20 adherence.ab. medication exposure.ab. 
21 compliance.ab. exposure period.ab. 
22 persistence.ab. adherence.ab. 
23 medication compliance/ compliance.ab. 
24 drug exposure/ persistence.ab. 
25 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 
17 or 18 or 19 or 20 or 21 or 22 or 23 
or 24 
26 6 and 15 and 25 6 and 16 and 25 
27 26 and 2012:2017.(sa_year). 26 and 2012:2017.(sa_year). 
Table 1 - List of literature search terms and limits used to discover papers in Medline and 
Embase 
 
2.2.3 Data extraction 
Data were extracted from the eligible articles relating to country, type of 
database, use of data linkage, primary aim, study population size, population 
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sub-group(s) investigated, drug/drug group investigated, and the method(s) used 
to classify drug exposure. Studies were assigned to four categories based on 
their primary aim (Table 2) adapted from a review of pharmacoepidemiological 
studies conducted using the Nordic prescription databases.(35) Studies which 
covered areas from multiple categories were assigned to the one which best 
described the primary aim of the paper. Drugs of interest were mapped to the 
relevant British National Formulary (BNF) chapter.(36) Databases were classified 
as either administrative or clinical and studies were considered to have used 
linked data if they connected records at individual patient level across multiple 
data sources. 
 Description 
Drug effect Studies into the efficacy of drug therapies, including studies aiming 
to validate or extend the results of randomized controlled trials in 
either whole or sub-populations and studies investigating the 
efficacy of approved drugs for off-label or alternative uses 
Drug safety Studies related to the negative outcomes associated with exposure 
to a drug, including the incidence of death, hospitalisations, 
adverse reactions and drug interactions 
Drug utilisation Studies investigating issues around prescribing, dispensing and 
consumption of medications including trends in prescribing, effects 
of changes in public policy, health economics and patient 
compliance with prescribing instructions 
Validation 
/methodology 
Studies whose main aim was to discuss methodological aspects of 
using routinely collected data to quantify drug exposure, or 
validating these databases as a source of information 




A summary of the number of papers found, excluded and retained at each stage 
of the review process can be found in Figure 1. A total of 1,267 papers were 
identified from Medline and Embase, 31 of which were duplicates. The review of 
titles and abstracts identified 1,008 ineligible results – these included 
conference abstracts, studies which collected primary data prospectively using 
case report forms or questionnaires, data which were repurposed from clinical 
trials instead of routinely collected data, and papers which focused on medical 




Figure 1 – PRISMA flow diagram (37) detailing the studies included and excluded from this 
review 
 
The full text of the remaining studies was retrieved for review, and the relevant 
information extracted, as described above, after which papers were deemed to 
eligible or ineligible for inclusion. A further 53 studies were removed during this 
stage, resulting in 175 articles eligible for inclusion in the review.  
2.3.1 Exposure assessment 
The methods section of each included study was reviewed to determine how 
exposure to the drug(s) of interest was quantified, and the methods were 
grouped into the classes shown in Table 3. Some papers used multiple methods 
to quantify exposure, so were included in more than one group. 
Records identified through database 
searching 
(n = 1,267) 
Records after duplicates removed 
(n = 1,236) 
Records screened 
(n = 1,236) 
Records excluded 
(n = 1,008) 
Full-text articles assessed 
for eligibility 
(n = 228) 
Full-text articles excluded: 
Unrelated to 
pharmacoepidemiology (n = 21) 
Non-routine data (n = 8) 
Full text unavailable (n = 10) 
Review articles (n = 12) 
No exposure quantification (n=2) 
Studies included in review 
(n = 175) 
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 Description Publications 
N (%) 
Ever use vs. 
never use 
Study classified patients as exposed or unexposed 
based on whether or not they had at least a threshold 
number of prescriptions for the drug(s) of interest)  
108 (61.7) 
Use at time 
point 
Study classified patients as exposed if they were 
prescribed the drug of interest at a specified point in 
time, or within a given time frame based on an index 




Study defined periods of exposure based on 
prescription dates and some form of daily dose 




Study defined length of treatment persistence by 
defining points of discontinuation based on the length 




Study estimated subjects’ adherence to medication 
using measures such as medication possession ratio or 
proportion of days covered 
45 (25.7) 
Population level Study assessed exposure at a population level, 
considering changes in measures such as number of 
prescriptions, DIDs or prevalence of medication use 
over time  
53 (30.3) 
Table 3 - Summary of methods used to quantify exposure to drugs in the included studies, n 
= 175 
 
The simplest method of classifying drug exposure was dichotomising patients 
based on whether or not they have ever had at least a threshold number of 
prescriptions, or ever versus never use. This method was commonly used to 
define inclusion and exclusion from a study population, or to define groups 
within a population. An example of how patients are split using this method can 
be seen in Figure 2 – the first two patients have at least 1 prescription for the 
drug of interest during the follow-up period and are classified as exposed, 
whereas the third is classified as unexposed. Using this method, no distinction is 
made between the first two patients even though they have different total 
numbers of prescriptions. 
 




The second class of methods involved classifying patients based on whether or 
not they had been prescribed a drug of interest within a specified time frame. 
Common examples of this method in the reviewed studies included classifying 
patients as new or existing users of the drug of interest at baseline based on 
whether or not they had prescriptions for the drug of interest before their index 
date (Figure 3), and classifying patients as current or past users of the drug of 
interest at an event such as death or hospitalisation based on whether or not 
they were prescribed the drug of interest within a set number of days before the 
event (Figure 4). 
 
Figure 3 - Example application of a use at time point definition to split patients into existing 
or new users at baseline 
 
The examples shown in Figure 3 and Figure 4 highlight the technical similarities 
of these methods; in both cases exposure is defined based on the presence or 
absence of prescriptions for the drug of interest adjacent to the event of 
interest. 
 
Figure 4 - Example application of a use at time point definition to split patients into current 
or past users of a drug at the time of a hospitalisation 
 
Another example of a method assessing use at a specific time involved splitting 
follow-up into time windows and checking for prescriptions within these 
windows. Example applications of this method included defining exposure as a 
continuous variable by splitting the whole follow-up period into windows and 
assessing exposure during each window separately and defining maternal 
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exposure to medications during the three trimesters of pregnancy when 
assessing the risk of later birth defects in their children. In the example shown in 
Figure 5, the patient would be considered exposed during the first and third 
windows but not during the second. 
 
Figure 5 - Example of defining exposure to a drug of interest within consecutive windows 
during follow-up 
 
Both ever use and use at time point methods were used in a number of studies to 
define exposure to additional drugs which were not the main focus of the study 
as a categorical variable for use as a covariate in statistical modelling, a study 
characteristic, or a proxy for an outcome or comorbid condition. For example, 
one study examining the prevalence of multimorbidity in a population of Scottish 
patients used prescriptions for relevant medications as a method of identifying 
patients with pain conditions, depression, anxiety, migraine and psoriasis.(38) 
Daily dose (DD) methods went a step further, defining periods of drug exposure 
by assigning expected durations to individual prescriptions based on the amount 
of a drug prescribed. The example patient timeline shown in Figure 6 
demonstrates how a duration of exposure is applied to individual prescriptions to 
define periods where the patient theoretically had access to the drug of 
interest. The specific method used depended on the type of data available. 
Some studies used a days’ supply variable included in their data or calculated a 
prescribed daily dose (PDD) based on the amount prescribed and dosage 
instructions. In the absence of individual instructions, other measures such as 
the defined daily dose (DDD), the number of tablets dispensed or a fixed 
duration for individual prescriptions were used. The DDD is the dose of a drug 
defined by the World Health Organisation (WHO) as ‘the assumed average 
maintenance dose per day for a drug used in its main indication in adults’.(39) 
Some studies also used the total number of DDDs prescribed to a patient as a 




Figure 6 - Example of defining duration of exposure using a daily dose method 
 
Another method used to define the duration of exposure was calculating 
persistence. Persistence can be defined as the length of time between when a 
patient is first being prescribed a medication and when they stop (or 
discontinue) treatment.(40) Persistence was typically measured using the refill 
gap method, where persistent time is defined by assessing the gaps between 
successive prescriptions, defining discontinuation as any point where the time 
between prescriptions exceeds an allowable gap. Figure 7 demonstrates how 
prescription records are connected using this method to define periods of 
persistent use and points of discontinuation.  
 
Figure 7 - Example application of the refill gap method for defining persistence without (A) 
and with (B) the coverage of individual prescriptions taken into account 
 
Some studies combined persistence and DD methods, applying the allowable gap 
from the assumed end of prescribed supply instead of the prescription date. 
Some studies also used the date of the first prescription of another drug of 
interest, or medication switching, as an additional discontinuation point. The 
example shown in Figure 7 highlights how taking prescription durations into 
account alters the periods of persistent use observed when using the same 
patient data and allowable gap length. 
Adherence methods describe the extent to which a patients’ medication-taking 
reflects instruction.(41) The most commonly used adherence calculations were 
the medication possession ratio (MPR) and the proportion of days covered (PDC), 
both of which calculate the percentage of time where the patient had 
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medication available. Figure 8 below illustrates the concept of calculating 
adherence using these methods. MPR is calculated as the ratio between the total 
days’ supply and the length of the observation period. The MPR can overestimate 
adherence for patients who regularly refill their medications early, resulting in a 
value greater than 1. The PDC is similar conceptually, but more conservative. It 
is calculated by defining the number of days which were ‘covered’ by 
medication and dividing by the total number of days. Oversupply from one 
prescription is moved to any gaps between supplies instead of accumulating, and 
the PDC is inherently capped at 100%. In most of the included studies, subjects 
were considered to have adhered to their medication if their adherence value 
was greater than 80%. A less commonly used method which is mathematically 
similar to MPR is continuous medication acquisition (CMA), calculated as the 
total supply divided by the length of the observation period. Some studies 
measured adherence using the continuous measure of medication gaps (CMG), 
which determines the number of days where there was no supply and divides this 
by the length of the observation period.(42) By definition, calculating adherence 
using any of these methods requires the use of one of the DD methods described 
above to define the expected supply of the medication of interest.  
 
Figure 8 - Example patient timeline demonstrating how adherence is calculated using 
individual prescription records 
 
The final class of methods focused on population-level exposure to a drug rather 
than individual patients’ exposure. These studies were often interested in the 
changes in prescribing over time, and reported measures such as the number of 
prescriptions, the number of DDDs per 1,000 inhabitants per day (DIDs), the 
prevalence or incidence of prescribing of a drug of interest or exposed person-
time across the population. An example showing how individual prescribing 




Figure 9 - Example of how individual prescription records can be used to measure 
population level exposure 
 
Examples of common variations on the methods within each category and how 
these were applied with references to representative studies can be found in 









Ever use Ever use vs. never use ≥ n prescriptions of drug X (43) 
Number of drugs prescribed no. drugs/classes with ≥ n 
prescriptions reported 
(44) 
Number of prescriptions no. prescriptions of drug X 
reported 
(45) 
Use at time Use within period of interest ≥ n prescriptions of drug X within 
n days of specified date 
(46) 
New user selection 0 prescriptions for drug X in the n 
days before index date 
(47) 
Use within windows ≥ n prescriptions of drug X within 
consecutive periods of m days 
(48) 
Concurrent use ≥ n prescriptions of drug X and 
drug Y within n days of each other 
(49) 
Current/past use drug X within n days before index 
date = current user 
drug X > n days before index date 




Defined daily doses (DDDs) Start date + DDDs dispensed (51) 
Prescribed daily doses (PDDs)  Start date + PDDs dispensed  (52) 
Days’ supply Start date + days’ supply 
dispensed 
(53) 
Quantity prescribed Start date + quantity dispensed (54) 
Fixed duration Start date + fixed n days per 
prescription 
(55) 
Cumulative supply Total no. DDDs dispensed (56) 
Persistence Refill gap Discontinued if no prescription 
after > n days from previous 
prescription 
(57) 
Refill gap with coverage Discontinued if no prescription 
after > n days from end of 
previous prescription duration 
(58) 
First prescription to last Persistent between the first and 
last prescriptions for drug X 
(59) 
Switching Drug X discontinued at date of 
first prescription for drug Y 
(60) 
Adherence Medication possession ratio 
(MPR) 
Ratio of total days’ supply 
obtained to length of study period  
(61) 
Proportion of days covered 
(PDC) 
Number of days covered by supply 
divided by the length of study 
period 
(62) 
Continuous measure of 
medication acquisition (CMA) 
Total days’ supply divided by the 
length of study period 
(63) 
Continuous measure of 
medication gaps (CMG) 
Length of study period minus the 
number of days’ supply, divided by 
length of the study period 
(64) 













No. DDDs of drug X per 1000 
inhabitants per day 
(66) 
Exposed person-time Total person-time exposed to drug 
X for population 
(67) 
Prevalence/incidence Proportion of new or ongoing 
users of drug X per unit time 
(68) 




The key characteristics of the studies included in this review are described in 
Table 5. The most common country of origin for the data used in the included 
studies was the United States (US), which accounted for 29.1% of the included 
studies. Six of the included studies used data from multiple countries. Only 
countries which accounted for more than 5 of the included studies are included 
in Table 5 – there were also studies reviewed which used data from Australia, 
Finland, Germany, Korea, Japan, Serbia, Spain, Brazil, Croatia, Ireland, Israel, 
New Zealand, Oman and Switzerland.  
2.3.3 Study aims 
The most common primary focus of the included studies was drug utilization, 
which encompassed a broad range of different study topics. These included 
studies on topics such as rates of adherence, persistence, discontinuation or 
medication switching and the factors affecting these behaviours. Other drug 
utilisation studies focused on changes in prescribing following changes in health 
system policy or legislation, the impact of healthcare costs, varying insurance 
coverage and other socioeconomic factors on prescribing, and potential for 
abuse of prescription medications.  
The validation and methodology studies were similarly varied in focus, including 
papers on topics such as methods for quantifying and avoiding exposure 
misclassification, the effects of restrictive insurance coverage, over the counter 
medications and medicine samples on data completeness, validation of 
databases compared to other sources of medication data, possible sources of 
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confounding and methods for reducing its effect on results. There were also 
studies describing methods for enhancing routinely collected prescribing 
datasets, including methods for estimating prescription durations where this 
information is not present in the data, generating structured dosing information 
from free text records and ways to combine different databases to address 
methodological issues occurring when only one source is used. 
2.3.4 Database type 
Administrative databases were the most common type of source database among 
the studies included in this review – 82.9% of studies used at least one 
administrative data source and 73.7% of studies used them exclusively. 
Administrative data were either in the form of transactional records from 
private or national health insurance claims and data taken from prescribing or 
disease registries. The data available varied according to the origin country’s 
healthcare system. The USA has a private healthcare system, so records here 
typically originated from the records of individual insurance companies or from 
records of government programs such as Medicare and Medicaid. In countries 
such as France, Japan, Canada and Taiwan, which all have national health 
insurance schemes data were typically obtained from reimbursement records for 
these schemes. Studies based in countries such as Denmark, Norway, Sweden 
and Scotland used data taken from prescribing registries.  
Clinical data were less common than administrative data in the included studies 
- 26.3% of studies used clinical databases, and 17.1% used them exclusively. 
These data were mostly primary care records from networks such as the Clinical 
Practice Research Datalink (CPRD) or the Italian Health Search network, 
although some secondary care data were also used, including data from the 
Veteran’s Administration in the USA. Linkage of multiple data sources was quite 
common in the identified studies, with 35.39% of studies using some form of 
record linkage. The most common example of this in the included studies was 
linkage between national prescribing registers and disease, birth and death 





 Publications N (%) 
Data Origin  
United States 51 (29.1) 
United Kingdom 19 (10.9) 
Denmark 18 (10.3) 
Canada 12 (6.9) 
Italy 10 (5.7) 
France 8 (4.6) 
Netherlands 8 (4.6) 
Sweden 6 (3.4) 
Taiwan 6 (3.4) 
Multiple 6 (3.4) 
Norway 5 (2.9) 
Other (<5 studies per country) 26 (14.6) 
Primary aim  
Drug effect (43, 49, 69-74) 8 (4.6) 
Drug safety  
(46, 48, 50, 55, 56, 58, 75-112) 
44 (25.1) 
Drug utilization  
(44, 45, 47, 51-54, 57, 59, 60, 62, 63, 65-67, 113-192) 
95 (54.3) 
Validation/methods (61, 64, 68, 193-217) 28 16.0) 
Database type  
Administrative 129 (73.7) 
Clinical 30 (17.1) 
Both 16 (9.1) 
Linked data 63 (36.0) 
Drug(s) of interest  
Gastro-Intestinal Drugs 4 (2.3) 
Cardiovascular Drugs 31 (17.7) 
Respiratory System 6 (3.4) 
Nervous System 52 (29.7) 
Infection 12 (6.9) 
Endocrine System 31 (17.7) 
Genito-Urinary System 1 (0.6) 
Malignant Disease 4 (2.3) 
Musculoskeletal System 8 (4.6) 
Eye 2 (1.1) 
Skin 1 (0.6) 
Multiple 23 (13.1) 
Study population  
< 999 20 (11.4) 
1000 – 9999 37 (21.1) 
10 000 – 49,999 49 (28.0) 
50 000 – 99,999 10 (5.7) 
100 000 – 499,999 23 (13.1) 
> 500,000 21 (12.0) 
Unknown/variable 15 (8.6) 
Sub-group  
Children (aged <18) 7 (4.0) 
Elderly (aged >60) 18 (10.3) 
Pregnant women 13 (7.4) 
N/A 137 (78.3) 




2.3.5 Drug group 
There was a wide range of drug classes investigated. Drugs acting on the central 
nervous system (CNS), including anti-depressants, anti-psychotics and other 
psychotropic drugs as well as anti-epileptics and opioids, were the most 
commonly studied, accounting for over 25% of all studies. Drugs affecting the 
cardiovascular and endocrine systems were also quite common, accounting for 
approximately 17% of studies each. Over 10% of the total number of studies 
investigated more than one type of medication – these were typically papers 
that investigated a range of drugs as part of a methodological study, papers that 
looked at patients’ entire medication history as part of a drug utilization or 
safety study or papers that investigated overall rates of prescribing across 
populations of interest.  
2.3.6 Study population size 
There was a wide variation in study population size across the included studies, 
ranging from 80 participants to 29.5 million participants with a median of 
22,152. Of the 175 studies included in this review, 55 had a population of more 
than 50,000 patients. The largest study had a population of over 29 million 
patients – this was an outlier, which made use of the entire dataset of a large US 
health insurance provider and studied utilization patterns of all drugs prescribed 
to these patients. Study population was not reported for 15 studies, either 
because these were conceptual methodology papers which did not apply the 
methods to a specific group of patients, or because they were population level 
studies where the study population varied over the study period. 
2.3.7 Sub-groups 
There were three main population sub-groups investigated across the reviewed 
studies – children, elderly patients and pregnant women. A number of different 
age cut-offs were used to define both children and elderly patients across these 
studies, so for the purposes of this review any paper that focused on patients 
aged 18 and under or 60 and over respectively were included in the relevant 
category. The studies of all three sub-groups focused on a range of different 
drugs, but around half of the studies in each sub-group were focused on CNS-




The aim of this systematic review was to identify the methods used to quantify 
patients’ exposure to drugs in studies using routinely collected prescribing data. 
A range of common classes of methods for quantifying exposure were identified 
based on the methodologies of the included studies: ever/never use, use at a 
specified time point, DD-related, refill gap, adherence measures and population 
level measures. 
2.4.1 Exposure quantification methods 
These methods provided different types of information on patients’ exposure to 
medication, and each has different advantages and potential sources of random 
error or bias. Ever use of a drug is easy to establish, even with limited data, but 
it does not differentiate between patients who are one-time or infrequent users 
of a drug and those who are long-term users. Some of the included studies 
calculated the total number of prescriptions for the drug of interest, but this is a 
simple measure of cumulative exposure and does not account for differences in 
the quantity prescribed or dosing. In some studies, thresholds other than one 
prescription were used. This may be clinically relevant and could help to select 
patients who are ongoing users of a drug, but still does not account for changing 
exposure status with time or cumulative exposure as shown in Figure 10, where 
all three patients meet the threshold for exposure but have different patterns of 
prescribing across the follow-up period. Despite these limitations, ever use can 
still be a useful method for defining a cohort, as it can establish a baseline of 
exposure which can be expanded upon through other methods.  
 
Figure 10 – Example of potential variation in patients who meet a 2-prescription threshold 
for exposure 
 
Use at a specified time point can provide a more precise definition of exposure 
by focusing on exposure only during the time adjacent to the outcome of 
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interest or by splitting users into categories based on recentness of use at time 
points of interest. This may provide more valid results, but these methods alone 
still do not account for variation in cumulative exposure. It is important to 
ensure that the timeframe of interest is set correctly to minimise exposure 
misclassification. When defining new use, shorter windows may misclassify 
existing users as new, which will affect the validity of the results obtained by 
blending different groups of users. Allowing for a longer window will increase 
the ability to identify genuinely new users of the drug of interest but could be 
overly selective and exclude patients who would be suitable for analysis or limit 
the size of the study population through the need to have data available for this 
lookback period. Similarly, when defining current use at the time of an event 
the timeframe of interest should be set to account for the amount of time where 
you would expect the drug of interest to affect the risk of the outcome. As with 
ever use, these methods can still be useful for defining cohorts, population sub-
groups or additional study characteristics such as comorbidity, but care has to be 
taken that the thresholds set are specific enough so as to minimise risk of bias. 
Creating more detailed exposure periods using a daily dose method provides 
even more detail, but the accuracy of these exposure periods will vary 
depending on which method is used to define the duration of each prescription. 
Using the number of DDDs dispensed can introduce bias, as it is based on the 
most common dose when used as a monotherapy for a specific indication. It may 
be suited to some patients, or drugs where there are a limited number of 
indications or dosage options, but it may not be an accurate reflection of many 
patients’ treatment. Figure 11 shows the different lengths of exposure 
calculated based on two prescriptions for simvastatin when using the DDD of 
30mg per day compared to a patient specific PDD of 10mg per day. In this 
example, using the DDD under-estimates the coverage of each individual 





Figure 11 – Comparison of the duration of exposure to simvastatin calculated using the 
DDD and PDD 
 
This is especially true for drugs with multiple indications, a wide range of 
potential dosages or where there is variation in dosing over time. Figure 12 
shows an example of the potential difference in the length of exposure from 1 
prescription for the anti-epileptic drug carbamazepine when using the DDD of 1g 
per day compared to a PDD of 200mg per day. In this example, the DDD 
overestimates the duration of the prescription significantly – if error of this 
nature is introduced for a number of similar prescriptions over the course of the 
follow-up period this could have a large impact on the results of a study. 
 
Figure 12 – Comparison of the duration of exposure to carbamazepine calculated using the 
DDD and PDD 
 
One study which investigated concordance between the DDD and a pharmacist-
defined value for days’ supply for eight drug classes found that using DDDs to 
define exposure duration could lead to exposure misclassification of different 
magnitudes depending on drug class.(209) This is less of an issue when using 
days’ supply or PDD as they are patient specific, but not all datasets include this 
information, and there is still room for error as we do not know whether patients 
follow instruction or take their medication. 
Persistence and discontinuation also allow for variation in exposure over time. 
Here, the main potential source of bias is the definition of the allowable gap. 
Defining the allowable gap requires understanding of the usual clinical practice 
with respect to the country, drug of interest and the healthcare system the data 
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represent. A study conducted by the Observational Medical Outcomes 
Partnership (OMOP) compared a 0-day and 30-day allowable gap and showed that 
a 30-day gap provided more clinically meaningful information.(218) Shorter 
windows may be more suitable in cases where medications are frequently 
reviewed by physicians, such as in cases where a narrow therapeutic window 
necessitates therapeutic drug monitoring. Where possible, combining daily dose 
and persistence may allow for more precision, as the allowable gap between 
prescriptions only needs to allow for a grace period between prescriptions for 
factors such as non-adherence, medication stockpiling and late refill of 
prescriptions. If no dosage information is available, larger allowable gaps are 
required to account for the supply of medication provided by each prescription. 
This will likely vary between patients or individual prescriptions, so the selected 
allowable gap may have to be larger to account for this variation in addition to 
the other factors listed above. Setting too long an allowable gap risks 
misclassifying genuinely non-persistent or unexposed time as exposed, which 
also introduces error. Figure 13 shows the potential variation in the observed 
persistent use periods based on two prescriptions depending on the methods 
used. In this example, both a 60-day allowable gap and a 30-day allowable gap 
between the end of the supply of one prescription and the next prescription are 
sufficient to define these as the same use period, whereas a 30-day allowable 
gap between prescriptions alone is not enough and results in two separate use 
periods. 
 
Figure 13 –Comparison of persistence measures using 30- and 60- day allowable gaps 
without coverage and a 30-day allowable gap with coverage 
 
The potential for error in adherence measures is similar, in that errors can occur 
in both the MPR and PDC if the follow-up period or coverage from drugs supplied 
are incorrectly defined. There is also potential for error in studies that combine 
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multiple observation periods, as early dispensing and high adherence in one 
period can offset late dispensing and poor adherence in another; giving a 
combined measure which does not accurately capture changes in the patient’s 
medication availability.(42)  Methods such as the MPR and CMA which use the 
sum total of medication dispensed over the study period can overestimate 
adherence if patients regularly refill early, and can return adherence values of 
greater than 1, or 100%.  As described above, adherence measures typically 
depend on the use of a DD method to define the amount of a drug supplied to a 
patient, introducing further potential for error depending on the method used.  
 
Figure 14 - Comparison of adherence values calculated based on the DDD and PDD from 
two prescriptions 
 
In the example shown in Figure 14 using the DDD as opposed to the PDD would 
result in an under-estimation of drug supply, and in turn of the patient’s level of 
adherence during the period of interest. Adherence and persistence methods 
were often used together, as measuring persistence can establish observation 
periods for adherence calculations. In these cases, errors made when defining 
the allowable gap will also affect the accuracy of the adherence measurement. 
Although the type of information and level of detail clearly varies across the 
different methods, few studies assessed the impact of using different methods 
to classify exposure on the definition of the study population or explored the 
potential effect that using different methods could have on the observed 
associations between drug exposure and outcomes. One study which did assess 
this compared the effect of different assumptions of daily dosage and methods 
of accounting for gaps and overlaps between individual prescriptions on the 
construction of treatment episodes, and the effect these methods had on the 
observed association between SSRI exposure and hospitalisation. The results 
showed that assumptions of 1 DDD per day or 1 unit per day had a significant 
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impact on the duration of exposed time compared to patient-specific dosages, 
and that this in turn gave rise to both over and under-estimations of risk 
associated with exposure to the drugs investigated depending on the 
method.(219) 
A similar study investigated the effect of using time-fixed definitions of exposure 
based on different threshold numbers of prescriptions and time-varying methods 
based on different prescription durations on the association between use of oral 
anti-hyperglycaemic drugs and mortality. The results of the study demonstrated 
large differences in the observed association based on the classification of 
exposure used.(220) This study also highlighted the potential for immortal time 
bias in these time-fixed definitions in cases where the follow-up time was not 
defined in the same way for the exposed and unexposed populations. In this 
case, starting follow-up for both groups from an index prescription for any anti-
hyperglycaemic drug introduced immortal time for the exposed patients 
between their index prescription and their first metformin prescription, which in 
turn   
Taken together, these studies show potential for variation in study results based 
on the exposure definition chosen and highlight the need to consider which 
methods are appropriate for the dataset being used and for the study design. 
However, more evidence is needed to further clarify the potential for error 
across a wider range of drugs of interest and using different methods. It is also 
important to highlight that routinely collected data provide information on drugs 
that have been prescribed or dispensed to patients, they do not provide 
information on whether dispensed drugs were actually taken; therefore, none of 
the methods discussed avoid this source of potential exposure misclassification. 
Although most of the reviewed studies typically contained enough information to 
categorise and summarise the methods used to generate exposure variables, 
many of the studies contained only limited detail regarding the structure of the 
database(s) being used or the computational processes involved in preparing the 
data for analysis. Since there is a great deal of heterogeneity across routinely 
collected databases, greater transparency when describing data exploration, 
cleaning and enrichment would give other researchers a clearer idea of the 
strengths and limitations of the published results, as well as enable easier 
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reproduction of the study on other datasets. Increasing the reproducibility of 
research using routinely collected data is important, as validating the results of 
studies in different populations or using different databases would serve to 
further increase the impact of the results obtained. Additionally, transparency in 
the methods used may lead to increased standardisation in how certain aspects 
of data preparation are handled, which would reduce the complexity of the 
process and comparability of results across different studies. The RECORD 
statement outlines the key elements which should be reported in 
epidemiological research using routinely collected data, and advises that the 
algorithms and codes used to derive all of the exposure variables used should be 
provided where possible, so adhering to this or other similar checklists when 
publishing research can help ensure that the relevant information is 
included.(221) 
2.4.2 Strengths 
Although there are published studies discussing individual methods for defining 
exposure this literature review is one of the first studies to collect and 
summarise information regarding the range of methods used across the published 
literature in the field. A number of reviews have been published examining 
aspects of pharmacoepidemiological research using routinely collected data. For 
example, reviews have been published which summarise the research output 
from specific databases or groups of databases, including the Swedish Prescribed 
Drug Register,(222) the Nordic prescription databases,(35) and the German LRx 
database.(223) There have also been reviews published focusing on evidence 
related to specific outcomes and drugs of interest, including a review of studies 
investigating the possible link between use of thiazolidinediones and risk of 
bladder cancer(224) and a review of treatment adherence in patients being 
treated for headaches.(225)  
As shown in Table 5, 16% of the studies reviewed had methodology or validation 
of routinely collected healthcare data as a primary aim, and although there was 
a general lack of evidence comparing the full range of different approaches to 
defining exposure, there are studies and reviews covering aspects of one or more 
of the methodological approaches discussed in this review. One study focused on 
exposure misclassification, using a probabilistic bias approach to identify 
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misclassified categorical exposures. The proportion of days covered was 
calculated using a DD measurement, and this was used to assess the effect of 
misclassification on hypothetical exposure-outcome associations. The authors 
concluded that misclassification was an important factor to consider in 
pharmacovigilance, and that measures such as the one demonstrated were 
useful sensitivity tests for estimating potential bias.(193)  
Other studies that were included in this review focused on other ways to expand 
and improve existing methods of assessing drug exposure. For example, one 
study proposed an extension to the PDC method of assessing adherence which 
took into account changes in adherence over time as opposed to assessing 
adherence as a single, time-fixed variable. The authors highlighted the potential 
for bias in the current method, and the benefit of a more accurate method for 
determining adherence in studies which associate adherence with a clinical 
outcome as well as those where having an understanding of how and why 
adherence changes over time is important.(200) A second study focused on the 
idea of modelling exposure as a time-dependent variable as opposed to a time-
fixed one. The Prescriptions to Drug Use Periods (PRE2DUP) method aims to 
create a model of individual patient’s exposure based on their prescribing 
history and the amount of the drug dispensed in DDDs among other factors. In a 
study aiming to validate the method by comparing the resulting model against 
patient interviews, the authors also highlight that an advantage of this method is 
that the core process of generating the exposure periods is iterative and takes 
into account the patient’s common refill patterns when imputing missing data 
for individual prescriptions. This allows for the consideration of behaviours such 
as stockpiling and early refilling which were highlighted as potential reasons for 
exposure misclassification in other literature.(203, 226)  
These studies discussing specific methods of quantifying exposure are part of a 
wider section of the literature relating to methodological issues in studies 
making use of routinely collected data. Understanding potential limitations 
specific to the data being used is an important part of the planning stage of any 
study, and a number of the reviewed studies cover methods for handling such 
issues. For example, there are a number of issues discussed across the included 
papers that should be considered in the case of health insurance claims data. 
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These can include unmeasured confounding factors, such as restrictive 
reimbursement policies, the use of free drug samples or out-of-pocket drug 
purchases. In each of these cases, it is possible that the patients’ available 
supply of the medication of interest is under-estimated based on claims data 
alone, and if this is not accounted for there is potential for exposure 
misclassification, even if exposure is correctly quantified for the data that is 
present. One study assessing the impact of restrictive reimbursement policies in 
two Canadian provinces found that the administrative data available only 
captured 61% of the dispensations for the drug of interest where such a policy 
was in place, and concluded that in cases where no attempt was made to 
account for this the resulting bias could be quite large.(227) Another study 
which investigated completeness of US commercial claims records for warfarin 
found that there were cases where patients paying out-of-pocket for the generic 
form of the drug resulted in the potential for incomplete data in the claims 
database.(198) These issues are all specific examples relating to the use of 
claims data, and may not apply to other database types. Dispensing records from 
a pharmacy would likely be able to account for out-of-pocket prescription drug 
purchases but may be missing medications available from other sources. This is 
highlighted by a study of the rates of free prescription drugs based on data taken 
directly from office-based physicians. The study found that rates of free sample 
provision varied across drug type, and between branded and generic drugs, but 
that there was potential for bias in studies relying solely on pharmacy claims 
data.(228) 
Even with an understanding of the database being used, the process of data 
preparation is usually one of the most time consuming parts of studies using this 
type of data.(229) Once data cleaning is complete, the process of data 
enrichment typically involves enhancing data either by deriving additional key 
variables using existing data or by linking multiple data sources. Two of the 
studies included in this review described the creation of structured data fields 
based on free text information encoded in prescribing records. In both cases, 
algorithms were created to recognise common phrases and numerical values in 
free text fields and convert this into standardised fields which could then be 
more easily used in further research using these databases.(230, 231) 
Development of a common data model was a large part of the work conducted 
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by OMOP, with the main aim being to facilitate the use of data from multiple 
sources and enable reproducible drug safety research. This model took a person-
centric approach, where drug exposure timelines were created in a standardised 
manner – two case studies were produced which demonstrated the potential to 
transform disparate source databases into comparable databases for use in 
research, with the researchers proposing that this meant that studies produced 
based on these data were more meaningfully comparable and therefore more 
able to appropriately impact public policy.(218) Another published study 
discussing the potential benefits of combining different sources for drug safety 
research highlighted that increasing the overall population size and diversity of 
the studied population would help increase validity of results. This study went 
on to discuss the need for data to share a common formatting to ensure ease of 
comparison of different records, but discussed that this can present a range of 
challenges, particularly where records from different countries are 
involved.(232) All of these potential issues should be taken into account when 
planning a study using routinely collected data, and these choices will impact 
the decisions made with respect to how data are cleaned and manipulated. 
Another strength of this review is that the studies included were not limited to a 
single database or data from a single country. This is beneficial when considering 
methods used to determine exposure based on routine data, as the nature and 
quality of the data available differ from country to country, particularly where 
there are differences in the way healthcare is provided. These differences have 
an effect on the way the data has to be processed. An example of this can be 
seen in the difference between healthcare provision in the USA and in the UK, 
and the studies included in this review based on data from these countries. The 
USA has a private healthcare system, and most of the data used in research in 
US-based studies in this review was taken from insurance companies. As has 
been discussed above, data from insurance companies can have issues around 
completeness resulting from factors such as out-of-pocket drug purchases and 
restrictive coverage. Additionally, the data will likely represent a specific subset 
of the population who are able to afford insurance, or even patients who are 
from a specific industry if the insurance provider from whom the data were 
sourced provides insurance through patients’ employers. Other sources of data 
commonly seen in US-based studies were data taken from specific benefit 
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programs such as Medicare and the Veteran’s Health Administration. As with 
insurance data, these sources will represent specific sub-populations as opposed 
to whole populations and will have data missing where drugs are not covered by 
the benefit program in question. In contrast, the UK has a mostly public 
healthcare system, with the NHS being the major healthcare provider. The most 
common database seen in the included studies published in the UK is the CPRD, 
a primary care dataset made up of medical records from a network of general 
practices in the UK which contains data on approximately 6.9% of the UK 
population.(233) As well as this primary care data, CPRD also offers linkage to 
other datasets such as secondary care and mortality records for around half of 
these patients. In contrast to the US datasets, there is not as much of a concern 
of fracturing the population based on coverage level as the NHS is the main 
healthcare provider, and CPRD data are broadly representative of the population 
as a whole.(233) However, most of the data regularly available is on primary 
care only, so there is still potential for missing data with relation to outcomes 
and prescribing in secondary care, as well as for medications purchased over the 
counter. The overall population size is also much smaller than the US, and so 
uncommon conditions, outcomes or drugs may be more difficult to study due to 
drawing subjects from a smaller population. In addition to these issues, there 
are likely differences in prescribing behaviours, legislation, approval status and 
public policy surrounding specific drugs.  This comparison highlights a number of 
potential reasons that different methods would be useful depending on the 
source of data for a study, and in turn highlights the benefit of examining 
studies published internationally rather than limiting to one database or country 
in this review. 
2.4.3 Limitations 
This review is not without its limitations. Although a wide range of studies were 
found, this is not a comprehensive review of all research published using routine 
data, so it would therefore be invalid to draw conclusions about time trends in 
the amount of research published based on routine data, or the overall 
prevalence of certain study characteristics in the field as a whole. However, the 
main aim of this literature review was to characterise different methods being 
used in pharmacoepidemiological research to quantify or classify exposure, and 
a range of methods were identified in the papers that were found. Although the 
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included studies were diverse, it is possible that some eligible studies were not 
identified from the search - expanding the search strategy to include other 
international database types such as ‘drug register’ may identify further eligible 
results. Additionally, the methods used to classify study characteristics in this 
review may not have adequately captured certain details of the included 
studies. Studies were only categorised by primary aim, when a number of studies 
could realistically belong to more than one category – for example, a number of 
drug safety studies also considered effectiveness of the drug of interest, and 
secondary components were relatively common in studies that were classified as 
having validation or methodology as a primary focus.  
This review focused specifically on the use of routine healthcare databases to 
measure drug exposure. Therefore, the findings cannot be generalised to using 
similar data sources to address other research questions. Additionally, 
information was gathered on the methods used as they were reported, so there 
may be information missing if not enough detail was given by the authors as to 
how data were handled, or if steps involved in cohort generation were not 
described in the text. Finally, while the review identified the types of methods 
used and their frequency, a systematic comparison of their relative capacity to 
minimise exposure misclassification was outside the scope of the review. 
2.4.4 Conclusion 
Research conducted using routinely collected healthcare data has the potential 
to be a valuable source of evidence for real-world clinical practice, and there is 
potential for this type of research to complement some of the limitations of 
other methodologies such as RCTs to provide a more complete picture of how 
effective a wide range of drug treatments are. This review highlighted a range of 
different methods for determining patients’ exposure to medicines based on 
routinely collected prescribing data; however, further work is required to better 
understand comparative strengths and limitations of these methods in 
minimising exposure misclassification, and the impact that choice of exposure 
measurement has on the associations between exposure and outcomes observed 
in studies using these data. Additionally, further work is required to increase the 
level of transparency and reproducibility in the reporting of how routinely 
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collected prescribing data are prepared for research in order to maximise the 
potential impact of results and evidence generated based on these data. 
The next chapter will describe the development of a set of flexible, reusable R 
functions for generating drug exposure variables using the various methods 
identified in this review. 
3 Documentation of R functions for quantifying 
drug exposure 
3.1 Introduction 
In the previous chapter, a review of published pharmacoepidemiology research 
identified a variety of potential research questions which can be answered using 
routinely collected data. These were split into four main categories; studies 
investigating the effectiveness of drug therapies, studies into the safety of 
medications, drug utilisation studies, and studies related to the methodology of 
using routinely collected data. Each of these study types required patients’ 
exposure to the drug(s) of interest to be quantified during the data preparation 
process. A range of different methods for quantifying drug exposure were also 
identified and grouped into classes. These classes were ever use vs. never use, 
use at a specified time point, daily dose or duration, persistence and 
discontinuation, adherence, and population level measures.  
3.1.1 Data preparation 
As described in Chapter 2, data preparation is essential in studies using routinely 
collected data, as it provides an opportunity to address the limitations of the 
raw data and minimise the potential for bias in the subsequent analyses. Data 
preparation is typically one of the most time-consuming stages of studies using 
routinely collected data.(229) Manual exploration of the data are required to 
understand the content and structure of the data and identify specific issues 
which must be resolved. Data cleaning involves making adjustments and then 
verifying the validity of the data. Further inspection of the data is then 
necessary to verify these new values and identify any additional issues. Once the 
existing data are considered to be valid, they can be used to generate additional 
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variables of interest which must also be verified. This entire process is iterative 
and can be particularly complicated when using especially large datasets, 
datasets which include variables stored as free text or when combining multiple 
datasets, as all of these factors will introduce greater variety to the data. 
Sources of error may not be initially obvious and may only become clear after 
some initial modifications such as standardising object types or correcting syntax 
issues. The need for manual data exploration and trial and error during data 
cleaning and enrichment mean that researchers often create code for data 
preparation on a project-by-project basis. This lack of standardisation between 
studies, combined with the variation in the level of transparency in the reporting 
of the specific processes used to transform raw data into analysis datasets can 
impact the reproducibility of research using routinely collected data.(234) While 
it is not feasible at present to create algorithms that can completely automate 
the process due to the potential complexity and variation of routinely collected 
data, it is possible to develop tools which will make it easier to standardise and 
repeat specific data cleaning or enrichment tasks. 
3.1.2 Data preparation in R 
An important consideration when working with routinely collected data is the 
choice of data management and analysis software. There are a wide range of 
options available, including programming languages such as SQL, R and Python 
and statistical software such as SAS, SPSS and Stata. When choosing software to 
use for research it is important to consider a number of factors including ease of 
use, functionality, flexibility and extensibility, cost and licensing issues, 
available sources of support or learning resources, scalability, integration with 
other software and the ability to produce output in the desired formats. For this 
project, the decision was made to develop a package for use in R.  
R is a programming language and computing environment for data manipulation 
and analysis, calculation and graphics. It was developed by Ross Ihaka and 
Robert Gentleman as an implementation of the S programming language.(235) 
One of the key advantages of R when it was first released was that while S was 
only available as a commercial software package, S-PLUS, R was free, open 
source software. S, and by extension R, has its roots in data analysis, and is 
useful for both interactive exploration of data and programming to create new 
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tools. R is typically accessed through the use of a command line interface. 
Commands to R take the form of expressions or assignments.(236) When an 
expression is given as a command, it is evaluated, and the result is printed and 
lost. Assignments are evaluated and then the results are passed to a variable and 
stored. Users can interact with R through the use of individual expressions, but 
one of the core benefits of R is that it is easy to build up to developing 
functions, essentially a series of commands executed in sequence. R is an 
object-oriented language, meaning that everything that is manipulated in R is an 
object, or a named data structure.(237) The simplest object type in R is a 
vector, which can contain a set of elements of the same basic data type (i.e. 
logical, integer, double, character, complex or raw). R has a range of basic 
object types, including matrices, arrays, lists and data frames, which vary by 
their dimensionality (1d, 2d or Nd), and whether they allow heterogenous or 
homogenous data types. Data frames are the most common format for storing 
data in R for data analysis. Technically, data frames are held in R as lists of 
equal-length vectors, meaning that they appear as matrices but are capable of 
storing data of different base types. 
There are a number of reasons why R was chosen as the analysis software for 
this project. As mentioned above, R is open source and free to download, use 
and update, making it a cost-effective option for data analysis in research. The 
fact that it is free to use and available across a number of different common 
platforms and operating systems also means there is a lower barrier to entry 
when collaborating with others or when sharing code.(238) Since it is widely 
used in both academia and industry, there are a wide range of support and 
learning resources available, including books, training courses and tutorials and 
community forums where users can raise questions and share solutions to 
problems. Although it is possible to interface with R using its base GUI, the use 
of an integrated development environment (IDE) such as RStudio makes it easier 
to maximise the potential of R as an analysis tool and development platform. 
RStudio is designed to improve the utility of R, providing a more intuitive and 
user-friendly interface and tools such as syntax highlighting, code validation and 
completion, debugging, version control, environment management and package 
development tools.(239)  
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3.1.3 Packages in R 
One of R’s major advantages is that it can be easily extended through the 
creation of new functions and packages. In R, a package is a collection of code, 
data, documentation and tests developed to expand the base functionality of R 
or add new capabilities. R is a powerful and flexible language, able to handle 
large amounts of data and complex calculations, and there are a wide range of 
packages available which build on R’s base data querying and manipulation 
capabilities, allow R to read data from a wide variety of formats, interact with 
other data analysis or statistical software and producing high quality, 
publication-ready outputs. There are currently over 15,000 packages available 
from the Comprehensive R Archive Network (CRAN) providing functions for a 
variety of data analysis tasks, including packages for use in healthcare research 
and data analysis.(240) This wide repository of packages provides a strong 
foundation for further expansion, as existing improvements to R’s data handling 
capabilities make it easier to develop tools for specific data analysis and 
manipulation tasks such as handling prescribing data.  
Creating a package is a good way to share code with others, as it is easy for 
other R users to download, install and use packages. Packages can be a useful 
way of writing and storing code even if it just for personal use, as the standard 
conventions for writing and storing a package provide an effective structure for 
a project and make it easier to reuse or update the code at a later date.  
Building a package containing functions for performing common data preparation 
tasks such as generating drug exposure variables has a number of benefits. As 
discussed above, R’s availability means that these tools can be easily 
distributed, can be used in conjunction with other R packages, and can be easily 
expanded if desired. When collaborating with others or publishing research, the 
methods used to generate exposure variables can be easily reported by referring 
to the packages and functions used, making it easier to understand how data 
have been processed or replicate the analysis. As mentioned above, improving 
the transparency and reproducibility of analyses makes it easier to validate 
findings using other datasets, which can, in turn, help to ensure that research 




The aim in this chapter was to use the information gathered on the common 
methods for defining drug exposure during the systematic review to build an R 
package, prescribeR, which contains a variety of functions for quantifying drug 
exposure based on routinely collected prescribing records. The remainder of this 
chapter will go into detail on the contents of the prescribeR package. Although 
six classes of methods were defined in the previous chapter, the decision was 
made to initially focus on four when creating the prescribeR package - ever use, 
use at a specified time point, daily dose related methods and persistence. 
Adherence was excluded as there is already a published R package, AdhereR, 
which contains a set of functions for measuring and visualising adherence to 
drugs using routinely collected data.(241) Some of the population-level measures 
described in the systematic review are included in the prescribeR package’s 
summary functions, but the decision was made to focus initially on the 
individual-level exposure methods as these were more commonly used in the 
studies included in the systematic review in Chapter 2. 
The functions in the prescribeR package can be split into three major groups; 
data standardisation, data summaries and exposure classification, with the 
latter split further into ever use, use at a specified time point, daily dose and 
persistence. The remainder of this chapter provides the rationale for each group 
and sub-group as well as any necessary definitions, then describes the individual 
functions, including the R code, as well as a plain language breakdown of the 
data manipulation process and output, the arguments, and usage examples 
demonstrating different possible analyses using synthetic data.  
3.2 Generation of synthetic datasets 
The data governance in place to safeguard personal healthcare information aim 
to balance the need to maintain patient privacy and confidentiality while 
allowing for the controlled use and sharing of information for purposes such as 
improving care or medical research. Data provided to researchers are typically 
anonymised, and there are restrictions on the sharing of research data with third 
parties or the use of data for other purposes in order to minimise the potential 
of accidental disclosure of sensitive patient information. There is, however, a 
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benefit to being able to show how the R functions described in this chapter 
interact with and transform data, so the decision was made to produce a 
synthetic dataset. The aim in constructing this synthetic dataset was to produce 
data which has the key characteristics of real prescribing data but does not 
contain any identifiable data from real patients and can therefore be shared or 
published alongside the exposure algorithms. 
Even when data preparation is complete, datasets can contain records for large 
numbers of patients and a wide range of different drugs. Including a small 
synthetic dataset with a limited number of patients and drugs in this R package 
allows new users to easily explore the data, and then test different functions 
and analyses quickly and easily to understand the functionality of the package 
before using it on real data. It also provides a sample dataset which can be used 
for any further development and testing. With a small dataset it is easier to 
anticipate the correct output from a function, and therefore easier to write 
sensible tests which help with the process of debugging and validating code. 
Initially, the plan was to produce a synthetic dataset to contain abstract and 
more clearly synthetic data, using simple names and codes for drugs, similar to 
the data included in the AdhereR package.(241) This was changed in favour of a 
dataset which uses the format of real Scottish prescribing data, including real 
drug names, BNF codes, formulations and strengths with a view to being able to 
produce more detailed and varied examples of the possible applications of the 
functions on real world data.  
The synthetic prescribing dataset produced, “synth_presc”, is based on the 
characteristics of a typical PIS dataset provided for patients followed up as part 
of a study. Fields were chosen based on the data required by the functions 
detailed in this chapter and structured in the same way as they are in PIS data 
(as described in the Information Services Division [ISD] Scotland PIS fields 
document, an excerpt of which is adapted in Table 6, below).(242) The 
generated dataset contains synthetic records for 1,478 individual prescriptions 
split across 100 patients, with each record containing 13 fields. There are four 
different drugs in the dataset - simvastatin, atorvastatin, omeprazole and 
citalopram which are commonly prescribed drugs, meaning there was more data 
and more variation to draw from when sampling to generate synthetic patients. 
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Drugs were chosen to represent a number of different drug classes, but two 
lipid-regulating drugs were chosen to allow for examples showing how results 
can differ if examining exposure to individual drugs or across drug categories. All 
of the drugs chosen are most often prescribed as either tablets or capsules and 
are most often prescribed as 1 unit per day - this was done to avoid 






Field name Description Format Example 
patient_id a unique patient identifier string (or numeric) 10001 
presc_date the date the prescription was written date 05/07/2020 
approved_name the approved name of the prescribed item string SIMVASTATIN 
qty_dispensed the quantity of the drug prescribed (e.g. number of tablets, volume of liquid) numeric 28 





codes corresponding to the location of the prescribed item in the British National 





bnf_item_code a 15-digit code - the first seven digits detail the BNF categories, and the last eight digits represent the medicinal product form, strength and generic equivalent string 0212000Y0AAADAD 
ddd_conversion a factor by which the quantity of drug prescribed should be divided to give the number of Defined Daily Doses (DDDs) prescribed numeric 0.75 
ddd_dispensed the number of DDDs dispensed, based on dispensed quantity and item strength numeric 37.333 
qty_per_day the prescriber’s instructions for how many units (e.g. tablets, capsules) should be taken per day numeric 1 





In order to determine which patients in the synthetic dataset would be 
prescribed which drugs each drug of interest was assigned a code within the 
sample PIS data, as shown in Table 7 below. This was used to create lists of 
pseudonymised patients who had at least one prescription for each drug. The 
lists and codes were combined, resulting in a list of patient IDs and codes 
corresponding to how many of the four drugs they had been prescribed. For 
example, a patient with at least one prescription for each of the four drugs 
would be coded ‘1111’, whereas a patient who had only been prescribed 
omeprazole and simvastatin would be coded ‘1001’. A frequency table for the 
codes was constructed, and a weighted sample was taken to give drug 
combinations to assign to the 100 synthetic patients. Each patient was assigned 
a start date for each of their drugs based on random sampling between 






Table 7 - Codes assigned to the drugs of interest when assessing the frequency of co-
prescribing in the real dataset to assign drug combinations to synthetic patients 
 
Then, for each drug, frequency tables were constructed detailing the number of 
prescriptions per patient, the number of days between successive prescriptions 
and the strength and formulation prescribed. From these, each patient was 
assigned a number of prescriptions for each drug they were given, and a 
corresponding set of differences, in days, between individual prescriptions which 
were added to the start date successively to give the remaining prescription 
dates. Patients were also assigned a strength for each drug and a number of 
tablets per prescription, again determined through weighted sampling and the 
same for each prescription the patient had for a particular drug. The DDD 
conversion factor and number of DDDs dispensed were calculated based on the 
WHO’s DDD index.(243) Every prescription was assigned a tablets per day value 
of 1 - this means that the PDDs dispensed will differ from the DDDs dispensed in 
some cases and therefore allows for demonstration of how these measurements 
differ. These records were then combined to give the complete dataset. 
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Although the synthetic dataset is based on data characteristics for subjects 
within a real study, none of the patients represented within it or the individual 
prescriptions are the same as any of the data within the original study. A second 
synthetic dataset, “synth_events”, was created to be used alongside the 
prescribing data in the functions which make use of event dates. This dataset 
contains the same 100 patient IDs, dates for the start and end of follow-up and 
up to two event dates per patient. The start date for each patient is the date of 
their first prescription for any drug, and the end date is the last day of the year 
in which they had their last prescription. Patients were randomly assigned either 
0, 1 or 2 events, and event dates were determined by adding a randomly 
assigned number of days between 1 and 270 to the start date (for event 1) or the 
first event date (for event 2) where applicable. Event dates generated after the 
end of follow-up were removed. A section of this data can be found in Table 8 
below.  
patient_id start_date end_date event_1 event_2 
10001 2020-07-05 2022-12-31 NA NA 
10002 2020-05-29 2022-12-31 2020-06-30 2020-08-06 
10003 2020-10-21 2021-12-31 2021-01-22 2021-10-02 
10004 2020-09-22 2021-12-31 2021-05-06 NA 
10005 2020-08-11 2020-12-31 NA NA 
10006 2020-05-27 2022-12-31 2020-09-06 2021-03-01 
Table 8 - Extract from the synthetic events dataset (‘synth_events’) showing the structure of 
the first 6 records 
 
It is important to note that while these synthetic datasets were generated based 
on characteristics of real data and can be used to demonstrate different 
methods of quantifying drug exposure, the results may not always make clinical 
sense due to the way the data was constructed based on random sampling of a 
limited number of characteristics from the real data and the fact that each 
patient was assigned one strength or formulation of a drug, and always received 
the same number of units per prescription. In particular, for patients with 
multiple drugs the prescriptions for each drug were generated separately, and so 
there may be overlap in treatments which do not reflect how the drugs would be 
prescribed in real clinical settings. Additionally, the event dates and number of 
events per patient were assigned at random, so links between, for example, 
adherence or persistence to treatment and time to event will not reflect actual 
clinical data. The synthetic dataset was to allow for quick validation of newly 
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written or updated code during the development of the package, but all of the 
functions were also tested on real-world datasets in order to ensure they could 
handle more complex data.  
3.3 Package overview 
Table 9 contains a full list of the functions contained within the prescribeR 
package, as well as the R commands for each function and a short summary of 
the purpose of each function.  
Function name R command Description 
Data standardisation tidy_presc Converts the field names and 
formats of the input dataset 
to the prescribeR package 
standards 
Data summaries   
Summarise prescribing 
dataset 
presc_data_summary Generates a high-level 




presc_top_drugs Determines the most 
commonly prescribed drugs 
Prescription time 
trends 
presc_by_time Generates a summary of the 
number of prescriptions over 
time 
Ever use ever_use Classified patients as exposed 
or unexposed based on a 
threshold number of 
prescriptions  
Use at time point   
Use within a fixed 
date range 
uat_fixed Determines exposure within a 
fixed time period for all 
patients 
Use within a fixed 
range from individual 
event dates 
uat_fixed_events Determines exposure within a 
set number of days from a 
patient-specific event 
Use within individual 
patient date ranges 
uat_var_events Determines exposure 
between two patient-specific 
dates 
New Users – fixed 
start date 
new_users_fixed Classifies patients as new or 
existing users of a drug based 
on a fixed start date 
New users - individual 
start dates 
new_users_var Classifies patients as new or 
existing users of a drug based 
on a patient-specific start 
date 
Current vs. past use at 
event date 
uat_recent Classifies exposed patients as 
current or past users of a drug 
of interest at an event date 
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Function name R command Description 
Two prescriptions 
within a specific 
timeframe 
uat_gap Determines exposure based 
on a definition of two 
prescriptions within a set 
number of days 
Split follow-up into 
exposure windows  
uat_windows Splits the follow-up period 
into equal length time periods 
and determines exposure in 
each 
Daily-dose related methods   
Calculate cumulative 
daily doses 
dd_sum Calculates the total daily 




dd_duration Calculates the expected 
duration for each prescription 
based on daily doses 
prescribed 
Calculate prescribed 
daily doses dispensed 
calculate_pdd Calculated the prescribed 
daily dose per prescription 
based on dosage instructions 
Persistence   
Refill gap only refill_gap Determines persistence to 
medications based on the 
number of days between 
prescriptions only 
Refill gap with 
coverage  
refill_gap_dd Determines persistence to 
medications based on the 
number of days between the 
end of estimated supply and 
the next prescription 
Table 9 - Summary of the functions contained in the prescribeR package 
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3.4 Data standardisation (tidy_presc) 
3.4.1 Rationale 
The function described in this section converts the field names and data formats 
of the user’s data to the standards used with the rest of the functions in the 
prescribeR package. It was created to help maintain consistent object, variable 
and argument names throughout the rest of the package code to make it easier 
to read and understand, to provide a standard data structure for use when 
adding additional functions and to help minimise errors.  
The function was initially written as an independent function which the user 
needed to apply to their data manually before using the other functions in the 
package, which would require either overwriting the original copy of the data or 
creating a new copy with the correct formatting. During the process of testing 
the package, it was decided that neither of these options was ideal. Overwriting 
the original dataset would mean that if, for example, the user wished to use a 
different drug identifier they would need to either re-import the dataset or 
manually undo the changes to field names and formats to run the 
standardisation function(s) again. Holding multiple copies of a dataset within the 
global R environment can also be impractical, as it can become difficult to keep 
track of the different datasets and holding large amounts of data in memory can 
cause performance issues when running code, particularly when using larger data 
sets.  
In order to make the package more user friendly, the decision was made to have 
each of the other functions in the package run the standardisation function first. 
The arguments to the standardisation function correspond to the required fields 
from the rest of the package and are used to indicate which fields are of interest 
and to create a new, correctly formatted copy of the data internally before 
performing any other data transformations. This allows users to try different 
analysis options with relative ease, and without the need to make manual 
changes to their original datasets. For example, the ‘drug_id’ field is used 
throughout to filter the data for prescriptions for the drug(s) of interest. By 
selecting the relevant field within their prescribing data, the user can filter by 
different identifiers such as approved names, brand names or codes such as BNF 
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codes, Anatomical Therapeutic Chemical (ATC) classification system codes or 
National Drug Codes as desired. 
The standardisation function is still available for users to apply directly to their 
data if they prefer. This allows for the creation of tidy versions of their data 
within the global R environment, which would cut down on the number of 
arguments that need to be passed to the other functions as the standard name 
for each column is the default value for each of the column name arguments. 
Table 10 below gives the details of the fields used by the other functions, as 
well as the standard names and formats these fields are converted to by the 
standardisation function.  
 Field name Data type Example(s) 
Patient ID patient_id character 10001 
Drug ID drug_id character SIMVASTATIN 
212000 
Prescription date presc_date_x date 2020-01-31 
Quantity dispensed qty_disp number 56 
DDs dispensed dd_disp number 28 
Quantity per day qty_per_day number 1 
Event date(s) ev_date_1 
ev_date_2 
date 2021-12-31 




This function standardises the field names and formats of a chosen data frame 
(df). The user specifies the current name of each desired field to the matching 
argument, and the function returns a copy of the data frame with the standard 
field names. Each of the column name arguments is optional, and the function 
will check if they have been entered before attempting to rename the relevant 
column. Once a column has been renamed, the function converts its contents to 
the standard formats as described in Table 10. The user needs also to provide 
the format of the dates contained in their data to the ‘date_format’ argument 
as a string containing an R date format (e.g. for dates stored as “2000/12/31” 
the format is “%Y/%m/%d”). If defined incorrectly, R will coerce the data 
contained in the relevant fields to a date object using the format provided, 
which can result in incorrect dates. For example, if the date “31/12/2012” is 
passed to R as a string for conversion and the format argument provided is 
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“%Y/%m/%d”, R will convert the dates incorrectly and return “0031-12-20”. all 
of the transformations have been completed, the function outputs the 
reformatted copy of the data. Additionally, all of the dates in the chosen field 
need to be in the stated format to prevent erroneous conversions. Each of the 
other functions in the prescribeR has arguments for each of the required data 
fields which are passed to the ‘tidy_presc’ function to standardise the input data 
before analysis – the same function is used for both prescribing and events data 
in functions which use both, with a separate call to the function used for each 
dataset.  
3.4.3 Arguments 
• df - a data frame containing prescribing records to be standardised 
• patient_id_col - a string, the name of the column in df containing the 
patient IDs 
• drug_id_col - a string, the name of the column in df containing the drug 
identifier to be used 
• presc_date_col - a string, the name of the column in df containing the 
prescription date 
• dd_disp_col - a string, the name of the column in df containing the 
number of daily doses of the drug dispensed 
• qty_disp_col - a string, the name of the column containing the quantity of 
the drug dispensed 
• qty_per_day_col - a string, the name of the column containing the 
quantity of drug to be taken per day 
• ev_date_1_col - a string, the name of the column containing the first 
event date 
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• ev_date_2_col - a string, the name of the column containing the second 
set of event dates 
• date_format - a string containing the format of the dates used in df 
3.4.4 R Code 
tidy_presc <- function(df, 
                       patient_id_col = NULL, 
                       drug_id_col = NULL, 
                       presc_date_col = NULL, 
                       dd_disp_col = NULL, 
                       qty_disp_col = NULL, 
                       qty_per_day_col = NULL, 
                       ev_date_1_col = NULL, 
                       ev_date_2_col = NULL, 
                       date_format) { 
  df1 <- df 
  if (!is.null(patient_id_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(patient_id = patient_id_col) 
    df1$patient_id <- as.character(df1$patient_id) 
  } 
  if (!is.null(drug_id_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(drug_id = drug_id_col) 
    df1$drug_id <- as.character(df1$drug_id) 
  } 
  if (!is.null(presc_date_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(presc_date_x = presc_date_col) 
    df1$presc_date_x <- 
      as.Date(df1$presc_date_x, format = date_format) 
  } 
  if (!is.null(dd_disp_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(dd_disp = dd_disp_col) 
    df1$dd_disp <- as.numeric(df1$dd_disp) 
  } 
  if (!is.null(qty_disp_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(qty_disp = qty_disp_col) 
    df1$qty_disp <- as.numeric(df1$qty_disp) 
  } 
  if (!is.null(qty_per_day_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(qty_per_day = qty_per_day_col) 
    df1$qty_per_day <- as.numeric(df1$qty_per_day) 
  } 
  if (!is.null(ev_date_1_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(ev_date_1 = ev_date_1_col) 
    df1$ev_date_1 <- as.Date(df1$ev_date_1, format = date_format) 
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  } 
  if (!is.null(ev_date_2_col)) { 
    df1 <- df1 %>% 
      dplyr::rename(ev_date_2 = ev_date_2_col) 
    df1$ev_date_2 <- as.Date(df1$ev_date_2, format = date_format) 
  } 
  return(df1) 
} 
3.4.5 Usage example 
In the example below, the input data contains a single prescription record, with 
a similar structure to the ‘synth_presc’ data and field names and formats which 
are not those used by the prescribeR functions. The names of the columns of 
interest are passed to the corresponding arguments, and the function returns a 
modified version of the input data frame. Only the specified columns are altered 
– in the output shown below, for example, the ‘presc_date’ field has been 
converted to the date format and relabelled and the ‘drug_name’ field has been 













10001 12/06/2020 18/06/2020 SIMVASTATIN 02 
synth_presc_tidy <- tidy_presc( 
  df = synth_presc, 
  patient_id_col = "patient_id", 
  drug_id_col = "approved_name", 
  presc_date_col = "presc_date", 
  dd_disp_col = "ddd_dispensed", 













10001 2020-06-12 18/06/2020 SIMVASTATIN 02 
 
3.5 Functions for deriving data summaries 
These functions all create tables containing descriptive statistics based on the 
chosen prescribing dataset. By default, they provide summaries of the whole 
dataset, but the ‘drug’ argument gives users the option to limit the results to 
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specific drug IDs - this can mean specific drug names, classes such as BNF 
categories, or some other grouping depending on which field is provided to the 
drug ID column argument. 
3.5.1 Summarise prescribing data (presc_data_summary) 
3.5.1.1 Description 
This function generates a summary of the prescription data contained within a 
data frame of interest. The data are tidied by the ‘tidy_presc’ function, then 
filtered to remove prescriptions where the ‘drug_id’ value does not match the 
value of the ‘drug’ argument. The number of prescriptions, number of unique 
drugs (based on distinct values in the ‘drug_id’ column) and the date of the first 
and last prescription for each patient are calculated. If the ‘summary’ argument 
is FALSE, this is returned as the output. If the ‘summary’ argument is TRUE, the 
total number of patients, total number of prescriptions and the date range 
covered by the data as a whole are calculated, along with the median and 
interquartile range of the number of prescriptions per patient, and this summary 
is returned as the output. 
3.5.1.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug - a string representing drug identifier of interest - if no value is 
entered, the counts and dates returned represent the dataset as a whole. 
This argument accepts regular expressions to allow for searching based on 
exact codes or sections of codes corresponding to e.g. drug groups 
• summary – logical – if FALSE the function returns the full results for all 
patients and if true the function returns summary values describing the 
dataset as a whole; set to TRUE by default 
• patient_id_col, drug_id_col, presc_date_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
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• date_format - a string containing the format of the dates used in df 
3.5.1.3 R Code 
presc_data_summary <- 
  function(df, 
           drug = ".", 
           summary = TRUE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    summ1 <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    summ1 <- summ1 %>% 
      dplyr::group_by(.data$patient_id) %>% 
      dplyr::summarise( 
        n_presc = dplyr::n(), 
        n_drugs = dplyr::n_distinct(.data$drug_id), 
        first_presc = min(.data$presc_date_x), 
        last_presc = max(.data$presc_date_x) 
      ) 
    if (summary == TRUE) { 
      summ1 <- summ1 %>% 
        dplyr::summarise( 
          total_presc = sum(.data$n_presc), 
          n_pat = dplyr::n_distinct(.data$patient_id), 
          median_n_presc = stats::median(.data$n_presc), 
          iqr_n_presc = stats::IQR(.data$n_presc), 
          first_presc = min(.data$first_presc), 
          last_presc = max(.data$last_presc) 
        ) 
    } 
    return(summ1) 
  } 
3.5.1.4 Usage examples 
The two examples below provide summaries of the ‘synth_presc’ dataset, 
highlighting the different outputs which can be obtained from this function 
based on the value of the ‘summary’ argument. In the first example, the 
summary argument is set to TRUE, so the results are returned for each patient 
individually. In the second example, the ‘summary’ argument is FALSE, so the 
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function performs the extra step of summarising the individual patient results 
before providing output.   
3.5.1.4.1 Example 1 
ex1 <- presc_data_summary(df = synth_presc,  
                          summary = TRUE, 
                          patient_id_col = "patient_id", 
                          drug_id_col = "approved_name", 
                          presc_date_col = "presc_date") 
 
Output: 
patient_id n_presc n_drugs first_presc last_presc 
10001 12 1 2020-07-05 2022-03-01 
10002 13 1 2020-05-29 2022-02-20 
10003 6 2 2020-10-21 2021-05-22 
10004 8 1 2020-09-22 2021-08-02 
10005 5 1 2020-08-11 2020-11-27 
10006 15 3 2020-05-27 2022-01-01 
 
3.5.1.4.2 Example 2 
ex2 <- presc_data_summary(df = synth_presc,  
                          summary = FALSE, 
                          patient_id_col = "patient_id", 
                          drug_id_col = "approved_name", 
                          presc_date_col = "presc_date") 
Output: 
total_presc n_pat median_n_presc iqr_n_presc first_presc last_presc 
1478 100 13 10.75 2020-01-02 2023-09-17 
 
3.5.2 Most commonly prescribed drugs (presc_top_drugs) 
3.5.2.1 Description 
This function generates a list of the most commonly prescribed drugs within the 
dataset (based on unique values in the drug ID field). The chosen data frame is 
filtered by the drug identifier provided to the ‘drug’ argument, and the 
prescriptions for each ID within the remaining data are counted. By default, the 
top 10 drugs and corresponding counts are returned, but the number of drugs 
returned can be changed by adjusting the ‘rank’ argument. The function returns 
a data frame containing the top drug identifiers and the number of prescriptions 
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in the database for the requested number of drugs, in descending order from the 
most commonly prescribed. 
3.5.2.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a prescription date and a drug identifier 
• drug – a string containing a drug identifier of interest – if no value is 
entered the function uses the whole data set. This argument accepts 
regular expressions 
• rank - the number of drugs to return; default is to return the top 10 drugs 
• drug_id_col – a string, the name of the column in df containing the 
drug_id variable, passed to the tidy_presc function 
3.5.2.3 R Code 
presc_top_drugs <- 
  function(df, 
           drug = "*", 
           rank = 10, 
           drug_id_col = "drug_id") { 
    tidy_df <- tidy_presc(df, drug_id_col = drug_id_col) 
    freq <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    freq <- freq %>% 
      dplyr::group_by(.data$drug_id) %>% 
      dplyr::summarise(n_presc = dplyr::n()) 
    freq <- freq %>% 
      dplyr::top_n(rank, .data$n_presc) %>% 
      dplyr::arrange(dplyr::desc(.data$n_presc)) 
    return(freq) 
  } 
3.5.2.4 Usage example 
In the example shown below the output from the function is a list of the top 3 
most commonly prescribed drugs in the ‘synth_presc’ dataset by approved drug 
name (as defined by the ‘drug_id_col’ argument. The number of entries 
corresponds to the value specified to the ‘rank’ argument, with the number of 
prescriptions for each value calculated. 
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ex1 <- presc_top_drugs(df = synth_presc, 
                       rank = 3, 






3.5.3 Prescription time trends (presc_by_time) 
3.5.3.1 Description 
This function creates a breakdown of the number of prescriptions matching a 
chosen drug identifier over time. The dataset is filtered by the drug ID provided 
to the ‘drug’ argument if applicable. The total number of daily doses of each 
drug dispensed per date to each patient is calculated. If the input data does not 
contain the number of daily doses dispensed, a dummy variable is generated and 
then removed before the output is generated. If the ‘flatten’ argument is set to 
TRUE, the function reduces the dataset so that it contains only one prescription 
per drug ID and patient for each date. The month, year, quarter and semester 
are then extracted from each prescription’s date – quarters and semesters are 
defined by splitting the year into three and six month periods respectively. The 
prescriptions are grouped by one of these values depending on the value of the 
‘group’ argument, and the number of prescriptions and number of daily doses 
dispensed in each group is calculated. Output for this function is a data frame 
containing number of prescriptions, within each date group, along with the 
number of DDs dispensed if present in the data 
3.5.3.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug - a string corresponding to a drug identifier to be matched, regular 
expressions allowed 
• flatten –logical, if TRUE the function only counts one prescription per 
patient for each drug per date; default value is FALSE 
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• group - a string corresponding to the desired grouping for results - either 
month ("M"), quarter ("Q"), semester ("S") or year ("Y"); default is to group 
by year 
• patient_id_col, drug_id_col, presc_date_col, dd_disp_col - strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
• date_format - a string containing the format of the dates used in df 
3.5.3.3 R Code 
presc_by_time <- function(df, 
                          drug = "*", 
                          flatten = FALSE, 
                          group = "Y", 
                          drug_id_col = "drug_id", 
                          patient_id_col = "patient_id", 
                          presc_date_col = "presc_date_x", 
                          dd_disp_col = NULL, 
                          date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      drug_id_col = drug_id_col, 
      patient_id_col = patient_id_col, 
      presc_date_col = presc_date_col, 
      dd_disp_col = dd_disp_col, 
      date_format = date_format 
    ) 
  tidy_df <- tidy_df %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) 
  if (is.null(dd_disp_col)) { 
    tidy_df <- tidy_df %>% 
      dplyr::mutate(dd_disp = 0) 
  } 
  if (flatten == TRUE) { 
    tidy_df <- tidy_df %>% 
      dplyr::group_by(.data$patient_id, .data$presc_date_x, .data$drug_i
d) %>% 
      dplyr::mutate(sum_dd = sum(.data$dd_disp)) %>% 
      dplyr::ungroup() %>% 
      dplyr::select(.data$patient_id, 
                    .data$presc_date_x, 
                    .data$drug_id, 
                    dd_disp = .data$sum_dd) %>% 
      dplyr::distinct() 
  } 
  summ1 <- tidy_df %>% 
    dplyr::mutate( 
      presc_month = lubridate::month(.data$presc_date_x), 
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      presc_year = lubridate::year(.data$presc_date_x), 
      presc_quarter = lubridate::quarter(.data$presc_date_x, with_year = 
TRUE), 
      presc_semester = lubridate::semester(.data$presc_date_x, with_year 
= TRUE) 
    ) %>% 
    dplyr::select( 
      .data$patient_id, 
      .data$presc_date_x, 
      .data$drug_id, 
      .data$dd_disp, 
      .data$presc_month, 
      .data$presc_year, 
      .data$presc_quarter, 
      .data$presc_semester 
    ) 
  if (group == "Y") { 
    result <- summ1 %>% 
      dplyr::group_by(.data$presc_year) %>% 
      dplyr::summarise( 
        n_presc = dplyr::n(), 
        n_patients = dplyr::n_distinct(.data$patient_id), 
        total_dds = sum(.data$dd_disp) 
      ) 
  } else if (group == "M") { 
    result <- summ1 %>% 
      dplyr::group_by(.data$presc_year, .data$presc_month) %>% 
      dplyr::summarise( 
        n_presc = dplyr::n(), 
        n_patients = dplyr::n_distinct(.data$patient_id), 
        total_dds = sum(.data$dd_disp) 
      ) 
  } else if (group == "S") { 
    result <- summ1 %>% 
      dplyr::group_by(.data$presc_semester) %>% 
      dplyr::summarise( 
        n_presc = dplyr::n(), 
        n_patients = dplyr::n_distinct(.data$patient_id), 
        total_dds = sum(.data$dd_disp) 
      ) 
  } else if (group == "Q") { 
    result <- summ1 %>% 
      dplyr::group_by(.data$presc_quarter) %>% 
      dplyr::summarise( 
        n_presc = dplyr::n(), 
        n_patients = dplyr::n_distinct(.data$patient_id), 
        total_dds = sum(.data$dd_disp) 
      ) 
  } 
  if (is.null(dd_disp_col)) { 
    result <- result %>% 
      dplyr::select(-.data$total_dds) 
  } 
  return(result) 
} 
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3.5.3.4 Usage examples 
The examples shown below highlight different outputs available using this 
function. In the first example, the number of prescriptions and number of 
patients with at least 1 prescription for atorvastatin are returned by year. 
Additionally, the ‘flatten’ argument is set to TRUE, meaning the total number of 
prescriptions returned only counts one prescription per patient per date. In the 
second example, the results are returned by quarter instead of by year. The 
output also contains the total DDDs dispensed as a column name was passed to 
the ‘dd_disp_col’ argument. The ‘drug_id’ column of interest is the BNF section, 
so the results represent the number of patients prescribed any drug in that 
section each quarter. 
3.5.3.4.1 Example 1 
ex1 <- presc_by_time(df = synth_presc,  
                     drug = "ATORVASTATIN",  
                     group = "Y",  
                     flatten = TRUE, 
                     drug_id_col = "approved_name",  




presc_year n_presc n_patients 
2020 94 23 
2021 68 14 
2022 16 5 
2023 5 2 
 
3.5.3.4.2 Example 2		
ex2 <- presc_by_time(df = synth_presc,  
                     drug = "212",  
                     group = "Q", 
                     drug_id_col = "bnf_section",  
                     presc_date_col = "presc_date",  
                     dd_disp_col = "ddd_dispensed") 
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Output: 
presc_quarter n_presc n_patients total_dds 
2020.1 22 14 1260.000 
2020.2 69 39 4559.333 
2020.3 113 62 6757.333 
2020.4 151 79 8549.333 
2021.1 150 78 8885.333 
2021.2 134 71 7728.000 
 
3.6 Ever use (ever_use) 
3.6.1 Rationale 
The simplest method for defining drug exposure based on prescribing data is to 
classify any subject who has ever had a prescription for the drug of interest as 
exposed, and those who have not as unexposed. Splitting subjects into two 
groups in this manner allows for the comparison of outcomes between those who 
are unexposed and exposed to assess the effectiveness of the drug of interest. 
Additionally, determining the subjects who were exposed to the drug of interest 
allows for further analysis of these subjects, for example assessing different 
levels of exposure or patterns of utilisation of the drug of interest. For the most 
part, ever use provides a dichotomous variable, which can be useful as a factor 
for inclusion in statistical models of risk.  
The studies reviewed in the previous chapter highlighted some variants and 
extensions to the ever use methodology. The threshold for classification of 
exposure could be higher than just one prescription in order to try and focus in 
on recurrent use as opposed to incident use, or cases where the drug was 
discontinued soon after prescription. In cases where a higher threshold is used, 
patients who have been prescribed the drug but did not meet the threshold for 
exposure are classified as unexposed. The number of prescriptions may also be 
of use in some cases to further classify extent of exposure, providing a 
continuous variable in addition to the categorical classification of exposure. 
After determining ever use, the date of the first prescription is often then used 
as an index date for exposure to determine when the patients entered into the 
cohort being created. Additionally, as well as considering ever use of a single 
drug, it could also be useful to consider more than one drug as a measure of co-
prescribing or polypharmacy, or exposure to one or more of a group of drugs, 
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e.g. all of the drugs appearing with a particular section of the BNF, as opposed 
to a single drug of interest. 
3.6.2 Description 
The function takes a data frame containing records of individual prescriptions 
(df) and applies the ‘tidy_presc’ function using the column IDs provided. A list of 
all of the patient IDs contained within df is created. The data are then filtered 
to remove prescriptions which do not match the drug identifier provided in the 
‘drug’ argument. If the ‘flatten’ argument is set to true, the function filters the 
dataset so that only one prescription per unique drug identifier is included for 
each patient per date. Next, the rows are grouped by patient ID and the date of 
the first prescription and number of prescriptions for each is determined. The 
function then assigns a flag to each patient record indicating if they meet the 
threshold for exposure (1) or not (0). In cases where the value of the ‘threshold’  
argument is not 1, patients who have prescriptions for the drug(s) but do not 
meet the threshold are classified as unexposed. If the ‘return_all’ argument is 
set to FALSE, patients who did not meet the threshold for exposure are removed 
from the result. If the ‘return_all’ argument Is set to TRUE, the result contains 
all of the patients from the input along with the exposure flags. If the ‘summary’ 
argument is set to FALSE, only the patient IDs and exposure flags are returned, 
whereas if the ‘summary’ variable is set to TRUE, the dates of first prescriptions 
and the total number of prescriptions per patient are also included in the 
output. 
3.6.3 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug – A string containing the drug identifier be matched, regular 
expressions allowed 
• flatten – logical, if TRUE the function only counts one prescription per 
unique drug identifier per date for each patient, default value is FALSE 
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• threshold – The minimum number of prescriptions that must be present 
for the patient’s ID to be included in the results; default value is 1 
• summary – If TRUE, the results returned will include the total number of 
prescriptions and the date of the first prescription for each patient ID 
where the number of prescriptions was more than the threshold value, 
default value is FALSE 
• return_all – logical, if TRUE the function returns all patient IDs from the 
original dataset along with a flag indicating if they met the threshold for 
exposure or not. If FALSE, the function only returns the details of the 
patients who met the threshold, default value is FALSE  
• patient_id_col, drug_id_col, presc_date_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
• date_format - a string containing the format of the dates used in df 
•  
3.6.4 R code 
ever_use <- 
  function(df, 
           drug, 
           flatten = FALSE, 
           threshold = 1, 
           summary = FALSE, 
           return_all = FALSE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    ids <- tidy_df %>% 
      dplyr::select(.data$patient_id) %>% 
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      dplyr::distinct() 
    ever1 <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    if (flatten == TRUE) { 
      ever1 <- ever1 %>% 
        dplyr::distinct(.data$patient_id, .data$drug_id, .data$presc_dat
e_x) 
    } 
    ever1 <- ever1 %>% 
      dplyr::group_by(.data$patient_id) %>% 
      dplyr::summarise(n_presc = dplyr::n(), 
                       first_presc = min(.data$presc_date_x)) %>% 
      dplyr::mutate(exposed = ifelse(.data$n_presc >= threshold, 1, 0)) 
    if (return_all == FALSE) { 
      ever1 <- ever1 %>% 
        dplyr::filter(.data$exposed == 1) 
    } else if (return_all == TRUE) { 
      ever1 <- dplyr::left_join(ids, ever1, by = "patient_id") 
      ever1$n_presc[is.na(ever1$n_presc)] <- 0 
      ever1$exposed[is.na(ever1$exposed)] <- 0 
    } 
    if (summary == TRUE) { 
      return(ever1) 
    } else if (summary == FALSE) { 
      ever1 <- ever1 %>% 
        dplyr::select(.data$patient_id, .data$exposed) 
      return(ever1) 
    } 
  } 
3.6.5 Usage examples 
In the first example below, the output contains a list of IDs corresponding to 
patients who had at least 1 prescription for omeprazole in the ‘synth_presc’ 
dataset. Since the summary and ‘return_all’ arguments are both FALSE by 
default, only the IDs for patients who met the threshold were returned. In the 
second example, the ‘summary’ argument is TRUE, so the number of 
prescriptions and the date of the first prescription are also returned for each 
patient. As the ‘return_all’ argument is set to TRUE, data was returned for all 
patients, with the flag indicating if they were exposed (=1) or unexposed (=0) 
based on the provided threshold. In this case, the ‘threshold’ argument was set 
to 2, meaning that patients with only 1 prescription are classified as unexposed. 
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3.6.5.1.1 Example 1 
ex1 <- ever_use(df = synth_presc,  
                drug = "OMEPRAZOLE",  
                summary = FALSE,  
                patient_id_col = "patient_id",  
                drug_id_col = "approved_name",  










3.6.5.1.2 Example 2  
ex2 <- ever_use(df = synth_presc,  
                drug = "OMEPRAZOLE",  
                summary = TRUE,  
                flatten = TRUE, 
                threshold = 2,  
                return_all = TRUE, 
                patient_id_col = "patient_id",  
                drug_id_col = "approved_name",  
                presc_date_col = "presc_date") 
Output 
patient_id n_presc first_presc exposed 
10001 0 NA 0 
10002 0 NA 0 
10003 2 2020-10-21 1 
10004 0 NA 0 
10005 0 NA 0 
10006 1 2020-12-10 0 
 
3.7 Use at time point 
3.7.1 Rationale 
Use at time point methods build on the ever use method described above by 
considering whether or not patients were prescribed a drug during a specific 
time period of interest. As with ever use, this often involves generating a 
categorical exposure variable, and can be a way of selecting a cohort of patients 
for further analysis - the definition of the timeframe of interest will depend on 
the research question. For example, exposure before a date of interest, either 
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at any time or within a set number of days, could be considered as part of 
assessing the impact of exposure to the drug of interest on the risk of an 
outcome of interest such as hospitalisation or death. This can be further refined 
by splitting subjects into those who were current or past users at the time of an 
event based on how recent their last prescription before the event date was. 
Exposure after a date of interest, including at set time points or within specific 
intervals can be used when examining effectiveness ongoing drug therapy after 
an event such as hospitalisation. Exposure can also be defined as a time-varying 
covariate by splitting follow-up time into windows of equal length and then 
determining whether patients were prescribed the drug of interest during each 
window.  
3.7.2 Fixed date range (uat_fixed) 
3.7.2.1 Description 
This function determines which patients were exposed to the drug(s) of interest 
within a standardised timeframe for all patients. After tidying the data through 
a call to the ‘tidy_presc’ function, the dataset is filtered to select prescriptions 
for the drug(s) of interest based on the drug identifier provided (‘drug’). If the 
‘flatten’ argument is set to true, the data are filtered to include only one 
prescription per unique drug ID for each patient per date. The definition of the 
timeframe of interest is then determined based on the ‘date_1’, ‘timeframe’ 
and ‘forward’ arguments. If the ‘timeframe’ argument is set to 0, the function 
filters for all prescriptions either before (‘forward = FALSE’) or after (‘forward = 
TRUE’) the date of interest entered in ‘date_1’. For other values of the 
‘timeframe’ argument, the function determines a second date by either adding 
or subtracting that number of days, based on the ‘forward’ variable as above, 
and then filters for prescription dates that fall within this timeframe. The 
function then returns the number of prescriptions and first prescription date 
within the timeframe of interest for each patient. 
3.7.2.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
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• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed 
• flatten – logical, if TRUE the function only counts one prescription per 
unique drug identifier per date for each patient 
• date_1 – a string containing the date of interest - depending on the value 
of forward, this is either the start or end date of the time window of 
interest 
• timeframe - the number of days in the time frame of interest - defaults to 
0, which means the function will check for any prescriptions before or 
after the date of interest depending on the value of forward 
• forward - when TRUE, the function will check for prescriptions after the 
date of interest, or when a value for timeframe is provided it will be 
added to the date to determine the end date. When FALSE, function 
checks for prescriptions before the date of interest, or the value of 
timeframe is subtracted to determine the start date of the window; set to 
TRUE by default 
• patient_id_col, drug_id_col, presc_date_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
• date_format - a string containing the format of the dates used in df 
3.7.2.3 R code 
uat_fixed <- 
  function(df, 
           drug, 
           date_1, 
           flatten = FALSE, 
           timeframe = 0, 
           forward = TRUE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
           date_format) { 
    tidy_df <- 
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      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    uat1 <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    if (flatten == TRUE) { 
      uat1 <- uat1 %>% 
        dplyr::distinct(.data$patient_id, .data$drug_id, .data$presc_dat
e_x) 
    } 
    date_1 <- as.Date(date_1, format = date_format) 
    if ((forward == TRUE) && (timeframe == 0)) { 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$presc_date_x >= date_1) 
    } else if ((forward == FALSE) && (timeframe == 0)) { 
      uat1 <- uat1 %>% 
        dplyr::filter(date_1 >= .data$presc_date_x) 
    } else if ((forward == TRUE) && (timeframe > 0)) { 
      date_2 <- date_1 + timeframe 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$presc_date_x >= date_1 & 
                        .data$presc_date_x <= date_2) 
    } else if ((forward == FALSE) && (timeframe > 0)) { 
      date_2 <- date_1 - timeframe 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$presc_date_x <= date_1 & 
                        .data$presc_date_x >= date_2) 
    } 
    uat_result <- uat1 %>% 
      dplyr::group_by(.data$patient_id) %>% 
      dplyr::summarise(n_presc = dplyr::n(), 
                       first_presc = min(.data$presc_date_x)) 
    return(uat_result) 
  } 
 
 
3.7.2.4 Usage examples  
The examples below highlight how the ‘timeframe’ argument alters the output 
from this function. In the first example, the value of the argument is set to 0, 
which means that the output contains details of the patients who had at least 1 
prescription for citalopram at any time after 01/01/2021, the value passed to 
the ‘date_1’ argument. In the second example, the ‘timeframe’ argument is set 
to 180, so only prescriptions in the 180 days after 01/01/2021 are used to define 
exposure, and therefore the number of prescriptions for some patients is lower 
than in the first example. 
  88 
 
3.7.2.4.1 Example 1 
ex1 <- uat_fixed(df = synth_presc, 
                 drug = "CITALOPRAM", 
                 date_1 = "2021-01-01", 
                 timeframe = 0, 
                 forward = TRUE, 
                 patient_id_col = "patient_id", 
                 drug_id_col = "approved_name", 
                 presc_date_col = "presc_date") 
patient_id n_presc first_presc 
10009 8 2021-01-22 
10035 2 2021-02-22 
10041 7 2021-01-17 
10061 6 2021-01-23 
10076 8 2021-01-21 
10083 3 2021-01-08 
 
3.7.2.4.2 Example 2 
ex2 <- uat_fixed(df = synth_presc, 
                 drug = "CITALOPRAM", 
                 date_1 = "2021-01-01", 
                 timeframe = 180, 
                 forward = TRUE, 
                 patient_id_col = "patient_id", 
                 drug_id_col = "approved_name", 
                 presc_date_col = "presc_date") 
patient_id n_presc first_presc 
10009 4 2021-01-22 
10035 2 2021-02-22 
10041 5 2021-01-17 
10061 3 2021-01-23 
10076 5 2021-01-21 
10083 3 2021-01-08 
 
3.7.3 Fixed range from individual patient event dates 
(uat_fixed_events) 
3.7.3.1 Description 
This function determines if patients had at least 1 prescription for the drug(s) of 
interest within a timeframe of interest, based on a standardised timeframe from 
patient-specific event dates. The prescription (‘df’) and events data (‘df2’) are 
standardised using the ‘tidy_presc’ function, the event dates contained in ‘df2’ 
are joined to the prescribing data, matched by the patient IDs and patients 
without a listed event date are removed. The data are filtered for prescriptions 
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matching the drug ID provided. If the ‘flatten’ argument is set to TRUE, the data 
are filtered to include only one prescription for each drug ID per date for each 
patient. If the timeframe argument is set to 0, the function filters for 
prescriptions at any point before or after before the event date (if ‘forward = 
FALSE’) or after the event date (‘forward = TRUE’). If the timeframe argument is 
not equal to zero, the function determines a start or end date by subtracting or 
adding the timeframe value, in days, from the event date, and filters for 
prescriptions that fall within this window (again depending on the value of the 
‘forward’ argument). The function then determines the first prescription date 
within the window and the number of prescriptions for each patient and returns 
these values.  
3.7.3.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• df2 – a data frame containing patient event records, consisting of at least 
a patient ID and an event date 
• drug - a string containing the identifier for the drug of interest, regular 
expressions allowed 
• flatten – logical, if TRUE the function only counts one prescription per 
unique drug identifier per date for each patient, FALSE by default 
• timeframe - the number of days in the time frame of interest - defaults to 
0, which means the function will check for any prescriptions before or 
after the date of interest depending on the value of forward 
• forward - when TRUE, the function will check for prescriptions after the 
date of interest, or when a value for timeframe is provided it will be 
added to the date to determine the end date. When FALSE, function 
checks for prescriptions before the date of interest, or the value of 
timeframe is subtracted to determine the start date of the window; set to 
TRUE by default 
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• patient_id_col, drug_id_col, presc_date_col, ev_date_col - strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
• date_format - a string containing the format of the dates used in df 
3.7.3.3 R code 
uat_fixed_events <- 
  function(df, 
           df2, 
           drug, 
           flatten = FALSE, 
           timeframe = 0, 
           forward = TRUE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
           ev_date_col = "ev_date_1", 
           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    tidy_ev <- 
      tidy_presc( 
        df2, 
        patient_id_col = patient_id_col, 
        ev_date_1_col = ev_date_col, 
        date_format = date_format 
      ) 
    uat1 <- dplyr::left_join(tidy_df, tidy_ev, by = "patient_id") 
    uat1 <- dplyr::filter(uat1,!is.na(.data$ev_date_1)) 
    uat1 <- uat1 %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    if (flatten == TRUE) { 
      uat1 <- uat1 %>% 
        dplyr::distinct(.data$patient_id, .data$drug_id, .data$presc_dat
e_x) 
    } 
    if ((forward == TRUE) && (timeframe == 0)) { 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$presc_date_x >= .data$ev_date_1) 
    } else if ((forward == FALSE) && (timeframe == 0)) { 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$ev_date_1 >= .data$presc_date_x) 
    } else if ((forward == TRUE) && (timeframe > 0)) { 
      uat1 <- uat1 %>% 
        dplyr::filter( 
  91 
 
          .data$presc_date_x >= .data$ev_date_1 & 
            .data$presc_date_x <= .data$ev_date_1 + timeframe 
        ) 
    } else if ((forward == FALSE) && (timeframe > 0)) { 
      uat1 <- uat1 %>% 
        dplyr::filter( 
          .data$presc_date_x <= .data$ev_date_1 & 
            .data$presc_date_x >= .data$ev_date_1 - timeframe 
        ) 
    } 
    uat_result <- uat1 %>% 
      dplyr::group_by(.data$patient_id) %>% 
      dplyr::summarise(n_presc = dplyr::n(), 
                       first_presc = min(.data$presc_date_x)) 
    return(uat_result) 
  } 
3.7.3.4 Usage example 
The example below shows a summary of the number of patients in the 
‘synth_presc’ dataset who had at least 1 prescription for any drug listed in BNF 
sub-section 2.12.00 in the 180 days before their first event from the 
‘synth_events’ dataset. Since the forward argument is ‘TRUE’, the value of 
‘timeframe’ is subtracted from the value of ‘event_1’ to determine the 
timeframe of interest.  
ex1 <- uat_fixed_events(df = synth_presc,  
                        df2 = synth_events, 
                        drug = "21200", 
                        timeframe = 180, 
                        forward = FALSE, 
                        patient_id_col = "patient_id", 
                        drug_id_col = "bnf_subsection", 
                        presc_date_col = "presc_date",  
                        ev_date_col = "event_1") 
patient_id n_presc first_presc 
10002 1 2020-05-29 
10003 1 2020-11-12 
10004 4 2021-01-25 
10006 2 2020-05-27 
10010 1 2020-07-02 
10011 4 2020-06-08 
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3.7.4 Individual patient date ranges (uat_var_events) 
3.7.4.1 Description 
This function determines if patients were exposed to the drug(s) of interest 
during timeframes based on patient-specific event dates (e.g. start and end of 
follow up, between two hospitalisations). Both datasets are standardised using 
the ‘tidy_presc’ function, the event dates are joined on to the prescribing 
records based on patient IDs and data for any patients who do not have two 
event dates listed are removed. The data are then filtered to select 
prescriptions where the drug ID matches the value provided in the ‘drug’ 
argument and filtered again to select prescriptions which fall between the two 
event dates, i.e. the prescribed date value is greater than the first event date 
but less than the second. If the ‘flatten’ argument is set to true, the function 
filters the dataset so that only one prescription per unique drug identifier is 
included for each patient per date. Once the relevant prescriptions are selected, 
the number of prescriptions per patient and date of each patient’s first 
prescription are determined and returned. 
3.7.4.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• df2 – a data frame containing event records consisting of at least a patient 
ID two event dates per patient 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
• flatten – logical, if TRUE the function only counts one prescription per 
unique drug identifier per date for each patient, FALSE by default 
• patient_id_col, drug_id_col, presc_date_col, ev_date_1_col, 
ev_date_2_col - strings, the names of the columns in df containing 
necessary variables, passed to the tidy_presc function 
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• date_format - a string containing the format of the dates used in df 
3.7.4.3 R code 
uat_var_events <- function(df, 
                           df2, 
                           drug, 
                           flatten = FALSE, 
                           patient_id_col = "patient_id", 
                           drug_id_col = "drug_id", 
                           presc_date_col = "presc_date_x", 
                           ev_date_1_col = "ev_date_1", 
                           ev_date_2_col = "ev_date_2", 
                           date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      patient_id_col = patient_id_col, 
      drug_id_col = drug_id_col, 
      presc_date_col = presc_date_col, 
      date_format = date_format 
    ) 
  tidy_ev <- tidy_presc( 
    df2, 
    patient_id_col = patient_id_col, 
    ev_date_1_col = ev_date_1_col, 
    ev_date_2_col = ev_date_2_col, 
    date_format = date_format 
  ) 
  uat1 <- dplyr::left_join(tidy_df, tidy_ev, by = "patient_id") 
  uat1 <- 
    dplyr::filter(uat1,!is.na(.data$ev_date_1) & 
                    !is.na(.data$ev_date_2)) 
  uat1 <- uat1 %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) 
  if (flatten == TRUE) { 
    uat1 <- uat1 %>% 
      dplyr::distinct(.data$patient_id, .data$drug_id, .data$presc_date_
x) 
  } 
    uat1 <- uat1 %>% 
      dplyr::filter(.data$presc_date_x > .data$ev_date_1 & 
                      .data$presc_date_x < .data$ev_date_2) 
  uat_result <- uat1 %>% 
    dplyr::group_by(.data$patient_id) %>% 
    dplyr::summarise(n_presc = dplyr::n(), 
                     first_presc = min(.data$presc_date_x)) 
  return(uat_result) 
} 
3.7.4.4 Usage example 
The example below shows the format of the output from this function, in this 
case a list of patients who were exposed to a drug from BNF section 4.03 in 
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between two hospitalisations (‘event_1’ and ‘event_2’). The definition of 
exposure in this function requires a value for both event dates, so only patients 
who have an event listed in both of the specified fields and at least 1 
prescription between those two dates are included in the output. 
ex1 <- uat_var_events(df = synth_presc,  
                      df2 = synth_events, 
                      drug = "403", 
                      patient_id_col = "patient_id", 
                      drug_id_col = "bnf_section", 
                      presc_date_col = "presc_date", 
                      ev_date_1_col = "event_1", 
                      ev_date_2_col = "event_2") 
patient_id n_presc first_presc 
10061 1 2020-09-11 
10076 1 2020-10-23 
10083 2 2020-09-11 
 
3.7.5 New users – fixed start date (new_users_fixed) 
3.7.5.1 Description 
This function determines whether patients are classified as new or existing users 
of the drug(s) of interest at a fixed start date. The prescribing records are 
standardised using the ‘tidy_presc’ function, and a copy of all patient IDs in the 
data are stored for later use. The records are filtered for prescriptions matching 
the drug ID provided in the ‘drug’ argument. If the timeframe argument is equal 
to 0, any patient with a prescription before the date given in the ‘start_date’ 
argument is flagged as an existing user. If the ‘timeframe’ argument is not equal 
to zero, the value of ‘timeframe’ is subtracted from ‘start_date’ to give the 
start of the lookback period, and any patients with prescriptions in that period is 
flagged as an existing user. Patients are then flagged as exposed or unexposed 
based on if they have at least 1 prescription during the period after the start 
date, and the first prescription date is recorded where applicable. The flags for 
existing users are then combined with the exposure status during follow-up, and 
any patients who are not flagged as existing users but are flagged as exposed 
during follow-up are flagged as new users. If the ‘return_all’ argument is FALSE, 
the data are then filtered to contain only new users exposed during follow-up. 
Otherwise, data for all patients is returned, with a flag indicating exposure and 
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new user status and the date of the first prescription for the drug(s) of interest 
after the start date. 
3.7.5.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
• start_date – a string, containing the date to be used as the start of follow-
up in the same format as the dates contained in df 
• timeframe – a number, the desired length of lookback period in days. If 
set to 0, all prescriptions before the start date will be used, default value 
is 0 
• return_all – logical, if TRUE only records for new users exposed during the 
period after the start date will be returned, if FALSE records will be 
returned for all patients with flags indicating if they were exposed and if 
they are a new user; default value is TRUE 
• patient_id_col, drug_id_col, presc_date_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
• date_format - a string containing the format of the dates used in df 
3.7.5.3 R code 
new_users_fixed <- 
  function(df, 
           drug, 
           start_date = NULL, 
           timeframe = 0, 
           return_all = TRUE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
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           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    ids <- tidy_df %>% 
      dplyr::select(.data$patient_id) %>% 
      dplyr::distinct() 
    tidy_df <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    start_date <- as.Date(start_date, format = date_format) 
    if (timeframe == 0) { 
      uat1 <- tidy_df %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::filter(.data$presc_date_x < start_date) %>% 
        dplyr::distinct(.data$patient_id) %>% 
        dplyr::mutate(new_user = 0) 
    } else if (timeframe != 0) { 
      uat1 <- tidy_df %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::filter(.data$presc_date_x < start_date & 
                        .data$presc_date_x > start_date - timeframe) %>% 
        dplyr::distinct(.data$patient_id) %>% 
        dplyr::mutate(new_user = 0) 
    } 
    uat2 <- tidy_df %>% 
      dplyr::group_by(.data$patient_id) %>% 
      dplyr::filter(.data$presc_date_x >= start_date) %>% 
      dplyr::summarise(first_presc = min(.data$presc_date_x)) %>% 
      dplyr::mutate(exposed = 1) 
    uat1 <- dplyr::left_join(ids, uat1, by = "patient_id") 
    uat1 <- dplyr::left_join(uat1, uat2, by = "patient_id") 
    uat1$new_user[is.na(uat1$new_user) & uat1$exposed == 1] <- 1 
    uat1$exposed[is.na(uat1$exposed)] <- 0 
    if (return_all == FALSE) { 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$exposed == 1 & .data$new_user == 1) 
      return(uat1) 
    } else { 
      return(uat1) 
    } 
  } 
3.7.5.4 Usage example 
In the example below, the patients in ‘synth_presc’ are split into new and 
existing users based on a lookback period of 45 days from 01/01/2021. In the 
output, patients who have a ‘new_user’ flag value of 1 did not have a 
prescription for the drug of interest in the lookback period defined, whereas 
patients who have a value of 0 had at least 1. Patients flagged as exposed had at 
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least 1 prescription for the drug of interest after this date. If the ‘return_all’ 
argument had been set to FALSE, only new users who were exposed during 
follow-up (i.e. patients who were flagged 1 in both columns) would be returned. 
ex1 <- new_users_fixed(df = synth_presc, 
                       drug = "SIMVASTATIN", 
                       start_date = "2021-01-01", 
                       timeframe = 45, 
                       return_all = TRUE, 
                       patient_id_col = "patient_id", 
                       drug_id_col = "approved_name", 
                       presc_date_col = "presc_date") 
patient_id new_user first_presc exposed 
10001 1 2021-01-02 1 
10002 0 2021-01-22 1 
10003 1 2021-01-29 1 
10004 1 2021-01-25 1 
10005 NA NA 0 
10006 0 2021-01-08 1 
  
3.7.6 New users – individual start dates (new_users_var) 
3.7.6.1 Description 
This function classifies patients as new or existing users of the drug(s) of interest 
at patient-specific start dates. The prescribing and events data are standardised 
using the ‘tidy_presc’ function, the event dates are joined onto the prescription 
records by patient ID and records for patients who do not have an event date are 
removed. A list of the remaining patient IDs is stored for future use. The data 
are filtered for prescriptions where the drug ID matches the ‘drug’ argument. If 
the timeframe argument is equal to 0, patients who have a prescription at any 
time before their listed event date are flagged as existing users. If the 
‘timeframe’ argument is not 0, the value is subtracted from the event dates to 
determine the start of the lookback period for each patient, and patients with 
prescriptions during that period are flagged as existing users. The patients are 
then flagged as exposed or unexposed to the drug(s) of interest based on 
whether or not they have a prescription after their event date, and the date of 
their first prescription is stored. The flags for existing users are added to the 
exposure status, and patients who are exposed but are not existing users are 
marked as new users. If the ‘return_all’ argument is FALSE, the data are then 
filtered to contain only new users exposed during follow-up. Otherwise, data for 
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all patients is returned, with a flag indicating exposure and new user status and 
the date of the first prescription for the drug(s) of interest after their event 
date.  
3.7.6.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• df2 – a data frame containing patient event records consisting of at least a 
patient ID and an event date 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
• timeframe – a number, the desired length of lookback period in days. If 
set to 0, all prescriptions before the start date will be used; default value 
is 0 
• return_all – logical, if TRUE only records for new users exposed during the 
period after the start date will be returned, if FALSE records will be 
returned for all patients with flags indicating if they were exposed and if 
they are a new user; set to TRUE by default 
• patient_id_col, drug_id_col, presc_date_col, ev_date_col - strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
• date_format - a string containing the format of the dates used in df 
3.7.6.3 R code 
new_users_var <- 
  function(df, 
           df2, 
           drug, 
           timeframe = 0, 
           return_all = TRUE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
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           presc_date_col = "presc_date_x", 
           ev_date_col = "ev_date_1", 
           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    tidy_ev <- 
      tidy_presc( 
        df2, 
        patient_id_col = patient_id_col, 
        ev_date_1_col = ev_date_col, 
        date_format = date_format 
      ) 
    tidy_df <- dplyr::left_join(tidy_df, tidy_ev, by = "patient_id") 
    tidy_df <- dplyr::filter(tidy_df,!is.na(.data$ev_date_1)) 
    ids <- tidy_df %>% 
      dplyr::select(.data$patient_id) %>% 
      dplyr::distinct() 
    tidy_df <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    if (timeframe == 0) { 
      uat1 <- tidy_df %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::filter(.data$presc_date_x < .data$ev_date_1) %>% 
        dplyr::distinct(.data$patient_id) %>% 
        dplyr::mutate(new_user = 0) 
    } else if (timeframe != 0) { 
      uat1 <- tidy_df %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::filter( 
          .data$presc_date_x < .data$ev_date_1 & 
            .data$presc_date_x > .data$ev_date_1 - timeframe 
        ) %>% 
        dplyr::distinct(.data$patient_id) %>% 
        dplyr::mutate(new_user = 0) 
    } 
    uat2 <- tidy_df %>% 
      dplyr::group_by(.data$patient_id) %>% 
      dplyr::filter(.data$presc_date_x >= .data$ev_date_1) %>% 
      dplyr::summarise(first_presc = min(.data$presc_date_x)) %>% 
      dplyr::mutate(exposed = 1) 
    uat1 <- dplyr::left_join(ids, uat1, by = "patient_id") 
    uat1 <- dplyr::left_join(uat1, uat2, by = "patient_id") 
    uat1$new_user[is.na(uat1$new_user) & uat1$exposed == 1] <- 1 
    uat1$exposed[is.na(uat1$exposed)] <- 0 
    if (return_all == FALSE) { 
      uat1 <- uat1 %>% 
        dplyr::filter(.data$exposed == 1 & .data$new_user == 1) 
      return(uat1) 
    } else { 
      return(uat1) 
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    } 
  } 
3.7.6.4 Usage example 
In the example below, patients are classified as new users if they did not have a 
prescription for omeprazole at any point before their first hospitalisation 
(‘event_1’). The ‘return_all’ argument is set to FALSE, so only data for patients 
who had a prescription after the event date and none before is returned. 
ex1 <- new_users_var(df = synth_presc, 
                     df2 = synth_events, 
                     drug = "OMEPRAZOLE", 
                     timeframe = 0, 
                     return_all = FALSE, 
                     patient_id_col = "patient_id", 
                     drug_id_col = "approved_name", 
                     presc_date_col = "presc_date", 
                     ev_date_col = "event_1") 
patient_id new_user first_presc exposed 
10006 1 2020-12-10 1 
10010 1 2020-10-18 1 
10015 1 2020-10-04 1 
10034 1 2020-12-18 1 
10038 1 2020-09-06 1 
10051 1 2020-08-17 1 
 
3.7.7 Current vs. past use at event date (uat_recent) 
3.7.7.1 Description 
This function defines the recentness of patients’ exposure to the drug(s) of 
interest at an event of interest, based on a user-selected cut-off for current vs. 
past use. The prescribing and events data are tidied using the ‘tidy_presc’ 
function, the event dates are appended to the prescribing data based on patient 
ID and records for patient without an event date are removed. The data are 
filtered to select only records which match the drug ID provided in the ‘drug’ 
argument and to remove any prescriptions from after the event date. This also 
filters out patients who have never had a prescription for the drug(s) of interest. 
Individual prescriptions are flagged as current use or past use at the event date 
based on whether or not the prescription date is during the recent use period. 
The start of the recent use period is calculated by subtracting the value of the 
‘timeframe’ argument from the patients’ event date. The number of 
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prescriptions each patient had during the recent and past use periods is 
calculated, and patients are categorised as current or past users at the event 
date based on whether or not they have at least 1 recent prescription. The 
prescription counts and categories are returned as output. 
3.7.7.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• df2 – a data frame containing patient event records consisting of at least a 
patient ID and an event date 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
• timeframe – a number, the desired number of days before the event date 
where prescriptions should be classified as recent use 
• patient_id_col, drug_id_col, presc_date_col, ev_date_col - strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
• date_format - a string containing the format of the dates used in df 
3.7.7.3 R code 
uat_recent <- function(df, 
                       df2, 
                       drug, 
                       timeframe, 
                       patient_id_col = "patient_id", 
                       drug_id_col = "drug_id", 
                       presc_date_col = "presc_date_x", 
                       ev_date_col = "ev_date_1", 
                       date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      patient_id_col = patient_id_col, 
      drug_id_col = drug_id_col, 
      presc_date_col = presc_date_col, 
      date_format = date_format 
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    ) 
  tidy_ev <- 
    tidy_presc( 
      df2, 
      patient_id_col = patient_id_col, 
      ev_date_1_col = ev_date_col, 
      date_format = date_format 
    ) 
  uat1 <- dplyr::left_join(tidy_df, tidy_ev, by = "patient_id") 
  uat1 <- dplyr::filter(uat1,!is.na(.data$ev_date_1)) 
  uat1 <- uat1 %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) %>% 
    dplyr::filter(.data$ev_date_1 >= .data$presc_date_x) 
  uat1 <- uat1 %>% 
    dplyr::mutate( 
      current_flag = dplyr::if_else(( 
        .data$presc_date_x <= .data$ev_date_1 & 
          .data$presc_date_x >= (.data$ev_date_1 - timeframe) 
      ), 
      1, 
      0 
      ), 
      past_flag = dplyr::if_else(.data$presc_date_x < (.data$ev_date_1 - 
timeframe), 1 , 0) 
    ) 
  uat1 <- uat1 %>% 
    dplyr::group_by(.data$patient_id) %>% 
    dplyr::summarise( 
      current_use_flag = max(.data$current_flag), 
      n_current = sum(.data$current_flag), 
      past_use_flag = max(.data$past_flag), 
      n_past = sum(.data$past_flag) 
    ) 
  uat1 <- uat1 %>% 
    dplyr::mutate(use_at_event = dplyr::if_else(.data$current_use_flag =
= 1, "current", "past")) 
} 
3.7.7.4 Usage example 
In the example below, patients are split into current or past users of 
atorvastatin at the date of the event of interest (‘event_1’), with the threshold 
for current use being any prescription in the 90 days before the event. The 
output provides the number of prescriptions in both the current and past use 
periods, and a flag indicating which category each user falls into. Patients who 
did not have any prescriptions for the drug of interest are not included.  
ex1  <- uat_recent(df = synth_presc, 
                   df2 = synth_events, 
                   drug = "ATORVASTATIN", 
                   timeframe = 90, 
                   patient_id_col = "patient_id", 
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                   drug_id_col = "approved_name", 
                   presc_date_col = "presc_date", 
                   ev_date_col = "event_1") 
patient_id current_user n_current past_use_flag n_past use_at_event 
10016 1 1 0 0 current 
10042 1 3 1 1 current 
10052 1 2 0 0 current 
10061 1 1 0 0 current 
10064 1 1 0 0 current 
10067 0 0 1 2 past 
 
3.7.8 Two prescriptions within a desired timeframe (uat_gap) 
3.7.8.1 Description 
This function classifies patients as exposed if they have been prescribed the 
same drug on two occasions within a defined timeframe. The prescribing records 
are tidied using the ‘tidy_presc’ function and filtered to remove prescriptions 
where the drug ID does not match the drug argument. The prescriptions are 
grouped by patient ID, and the number of days between successive prescriptions 
is calculated. The records are then checked for instances where the number of 
days between prescriptions is equal to or less than the ‘timeframe’ argument. If 
the patient has at least 1 pair of prescriptions matching the exposure threshold 
they are flagged as exposed, and the dates of the first relevant prescriptions are 
extracted. Patients who have a prescription for the drug(s) of interest but do not 
meet the exposure definition are classified as unexposed. If the ‘return_all’ 
argument is FALSE, the output contains the patient IDs and first and second 
prescription dates for exposed patients only. If the ‘return_all’ argument is true, 
data are returned for all patients, including a flag indicating if they were 
exposed or unexposed, and the prescription dates where applicable. 
3.7.8.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
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• timeframe – a number, the maximum length of time in days which should 
be allowed between successive prescriptions for users to be classified as 
exposed 
• return_all – logical, if TRUE return results for all patients, if FALSE only 
return results for patients who meet the exposure definition; default 
value is FALSE 
• patient_id_col, drug_id_col, presc_date_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
• date_format - a string containing the format of the dates used in df 
3.7.8.3 R code 
uat_gap <- function(df, 
                    drug, 
                    timeframe, 
                    return_all = FALSE, 
                    patient_id_col = "patient_id", 
                    drug_id_col = "drug_id", 
                    presc_date_col = "presc_date_x", 
                    date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      patient_id_col = patient_id_col, 
      drug_id_col = drug_id_col, 
      presc_date_col = presc_date_col, 
      date_format = date_format 
    ) 
  ids <- tidy_df %>% 
    dplyr::select(.data$patient_id) %>% 
    dplyr::distinct() 
  df1 <- tidy_df %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) 
  df1 <- df1 %>% 
    dplyr::group_by(.data$patient_id) %>% 
    dplyr::arrange(.data$patient_id, .data$presc_date_x) %>% 
    dplyr::mutate(difference = c(0, diff(.data$presc_date_x))) 
  df1 <- df1 %>% 
    dplyr::mutate(flag = ifelse(dplyr::lead(.data$difference) <= timefra
me, 1, 0)) 
  df1$flag[is.na(df1$flag)] <- 0 
  df1 <- df1 %>% 
    dplyr::mutate(exposed = max(.data$flag)) %>% 
    dplyr::filter(.data$exposed == 1) 
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  df2 <- df1 %>% 
    dplyr::group_by(.data$patient_id) %>% 
    dplyr::filter(.data$flag == 1) %>% 
    dplyr::summarise(presc_date_x = min(.data$presc_date_x)) %>% 
    dplyr::mutate(presc1 = 1) 
  df1 <- 
    dplyr::left_join(df1, df2, by = c("patient_id", "presc_date_x")) 
  df1$presc1[is.na(df1$presc1)] <- 0 
  df1 <- df1 %>% 
    dplyr::mutate(presc2 = ifelse(dplyr::lag(.data$presc1) == 1, 1, 0)) 
  df1$presc2[is.na(df1$presc2)] <- 0 
  df2 <- df1 %>% 
    dplyr::filter(.data$presc1 == 1 | .data$presc2 == 1) %>% 
    dplyr::group_by(.data$patient_id) %>% 
    dplyr::summarise(presc1 = min(.data$presc_date_x), 
                     presc2 = max(.data$presc_date_x)) 
  if (return_all == TRUE) { 
    df2 <- df2 %>% 
      dplyr::mutate(exposed = 1) 
    df2 <- dplyr::left_join(ids, df2, by = "patient_id") %>% 
      dplyr::select(.data$patient_id, 
                    .data$exposed, 
                    .data$presc1, 
                    .data$presc2) 
    df2$exposed[is.na(df2$exposed)] <- 0 
  } 
  return(df2) 
} 
3.7.8.4 Usage example 
In the example below, patients are defined as exposed if they have two 
prescriptions for simvastatin within 30 days of each other. The output contains 
records for all patients in the dataset, a flag indicating if they met the threshold 
for exposure, and the dates of their first and second prescriptions where 
applicable. 
ex1 <- uat_gap(df = synth_presc, 
               drug = "SIMVASTATIN", 
               timeframe = 30, 
               return_all = TRUE, 
               patient_id_col = "patient_id", 
               drug_id_col = "approved_name", 
               presc_date_col = "presc_date") 
patient_id exposed presc1 presc2 
10001 1 2020-09-29 2020-10-26 
10002 1 2020-07-29 2020-08-27 
10003 1 2021-01-29 2021-02-24 
10004 1 2020-09-22 2020-10-20 
10005 0 NA NA 
10006 1 2020-12-09 2021-01-08 
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3.7.9 Split follow-up into windows (uat_windows) 
3.7.9.1 Description 
This function splits the period covered by the prescribing data into equal length 
windows and determines exposure status within each window based on whether 
or not patients have at least 1 prescription per window. The prescribing and 
events data are standardised using the ‘tidy_presc’ function, and the follow-up 
start and end dates are joined to the prescribing data based on patient ID. 
Patients who do not have two event dates are removed from the dataset, and 
the data are filtered to remove prescriptions where the drug ID does not match 
the value of the ‘drug’ argument. If the individual argument is TRUE, the follow-
up period is split into periods based on the value of the ‘timeframe’ argument 
and the patients’ individual start and end dates. If the ‘individual’ argument is 
FALSE, the minimum start date and maximum start date is used to define the 
start and end of follow-up for all patients, and this period is divided into 
windows based on the value of ‘timeframe’. The prescriptions are then split into 
windows and any prescriptions which fall outside of the follow-up period defined 
by these dates are removed. The number of prescriptions each patient has 
within each time window is calculated, and an exposure status is assigned to 
each time window. If the ‘return_all’ argument is set to TRUE, data are returned 
for all windows for all patients, indicating the exposure status and number of 
prescriptions in each window. If the ‘return_all’ argument is FALSE, only 
windows where patients had at least 1 prescription are returned. 
3.7.9.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• df2 – a data frame containing event records consisting of at least a patient 
ID and the dates of the start and end of follow-up for each patient 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
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• individual – logical, if TRUE create individual time windows for each 
patient based on their start and end dates. If FALSE, use the same 
windows for all patients based on the first start date and last end date 
from across all patient records; default value is FALSE 
• timeframe – a number, the desired length of each follow-up window in 
days 
• return_all – logical, if TRUE return all windows for all patients, if FALSE 
only return windows where patients had at least 1 prescription; default 
value is FALSE 
• patient_id_col, drug_id_col, presc_date_col, ev_date_1_col, 
ev_date_2_col - strings, the names of the columns in df containing 
necessary variables, passed to the tidy_presc function 
• date_format - a string containing the format of the dates used in df 
3.7.9.3 R code 
uat_windows <- 
  function(df, 
           df2, 
           drug, 
           individual = FALSE, 
           timeframe, 
           return_all = FALSE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
           ev_date_1_col = "ev_date_1", 
           ev_date_2_col = "ev_date_2", 
           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    tidy_ev <- tidy_presc( 
      df2, 
      patient_id_col = patient_id_col, 
      ev_date_1_col = ev_date_1_col, 
      ev_date_2_col = ev_date_2_col, 
  108 
 
      date_format = date_format 
    ) 
    uat1 <- dplyr::left_join(tidy_df, tidy_ev, by = "patient_id") 
    uat1 <- 
      dplyr::filter(uat1,!is.na(.data$ev_date_1) & 
                      !is.na(.data$ev_date_2)) 
    uat1 <- uat1 %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    if (individual == TRUE) { 
      uat1 <- uat1 %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::mutate(date_group = cut( 
          .data$presc_date_x, 
          seq( 
            min(.data$ev_date_1), 
            max(.data$ev_date_2) + timeframe, 
            by = timeframe 
          ) 
        ) 
        %>% as.Date) 
    } else if (individual == FALSE) { 
      uat1 <- uat1 %>% 
        dplyr::mutate(date_group = cut(.data$presc_date_x, 
                                       seq( 
                                         min(.data$ev_date_1), 
                                         max(.data$ev_date_2), 
                                         by = timeframe 
                                       )) 
                      %>% as.Date) 
    } 
    uat1 <- uat1 %>% 
      dplyr::filter(!is.na(.data$date_group)) 
    uat1 <- uat1 %>% 
      dplyr::group_by(.data$patient_id, .data$date_group) %>% 
      dplyr::summarise(n_presc = dplyr::n()) 
    if (return_all == TRUE) { 
      uat1 <- uat1 %>% 
        dplyr::group_by(.data$patient_id) %>% 
        tidyr::complete(date_group = seq.Date( 
          from = min(.data$date_group), 
          to = max(.data$date_group), 
          by = timeframe 
        )) 
      uat1$n_presc[is.na(uat1$n_presc)] <- 0 
      uat1 <- uat1 %>% 
        dplyr::mutate( 
          end_date = .data$date_group + timeframe - 1, 
          exposed = ifelse(.data$n_presc > 0, 1, 0) 
        ) %>% 
        dplyr::select( 
          .data$patient_id, 
          .data$date_group, 
          .data$end_date, 
          .data$exposed, 
          .data$n_presc 
        ) 
    } else if (return_all == FALSE){ 
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      uat1 <- uat1 %>% 
        dplyr::mutate( 
          end_date = .data$date_group + timeframe - 1) %>% 
        dplyr::select( 
          .data$patient_id, 
          .data$date_group, 
          .data$end_date, 
          .data$n_presc 
        ) 
    } 
    return(uat1) 
  } 
3.7.9.4 Usage examples 
The examples below highlight two different methods of using this function. In 
the first example, the ‘individual’ and ‘return_all’ arguments are both FALSE, so 
the follow-up period is split into the same time windows for each patient, and 
only time windows where patients had at least 1 prescription are returned. In 
the second example, both arguments are set to TRUE, so the start and stop 
dates for follow-up (and therefore the start and end of each window) are 
individualised for each patient, and all time windows are returned with a flag 
indicating whether or not the patient was exposed in each.  
3.7.9.4.1 Example 1 
ex1 <- uat_windows(df = synth_presc,  
                   df2 = synth_events, 
                   drug = "CITALOPRAM", 
                   individual = FALSE, 
                   timeframe = 90, 
                   return_all = FALSE, 
                   patient_id_col = "patient_id", 
                   drug_id_col = "approved_name", 
                   presc_date_col = "presc_date", 
                   ev_date_1_col = "start_date", 
                   ev_date_2_col = "end_date") 
patient_id date_group end_date n_presc 
10007 2020-07-12 2020-10-09 1 
10007 2020-10-10 2021-01-07 1 
10009 2020-01-14 2020-04-12 3 
10009 2020-04-13 2020-07-11 3 
10009 2020-07-12 2020-10-09 3 
10009 2020-10-10 2021-01-07 3 
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3.7.9.4.2 Example	2	
ex2 <- uat_windows(df = synth_presc,  
                   df2 = synth_events, 
                   drug = "CITALOPRAM", 
                   individual = TRUE, 
                   timeframe = 90, 
                   return_all = TRUE, 
                   patient_id_col = "patient_id", 
                   drug_id_col = "approved_name", 
                   presc_date_col = "presc_date", 
                   ev_date_1_col = "start_date", 
                   ev_date_2_col = "end_date") 
patient_id date_group end_date exposed n_presc 
10007 2020-07-16 2020-10-13 1 1 
10007 2020-10-14 2021-01-11 1 1 
10009 2020-03-21 2020-06-18 1 6 
10009 2020-06-19 2020-09-16 1 3 
10009 2020-09-17 2020-12-15 1 2 
10009 2020-12-16 2021-03-15 1 3 
 
3.8 Daily-dose related methods 
3.8.1 Rationale 
The concept of a daily dose – how much of a medication a subject is prescribed 
for each day - allows for assumptions to be made about the duration or coverage 
of prescriptions. The DDD is a unit of measurement that is defined by the WHO 
as ‘the assumed average maintenance dose per day for a drug used in its main 
indication in adults’. The DDD is a useful unit of measurement for presenting 
drug utilisation figures, as it allows for assessment of total drug consumption and 
comparison across patients, patient groups or populations. Depending on the 
drug in question, the utility of the DDD for assuming prescription duration varies, 
as it does not always correspond to individual dosing instructions, particularly in 
cases where drugs are prescribed for multiple indications, where dosage tends to 
be adjusted over time, or in population groups such as elderly patients or 
children. The DDD for some drugs may not even be a dosage of a drug which is 
typically prescribed since it is an average value. The PDD on the other hand, is 
the actual dose per day that a patient has been instructed to take when they 
have been prescribed a drug. An assumed coverage period for a prescription can 
be calculated using the date of the prescription and the number of PDDs 
dispensed, or in cases where this is not available using assumptions based on the 
number of DDDs dispensed and a number of DDDs per day. Assumptions on the 
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number of DDDs per day vary across studies, as the concordance between the 
DDD and days’ supply dispensed varies depending on drug class.(209) Daily doses 
can also be used in a variant of an ever use method, using a minimum number of 
daily doses dispensed as a threshold for exposure as a categorical variable, or 
the cumulative number of daily doses dispensed over the follow up period as a 
continuous exposure variable. 
3.8.2 Cumulative daily doses (dd_sum) 
3.8.2.1 Description 
This function calculates the total number of daily doses of a drug or drugs of 
interest dispensed per patient by totalling the values of the user-specified daily 
dose variable in each of the individual prescription record. Records are 
standardised using the ‘tidy_presc’ function, and the dataset is filtered on the 
drug identifier provided (‘drug’). Prescriptions are grouped by patient ID, and 
the total number of prescriptions and the total number of daily doses dispensed 
are calculated and date of the first prescription for each ID are determined. By 
default, the function returns this information for each patient who has been 
prescribed at least 1 daily dose for the drug(s) of interest, but the ‘threshold’ 
argument can be adjusted to set a new minimum value.  
3.8.2.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier and the number 
of daily doses dispensed 
• drug – a string containing the drug identifier to filter on, regular 
expressions allowed 
• threshold – The function will only return details for patients whose 
cumulative DDs exceed this value, set to 1 by default 
• patient_id_col, drug_id_col, presc_date_col, dd_disp_col - strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
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• date_format - a string containing the format of the dates used in df 
3.8.2.3 R code 
dd_sum <- function(df, 
                   drug, 
                   threshold = 1, 
                   patient_id_col = "patient_id", 
                   drug_id_col = "drug_id", 
                   presc_date_col = "presc_date_x", 
                   dd_disp_col = "dd_disp", 
                   date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      patient_id_col = patient_id_col, 
      drug_id_col = drug_id_col, 
      presc_date_col = presc_date_col, 
      dd_disp_col = dd_disp_col, 
      date_format = date_format 
    ) 
  dd1 <- tidy_df %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) 
  dd1 <- dd1 %>% 
    dplyr::group_by(.data$patient_id) %>% 
    dplyr::summarise( 
      n_presc = dplyr::n(), 
      total_dds = sum(.data$dd_disp), 
      first_presc = min(.data$presc_date_x) 
    ) %>% 
    dplyr::filter(.data$total_dds >= threshold) 
  return(dd1) 
} 
3.8.2.4 Usage example 
In the example below, the total number of DDDs of simvastatin dispensed to 
each patient is calculated. The ‘threshold’ argument is set to 0, so the output 
contains data for all patients who had at least 1 prescription for simvastatin in 
the dataset. 
ex1 <- dd_sum(df = synth_presc, 
              drug = "SIMVASTATIN", 
              threshold = 0, 
              patient_id_col = "patient_id", 
              drug_id_col = "approved_name", 
              presc_date_col = "presc_date", 
              dd_disp_col = "ddd_dispensed") 
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patient_id n_presc total_dds first_presc 
10001 12 448.0000 2020-07-05 
10002 13 970.6667 2020-05-29 
10003 4 298.6667 2020-11-12 
10004 8 298.6667 2020-09-22 
10006 13 485.3333 2020-05-27 
10007 10 746.6667 2020-09-08 
 
3.8.3 Prescription durations (dd_duration) 
3.8.3.1 Description 
This function calculates a duration (in days) for each prescription. The data are 
standardised using the ‘tidy_presc’ function. The database is filtered based on 
the drug identifier specified, and then durations for each prescription are 
calculated by multiplying the number of daily doses dispensed by the user-
defined factor (‘dd_factor’). This value is rounded down to the nearest whole 
number of days’ supply. An end date is then determined for each prescription by 
adding the duration to the prescribed date - these additional fields are 
appended to the prescribing data and the modified data are returned as the 
output. 
3.8.3.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier and a number 
of daily doses dispensed 
• drug – a string containing the drug identifier to filter on, regular 
expressions allowed 
• dd_factor - multiplier to be applied to the number of DDs dispensed to 
calculate the duration and end date for each prescription – adjusting this 
variable allows for different assumptions regarding the number of DDs per 
day. Set to 1 by default, and 1 should be used if the DDs dispensed 
column contains prescribed daily doses 
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• patient_id_col, drug_id_col, presc_date_col, dd_disp_col - strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
• date_format - a string containing the format of the dates used in df 
3.8.3.3 R code 
dd_duration <- function(df, 
                        drug, 
                        dd_factor = 1, 
                        patient_id_col = "patient_id", 
                        drug_id_col = "drug_id", 
                        presc_date_col = "presc_date_x", 
                        dd_disp_col = "dd_disp", 
                        date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      patient_id_col = patient_id_col, 
      drug_id_col = drug_id_col, 
      presc_date_col = presc_date_col, 
      dd_disp_col = dd_disp_col, 
      date_format = date_format 
    ) 
  dd1 <- tidy_df %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) 
  dd1 <- dd1 %>% 
    dplyr::mutate( 
      duration = floor(.data$dd_disp * dd_factor), 
      end_date = .data$presc_date_x + floor(.data$dd_disp * dd_factor) 
    ) 
} 
3.8.3.4 Usage example 
In the example below, the duration of coverage for individual prescriptions of 
citalopram is calculated based on a dosage assumption of 0.75 DDDs per day. 
The output contains a record for each prescription for citalopram from the 
original data, with the estimate duration and end date appended to the dataset. 
ex1 <- dd_duration(df = synth_presc, 
                   drug = "CITALOPRAM", 
                   dd_factor = 0.75, 
                   patient_id_col = "patient_id", 
                   drug_id_col = "approved_name", 
                   presc_date_col = "presc_date", 
                   dd_disp_col = "ddd_dispensed") 
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patient_id presc_date_x drug_id dd_disp duration end_date 
10007 2020-09-18 CITALOPRAM 14 10 2020-09-28 
10007 2020-11-15 CITALOPRAM 14 10 2020-11-25 
10009 2020-03-21 CITALOPRAM 28 21 2020-04-11 
10009 2020-03-21 CITALOPRAM 28 21 2020-04-11 
10009 2020-03-23 CITALOPRAM 28 21 2020-04-13 
10009 2020-04-17 CITALOPRAM 28 21 2020-05-08 
 
3.8.4 Calculate number of prescribed daily doses dispensed 
(calculate_pdd) 
3.8.4.1 Description 
This function calculates the number of prescribed daily doses (PDDs) dispensed 
based on an individual’s dosing instructions (i.e. how many tablets they should 
be taking per day). The data are tidied using the ‘tidy_presc’ function, then 
filtered based on the drug ID provided. The number of prescribed daily doses for 
each prescription is calculated by dividing the number of tablets dispensed by 
the instructed number of tablets per day, and this value is appended to the 
original data as a new column, ‘dd_disp’ and the modified data frame is 
returned as output.  
3.8.4.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a drug identifier the quantity dispensed and the 
quantity to be taken per day 
• drug – a string containing drug identifier to filter for, regular expressions 
allowed 
• drug_id_col, qty_disp_col, qty_per_day_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
3.8.4.3 R code 
calculate_pdd <- function(df, 
                          drug, 
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                          drug_id_col = "drug_id", 
                          qty_disp_col = "qty_disp", 
                          qty_per_day_col = "qty_per_day") { 
  tidy_df <- tidy_presc( 
    df, 
    drug_id_col = drug_id_col, 
    qty_disp_col = qty_disp_col, 
    qty_per_day_col = qty_per_day_col 
  ) 
  dd1 <- tidy_df %>% 
    dplyr::filter(grepl(drug, .data$drug_id)) 
  dd1 <- dd1 %>% 
    dplyr::mutate(pdd_disp = .data$qty_disp / .data$qty_per_day) 
  return(dd1) 
} 
3.8.4.4 Usage example 
The example below contains shows the results of calculating the number of 
prescribed daily doses of drugs appearing in BNF section 2.12 dispensed based on 
the dosage instructions provided. The output contains all of the fields of the 
input data, with the number of PDDs dispensed appended. 
ex1 <- calculate_pdd(df = synth_presc, 
                     drug = "212", 
                     drug_id_col = "bnf_section", 
                     qty_disp_col = "qty_dispensed", 
                     qty_per_day_col = "qty_per_day") 
patient_id presc_date approved_name drug_id  qty_disp qty_per_day pdd_disp 
10001 2020-07-05 SIMVASTATIN 212  28 1 28 
10001 2020-09-29 SIMVASTATIN 212  28 1 28 
10001 2020-10-26 SIMVASTATIN 212  28 1 28 
10001 2021-01-02 SIMVASTATIN 212  28 1 28 
10001 2021-04-04 SIMVASTATIN 212  28 1 28 




Medication persistence can be defined as the period of time from initiation to 
discontinuation of drug therapy. Discontinuation is the point where a patient can 
be considered to have stopped taking the drug(s) of interest, based on a lack of 
evidence of further prescribing or dispensing. At an individual subject level, 
persistence is typically determined by assessing the number of days from the 
initial prescription until there a gap in therapy of a specified number of days, 
with the allowable gap between prescriptions typically depending on clinical 
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relevance and factors related to the number of days’ supply provided by an 
individual prescription - common examples of allowable gaps used in the studies 
reviewed in Chapter 2 include 14, 30, 60 and 180 days.  
The basic refill gap method can be expanded to take account of the estimated  
coverage of each prescription as determined, for example, by the number of 
daily doses dispensed. Here, instead of comparing the time between the 
prescribed date of each prescription the end date of one coverage period is 
compared with the start date of the next to determine if the allowable gap is 
exceeded and therefore the patient has discontinued the drug of interest. This 
can also include extending the coverage period to account for medication 
stockpiling, where patients have leftover supply of the drug of interest from one 
prescription when they fill the next prescription before the anticipated end of 
the previous prescription’s supply. 
3.9.2 Refill gap only (refill_gap) 
3.9.2.1 Description 
This function uses a basic refill gap method to determine periods of persistent 
medication use and points of discontinuation. The prescribing records are 
standardised using the ‘tidy_presc’ function and based on the drug identifier 
entered (‘drug’).  The prescriptions are grouped by patient ID and drug ID and 
sorted in ascending date order. The number of days between successive 
prescriptions is calculated, and a flag is created indicating if this difference is 
greater than or less than the allowable gap. Each time the gap is greater than 
the allowable gap, the prescription is tagged as a discontinuation point. Based 
on these termination points, the function then generates a list of patient IDs, 
first and last prescription dates in each period of exposure and the length of 
each exposure (calculated as the difference between the two dates plus the 
length of the allowable gap). If the ‘first_period’ argument is set to TRUE, the 
function removes any periods of use beyond the patient’s first exposure to each 
drug. If the ‘threshold’ value is set to 0, as by default, all periods are returned. 
If the value is not equal to zero, only exposures whose length is greater than or 
equal to the ‘threshold’ variable are returned - for example, if ‘threshold’ is 
365, only details of subjects’ who were persistent for a year or longer after 
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initial prescription will be returned. If the ‘summary’ argument is TRUE, instead 
of returning individual periods of exposure the function calculates the number of 
periods of exposure, total number of prescriptions, the dates of the first and last 
prescriptions and the total length of exposure across all periods for each patient 
– when the ‘summary’ argument is TRUE, the threshold argument is applied to 
the total length of exposure, not the length of the individual periods. 
3.9.2.2 Arguments 
• df - a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
• gap - the allowable gap between prescriptions for the drug of interest 
before the patient is considered to have discontinued the medication 
• threshold - this value is used to limit the results so that the output 
contains only exposures with duration greater than or equal to this value, 
default value is 0 
• first_period – logical, if TRUE the function only returns the first period of 
persistent use for each drug per patient, default value is FALSE 
• summary – logical, if TRUE the function returns a summary of all periods 
of use instead of details of the individual periods; default value is FALSE 
• patient_id_col, drug_id_col, presc_date_col - strings, the names of the 
columns in df containing necessary variables, passed to the tidy_presc 
function 
• date_format - a string containing the format of the dates used in df 
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3.9.2.3 R code 
refill_gap <- 
  function(df, 
           drug, 
           gap, 
           threshold = 0, 
           first_period = FALSE, 
           summary = FALSE, 
           patient_id_col = "patient_id", 
           drug_id_col = "drug_id", 
           presc_date_col = "presc_date_x", 
           date_format) { 
    tidy_df <- 
      tidy_presc( 
        df, 
        patient_id_col = patient_id_col, 
        drug_id_col = drug_id_col, 
        presc_date_col = presc_date_col, 
        date_format = date_format 
      ) 
    pers1 <- tidy_df %>% 
      dplyr::filter(grepl(drug, .data$drug_id)) 
    pers1 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
      dplyr::arrange(.data$patient_id, .data$presc_date_x) %>% 
      dplyr::mutate(difference = c(0, diff(.data$presc_date_x))) 
    pers1 <- 
      dplyr::mutate(pers1, terminated = ifelse(.data$difference > gap, 1
, 0)) 
    pers1 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
      dplyr::mutate(period = cumsum(.data$terminated)) %>% 
      dplyr::select( 
        .data$patient_id, 
        .data$drug_id, 
        .data$presc_date_x, 
        .data$difference, 
        .data$terminated, 
        .data$period 
      ) 
    pers1 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id, .data$period) %>% 
      dplyr::summarise( 
        first_presc = min(.data$presc_date_x), 
        last_presc = max(.data$presc_date_x), 
        end_date = max(.data$presc_date_x) + gap, 
        n_presc = dplyr::n(), 
        duration = (max(.data$presc_date_x) - min(.data$presc_date_x)) + 
gap 
      ) 
    if (first_period == TRUE) { 
      pers1 <- pers1 %>% 
        dplyr::filter(.data$period == 0) 
    } 
    if (threshold == 0 & summary == FALSE) { 
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      return(pers1) 
    } else if (threshold != 0 & summary == FALSE) { 
      pers2 <- pers1 %>% 
        dplyr::filter(.data$duration >= threshold) 
      return(pers2) 
    } else if (threshold == 0 & summary == TRUE) { 
      pers2 <- pers1 %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::summarise( 
          n_periods = dplyr::n(), 
          total_n_presc = sum(.data$n_presc), 
          first_presc = min(.data$first_presc), 
          last_presc = max(.data$last_presc), 
          total_length = sum(.data$duration) 
        ) 
    } else if (threshold != 0 & summary == TRUE) { 
      pers2 <- pers1 %>% 
        dplyr::group_by(.data$patient_id) %>% 
        dplyr::summarise( 
          n_periods = dplyr::n(), 
          total_n_presc = sum(.data$n_presc), 
          first_presc = min(.data$first_presc), 
          last_presc = max(.data$last_presc), 
          total_length = sum(.data$duration) 
        ) %>% 
        dplyr::filter(.data$total_length >= threshold) 
    } 
  } 
3.9.2.4 Usage examples 
The examples below highlight the differences in output from the ‘refill_gap’ 
function based on the use of different arguments. In each example, persistence 
to simvastatin is determined allowing for a 30-day gap in between prescriptions 
before discontinuation. In the first example, no additional arguments are used, 
so the results returned include each individual period of persistent for all 
exposed patients. In the second example, the ‘threshold’ argument is set to 60, 
so only periods of use which are at least 60 days long are included in the results. 
In the third example, the ‘threshold’ argument is set to 60 and the ‘summary’ 
argument is set to TRUE, so summaries of the overall exposure for each patient 
are returned for patients whose total duration of persistent use was over 60 
days.  
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3.9.2.4.1 Example 1 
ex1 <- refill_gap(df = synth_presc, 
                  drug = “SIMVASTATIN”, 
                  gap = 30, 
                  patient_id_col = “patient_id”, 
                  drug_id_col = “approved_name”, 
                  presc_date_col = “presc_date”) 
patient_id period first_presc last_presc end_date n_presc duration 
10001 0 2020-07-05 2020-07-05 2020-08-04 1 30 days 
10001 1 2020-09-29 2020-10-26 2020-11-25 2 57 days 
10001 2 2021-01-02 2021-01-02 2021-02-01 1 30 days 
10001 3 2021-04-04 2021-04-04 2021-05-04 1 30 days 
10001 4 2021-06-02 2021-06-02 2021-07-02 1 30 days 
10001 5 2021-07-24 2021-08-23 2021-09-22 2 60 days 
 
3.9.2.4.2 Example 2 
ex2 <- refill_gap(df = synth_presc, 
                  drug = “SIMVASTATIN”, 
                  gap = 30, 
                  threshold = 60, 
                  patient_id_col = “patient_id”, 
                  drug_id_col = “approved_name”, 
                  presc_date_col = “presc_date”) 
patient_id period first_presc last_presc end_date n_presc duration 
10001 5 2021-07-24 2021-08-23 2021-09-22 2 60 days 
10004 2 2021-03-28 2021-05-02 2021-06-01 3 65 days 
10006 3 2020-12-09 2021-01-08 2021-02-07 2 60 days 
10006 4 2021-02-08 2021-03-26 2021-04-25 3 76 days 
10007 0 2020-09-08 2020-10-08 2020-11-07 2 60 days 
10007 5 2021-08-16 2021-09-15 2021-10-15 2 60 days 
 
3.9.2.4.3 Example 3 
ex3 <- refill_gap(df = synth_presc, 
                  drug = “SIMVASTATIN”, 
                  gap = 30, 
                  threshold = 60, 
                  summary = TRUE, 
                  patient_id_col = “patient_id”, 
                  drug_id_col = “approved_name”, 
                  presc_date_col = “presc_date”) 
patient_id n_periods total_n_presc first_presc last_presc total_length 
10001 9 12 2020-07-05 2022-03-01 355 days 
10002 12 13 2020-05-29 2022-02-20 389 days 
10003 3 4 2020-11-12 2021-05-22 116 days 
10004 5 8 2020-09-22 2021-08-02 213 days 
10006 9 13 2020-05-27 2022-01-01 374 days 
10007 6 10 2020-09-08 2021-09-15 296 days 
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3.9.3 Refill gap with coverage (refill_gap_dd) 
3.9.3.1 Description 
This function determines periods of persistent use of the drug(s) of interest, 
taking into account the coverage or days’ supply given with each prescription 
and the gap between prescriptions, with the option to consider medication 
stockpiling. The data are tidied by the ‘tidy_presc’ function, and then filtered 
for prescriptions matching the drug identifier provided (‘drug’). Then, duration 
and end date for each prescription are calculated by the ‘dd_duration’ function, 
based on the number of daily doses dispensed and the user-selected factor 
(‘dd_disp’ and ‘dd_factor’). The prescriptions are grouped by patient ID and 
drug ID, and arranged in date order, and the difference between the end date of 
one prescription and the start date of the next is calculated sequentially. If the 
‘stockpile’ argument is TRUE, the function checks if the prescribed date for the 
next prescription is before the predicted end date of the previous prescription 
and carries over any excess supply. For example, if the new prescription’s date 
is two days before the end date assigned to the previous prescription, the 
duration of the next prescription is increased by 2. Discontinuation points are 
determined by checking if the difference between the end of one prescriptions 
coverage and the date of the next prescription is greater than the allowable gap 
(gap). Numbered periods of continuous exposure are created based on these 
discontinuation points. Output is a data frame containing the patient ID, first 
and last prescription dates, end dates (last prescription date plus duration plus 
the allowable gap), number of prescriptions and total length of exposure for 
each period is generated. If the ‘first_period’ argument is TRUE, the function 
only returns the first period of exposure for each drug the patient was exposed 
to. Then, if the value for the ‘threshold’ argument is zero, this table is returned 
in full. If another value has been chosen, only periods where the number of days 
is greater than or equal to the ‘threshold’ value are returned. If the ‘summary’ 
argument is TRUE, instead of returning individual periods of exposure the 
function calculates the number of periods of exposure, total number of 
prescriptions, the dates of the first and last prescriptions and the total length of 
exposure across all periods for each patient – when the ‘summary’ argument is 
TRUE, the ‘threshold’ argument is applied to the total length of exposure, not 
the length of the individual periods. 
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3.9.3.2 Arguments  
• df – a data frame containing individual prescription records consisting of 
at least a patient ID, a prescription date, a drug identifier 
• drug – a string containing an identifier for the drug of interest, regular 
expressions allowed  
• gap – the allowable gap between prescriptions for the drug of interest 
before the patient is considered to have discontinued the medication 
• threshold – this value is used to limit the results so that the output 
contains only exposures with duration greater than or equal to this value 
• dd_factor – multiplier to be applied to the number of DDs dispensed to 
calculate the duration and end date for each prescription – adjusting this 
variable allows for different assumptions regarding the number of DDs per 
day. Set to 1 by default, and 1 should be used if the DDs dispensed 
column contains prescribed daily doses 
• stockpile – logical, if TRUE any remaining days’ supply from one period 
are carried over to the end of the next period in cases where the second 
prescription is before the predicted end of the previous supply; default 
value is FALSE 
• first_period – logical, if TRUE the function only returns the first period of 
persistent use for each drug per patient; default value is FALSE 
• summary – logical, if TRUE the function returns a summary of all periods 
of use instead of details of the individual periods; default value is FALSE 
• patient_id_col, drug_id_col, presc_date_col, dd_disp_col- strings, the 
names of the columns in df containing necessary variables, passed to the 
tidy_presc function 
• date_format – a string containing the format of the dates used in df 
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3.9.3.3 R code 
refill_gap_dd <- function(df, 
                          drug, 
                          gap, 
                          dd_factor = 1, 
                          threshold = 0, 
                          stockpile = FALSE, 
                          first_period = FALSE, 
                          summary = FALSE, 
                          patient_id_col = “patient_id”, 
                          drug_id_col = “drug_id”, 
                          presc_date_col = “presc_date_x”, 
                          dd_disp_col = “dd_disp”, 
                          date_format) { 
  tidy_df <- 
    tidy_presc( 
      df, 
      patient_id_col = patient_id_col, 
      drug_id_col = drug_id_col, 
      presc_date_col = presc_date_col, 
      dd_disp_col = dd_disp_col, 
      date_format = date_format 
    ) 
  pers1 <- tidy_df %>% 
    dd_duration(drug = drug, dd_factor = dd_factor) 
  if (stockpile == FALSE) { 
    pers1 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
      dplyr::arrange(.data$patient_id, .data$drug_id, .data$presc_date_x
) %>% 
      dplyr::mutate(difference = as.numeric(.data$presc_date_x – dplyr::
lag(.data$end_date))) 
    pers1$difference[is.na(pers1$difference)] <- 0 
  } else if (stockpile == TRUE) { 
    pers1 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
      dplyr::arrange(.data$patient_id, .data$drug_id, .data$presc_date_x
) %>% 
      dplyr::mutate(stockpile = dplyr::if_else((dplyr::lag(.data$end_dat
e) > .data$presc_date_x), 
                                               as.numeric(dplyr::lag(.da
ta$end_date) - .data$presc_date_x), 
                                               0 
      )) 
    pers1$stockpile[is.na(pers1$stockpile)] <- 0 
    pers1 <- pers1 %>% 
      dplyr::mutate(end_date = .data$presc_date_x + (.data$duration + .d
ata$stockpile)) %>% 
      dplyr::mutate(difference = as.numeric(.data$presc_date_x – dplyr::
lag(.data$end_date))) 
    pers1$difference[is.na(pers1$difference)] <- 0 
  } 
  pers1 <- 
    dplyr::mutate(pers1, terminated = dplyr::if_else(.data$difference > 
gap, 1, 0)) 
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  pers1 <- pers1 %>% 
    dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
    dplyr::mutate(period = cumsum(.data$terminated)) %>% 
    dplyr::select( 
      .data$patient_id, 
      .data$presc_date_x, 
      .data$drug_id, 
      .data$end_date, 
      .data$dd_disp, 
      .data$difference, 
      .data$terminated, 
      .data$period 
    ) 
  if(first_period == TRUE){ 
    pers1 <- pers1 %>% 
      dplyr::filter(period == 0) 
  } 
  pers1 <- pers1 %>% 
    dplyr::group_by(.data$patient_id, .data$drug_id, .data$period) %>% 
    dplyr::summarise( 
      first_presc = min(.data$presc_date_x), 
      last_presc = max(.data$presc_date_x), 
      end_date = max(.data$end_date) + gap, 
      n_presc = dplyr::n(), 
      duration = as.numeric(max(.data$end_date) – min(.data$presc_date_x
)) + gap 
    ) 
  if (threshold == 0 & summary == FALSE) { 
    return(pers1) 
  } else if (threshold != 0 & summary == FALSE) { 
    pers2 <- pers1 %>% 
      dplyr::filter(.data$duration >= threshold) 
    return(pers2) 
  } else if (threshold == 0 & summary == TRUE) { 
    pers2 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
      dplyr::summarise( 
        n_periods = dplyr::n(), 
        total_n_presc = sum(.data$n_presc), 
        first_presc = min(.data$first_presc), 
        last_presc = max(.data$last_presc), 
        end_of_exposure = max(.data$end_date), 
        total_length = sum(.data$duration) 
      ) 
  } else if (threshold != 0 & summary == TRUE) { 
    pers2 <- pers1 %>% 
      dplyr::group_by(.data$patient_id, .data$drug_id) %>% 
      dplyr::summarise( 
        n_periods = dplyr::n(), 
        total_n_presc = sum(.data$n_presc), 
        first_presc = min(.data$first_presc), 
        last_presc = max(.data$last_presc), 
        end_of_exposure = max(.data$end_date), 
        total_length = sum(.data$duration) 
      ) %>% 
      dplyr::filter(.data$total_length >= threshold) 
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  } 
} 
3.9.3.4 Usage examples 
As in the examples of the use of the ‘refill_gap’ function above, the two 
examples below define periods of persistent use of simvastatin based on an 
allowable gap of 30 days between successive prescriptions. In this case, the 
expected duration of each prescription is calculated using the number of DDDs 
dispensed and an assumption of 1 DDD per day. In the first example, the 
‘stockpile’ argument is set to FALSE, so only the supply of each individual 
prescription is considered when defining discontinuation. In the second example, 
‘stockpile’ is TRUE so any remaining days’ supply from the previous prescription 
are carried over to the end of the next period. This results in different points of 
discontinuation for some patients, and therefore different periods of persistent 
use. 
3.9.3.4.1 Example 1 
ex1 <- refill_gap_dd(df = synth_presc, 
                     drug = “SIMVASTATIN”, 
                     gap = 30, 
                     dd_factor = 1, 
                     stockpile = FALSE, 
                     patient_id_col = “patient_id”, 
                     drug_id_col = “approved_name”, 
                     presc_date_col = “presc_date”, 
                     dd_disp_col = “ddd_dispensed”) 
 
patient_id period first_presc last_presc end_date n_presc duration 
10001 0 2020-07-05 2020-07-05 2020-09-10 1 97 
10001 1 2020-09-29 2020-10-26 2021-01-01 2 124 
10001 2 2021-01-02 2021-01-02 2021-03-10 1 97 
10001 3 2021-04-04 2022-03-01 2022-05-07 8 428 
10002 0 2020-05-29 2021-01-22 2021-05-06 6 372 
10002 1 2021-05-24 2022-02-20 2022-06-04 7 406 
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3.9.3.4.2 Example 2 
ex2 <- refill_gap_dd(df = synth_presc, 
                     drug = "SIMVASTATIN", 
                     gap = 30, 
                     dd_factor = 1, 
                     stockpile = TRUE, 
                     drug_id_col = "approved_name", 
                     presc_date_col = "presc_date", 
                     dd_disp_col = "ddd_dispensed") 
patient_id period first_presc last_presc end_date n_presc duration 
10001 0 2020-07-05 2020-07-05 2020-09-10 1 97 
10001 1 2020-09-29 2021-01-02 2021-03-10 3 192 
10001 2 2021-04-04 2022-03-01 2022-05-07 8 428 
10002 0 2020-05-29 2022-02-20 2022-06-16 13 778 
10003 0 2020-11-12 2021-05-22 2021-09-03 4 325 
10004 0 2020-09-22 2020-10-20 2021-01-04 2 134 
 
3.10 Conclusions 
This chapter has described the development and contents of the prescribeR 
package. The primary aim in developing this package was to create a set of 
functions which could be used by researchers to generate drug exposure 
variables when preparing routinely collected prescribing data for analysis 
without having to develop code for each study or project. The structure of these 
functions makes it relatively simple to test variations of the individual methods 
or run multiple different methods by changing arguments or using a different 
function, without having to write and test full scripts. Use of an existing package 
rather than new code also makes it easier to report on how exposure variables 
were generated. Instead of having to provide the entire script used or try to 
summarise the process, reporting can be done by providing the details of the 
package, function and arguments used, as seen in the usage examples 
throughout this chapter. Standardising the methods used in this manner then 
makes it easier for other researchers to reproduce these analyses using other 
datasets in order to validate the results. 
In order to ensure the functions within the prescribeR package were operating as 
intended, manual validation was performed throughout the development and 
testing process using both real-world prescribing data and the synthetic datasets 
included in the package. The synthetic data were used initially to ensure that 
each function was running as intended, that the output was in the correct 
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format and the results matched what was expected. The benefit of using the 
synthetic data in this initial step is that the limited number of records makes it 
easier to manually examine the data and determine the expected results for the 
full dataset, and quicker to compare these to the test output. After this step is 
complete and the package appeared to be functioning as intended, the process 
was repeated on real world data. In this step, the output for several patients 
was compared against manually derived outputs; in particular, outliers and any 
seemingly implausible outputs were checked to ensure that they were not 
produced as a result of errors within the functions. 
Although the package was developed using Scottish prescribing data as a 
reference, the arguments used in the functions are all content neutral. In 
particular, all of the functions accept regular expressions as the drug argument, 
meaning that the value entered only has to match the structure of the data 
stored in the column specified by the user and not a pre-defined standard coding 
system. Additionally, all of the functions in the prescribeR package use dates in 
the format specified by the user, not a pre-determined format. 
The package is available for download through the repository hosting service 
GitHub (github.com/amarshall1/prescribeR). In addition to providing a place to 
store code in a way that allows it to be viewed and used by others, GitHub 
automatically tracks changes made to the code within the repository and keeps 
track of different versions, making it easy to revert to a previous version if 
serious issues arise with new code. GitHub also promotes collaboration, allowing 
other users to raise issues to highlight bugs in the code and can even create their 
own branches in the code to add new functionality, which can then be merged 
into the main branch by the package owner. The package has been assigned a 
Digital Object Identifier (DOI) (10.5281/zenodo.3834346) which allows others to 
cite the package if they have used it during their analysis. Further plans for the 
dissemination of the package include submitting it for inclusion in the CRAN 
repository, seeking to publish it in a journal and sharing it with colleagues 
working with routinely collected data within the university. 
The next chapter demonstrates the utility of the prescribeR package by using it 
to prepare exposure variables in a clinical study investigating the rates of drug 
persistence in a cohort of epilepsy patients. 
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4 Persistence to anti-epileptic drugs 
4.1 Introduction 
The previous chapter detailed the contents of the R package prescribeR, written 
to standardise and simplify the generation of drug exposure variables from 
routinely collected prescribing datasets. In order to assess the suitability of the 
package for use in research, testing on a larger, more complex real-world 
dataset for a defined clinical epidemiology purpose was necessary. Therefore, 
this chapter discusses the creation of a disease cohort constructed using record-
linkage within the NHS Safe Haven environment and its use to demonstrate the 
utility of the prescribeR package within a clinical research study investigating 
the rates of persistence to anti-epileptic drugs (AEDs) in a cohort of patients 
with epilepsy.  
4.1.1 Epilepsy 
Epilepsy is a common neurological condition typically characterised by recurrent 
seizures. According to the WHO around 50 million people worldwide have 
epilepsy and an estimated 5 million people are diagnosed with epilepsy each 
year.(244) A National Institute for Health and Care Excellence (NICE) guideline 
on the diagnosis and management of epilepsy, published in 2012, estimated the 
prevalence of active epilepsy (i.e. patients with continuing seizures or continued 
need for treatment) in the UK to be 5-10 cases per 1,000 population and 
estimated the incidence of newly diagnosed epilepsy to be 50 per 100,000 
population per year.(245) There is a known association between epilepsy and 
socioeconomic status, with higher incidence and prevalence amongst less 
affluent people and in low and middle-income countries.(244)  
A number of different epilepsy syndromes exist, typically classified according to 
clinical features such as type of seizure, neurologic or developmental 
abnormalities and electroencephalographic (EEG) measurements.(246) Epilepsy 
syndromes can be split into two broad categories – generalised and partial (or 
localised) seizure syndromes. In generalised epilepsy syndromes, seizures 
typically begin simultaneously in both cerebral hemispheres whereas in partial 
epilepsy syndromes seizures have more localised focal points but can spread to 
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the rest of the brain. There are a number of potential disease mechanisms which 
can lead to epilepsy, which can be split into structural, genetic, infective, 
metabolic, immune and unknown causes. 
Epilepsy is associated with higher rates of mortality(247) and both physical and 
mental comorbidities compared to the general population.(248, 249) One study 
of comorbidities amongst people with epilepsy in Scotland found higher rates of 
stroke, transient ischaemic attack, chronic liver disease, migraines, learning 
difficulties and depression amongst people with epilepsy compared to the 
general population.(248) Another study focusing on the risk of myocardial 
infarction, stroke and all-cause mortality found that patients with epilepsy 
exhibited higher risk of all three compared to the general population.(250) 
Additionally, a Canadian study of psychiatric comorbidity in epileptic patients 
found there was an increased prevalence of mental health disorders and suicidal 
ideation in people with epilepsy compared to the general population.(249) 
4.1.2 Anti-epileptic drugs 
Epilepsy is largely managed through the use of anti-epileptic drug (AED) 
treatment, with the specific treatment plan typically individualised according to 
the patients’ seizure type, epilepsy syndrome, other medications and 
comorbidities.(245) When treating epilepsy, the aim is to achieve seizure 
freedom through the use of AED monotherapy where possible. This often 
requires atrial-and-error process, and if first-line therapies are ineffective, 
alternative monotherapies and finally combination therapies are recommended. 
Approximately two thirds of patients with epilepsy achieve seizure freedom 
through the use of AEDs.(245)  
AEDs act on a diverse set of molecular targets in the central nervous system, 
with the main aim of modifying the excitability of neurones to block seizure 
activity.(251) The main mechanisms of action for AEDs are the modulation of 
voltage-dependent ion channels and the modulation of GABAergic and 
glutamatergic synaptic activity. In addition to the medications prescribed to 
prevent seizures from occurring, drugs such as benzodiazepines can be used in 
emergencies in the case of prolonged or serial convulsive seizures.  
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The first generation of AEDs (carbamazepine, ethosuximide, phenobarbital, 
phenytoin, primidone and valproate) were introduced several decades ago, and 
have complex pharmacokinetic properties and narrow therapeutic windows.(252) 
Starting in the 1990s, a second generation of AEDs were approved, including 
gabapentin, lamotrigine, levetiracetam and pregabalin which have generally 
better safety profiles and wider therapeutic windows(253). Studies investigating 
the trends in prescribing and utilisation of different AEDs in the UK,(254, 255) 
Sweden(256), Norway(122) and Australia(257) have shown that while they are 
still commonly prescribed, the use of older AEDs such as carbamazepine, 
phenytoin and valproate has decreased over the last 20-25 years, and the use of 
newer agents such as lamotrigine and levetiracetam as first-line therapies has 
steadily increased, particularly amongst younger patients. 
The NICE guidelines for treatment and management of epilepsy recommend that 
the decisions regarding which AED to use for each patient should be made based 
on the patient’s seizure type and epilepsy syndrome, as well as their 
comorbidities and any additional medications they are being prescribed.(245) 
The large number of AEDs currently available offers a great deal of flexibility to 
clinicians in specifically tailoring a treatment strategy for each patient, but 
selecting the best AED can be challenging due to the number of options 
available. Around 50% of adult patients achieve seizure freedom with their first 
AED without side effects.(258) The remaining patients will either need to switch 
to an alternative AED or add a second drug to their regimen, either due to 
inadequate seizure control or unmanageable adverse effects. 
Understanding when and why patients discontinue treatment of different AEDs, 
and the associations between the duration of persistent use and rates of 
discontinuation and key demographic and clinical factors could assist in the 
refinement of prescribing guidance for clinicians on which drugs are more 
suitable for individual patients with specific characteristics, therefore reducing 
the need for trial and error in the management of epilepsy and improving 
patient care. 
Although there are a number of published studies investigating rates of 
adherence to AEDs and the factors which impact adherence, there are few 
studies focusing on measuring persistence using routinely collected data. One 
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study which investigated persistence to AEDs in a cohort of Taiwanese patients 
with epilepsy observed a lower risk of non-persistence in patients prescribed 
oxcarbazepine, valproate, lamotrigine and topiramate compared to patients 
prescribed carbamazepine, and higher risk of non-persistence in patients 
prescribed phenytoin compared to those prescribed carbamazepine.(259) The 
study also found that the mean treatment duration during the first year varied 
across the drugs investigated, ranging from 218.8 days for gabapentin to 275.9 
days for oxcarbazepine.  
A second study which examined persistence in a cohort of epilepsy patients in 
Germany found that less than 50% of cohort patients were persistent to AED 
treatment after 5 years.(260) Cox proportional hazard regression was used to 
estimate the risk of discontinuation associated with different demographic and 
clinical factors. Patients over 60 years of age were at a lower risk of 
discontinuation than younger patients, and patients with depression were more 
likely to discontinue therapy than those without depression. Patients prescribed 
older AEDs (drugs approved before 1980) were found to be more likely to 
discontinue therapy than patients prescribed newer drugs. Compared to patients 
who were prescribed valproate, patients prescribed levetiracetam and 
lamotrigine were at lower risk of non-persistence and patients prescribed 
gabapentin were at a higher risk. These studies highlight differences in 
persistence across different drugs, as well as differences across different patient 
sub-groups, but further work is needed to validate and clarify these findings. 
4.1.3 Using routinely collected data for research 
As described previously in Chapter 1, everyone who is registered with a GP in 
Scotland has a CHI number which is associated with all of their encounters with 
NHS services.(23) The data collected during the provision of these services can 
be linked using the CHI and anonymised to be used in research through the NHS 
Safe Havens. 
The Safe Havens are a secure environment designed to facilitate the use of 
anonymised NHS electronic data in research in a way that complies with 
information governance and maintains patient confidentiality.(261) Currently 
there are five Safe Havens in Scotland- a national Safe Haven and four regional 
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Safe Havens located in Aberdeen, Dundee, Edinburgh and Glasgow. They provide 
access to a range of both nationally collected data and more specialised locally 
assembled datasets. The approval process for the Greater Glasgow and Clyde 
(GGC) Safe Haven involves submitting an application containing details of the 
research question being examined and the datasets required as well as a study 
protocol, cohort criteria and an analysis plan.(262) Study applications are 
reviewed by a Local Privacy and Advisory committee consisting of a mixture of 
clinical staff, academics and members of the public who offer guidance 
regarding data protection before projects are approved. Researchers are also 
required to submit documentation regarding their source of funding and current 
accreditation status. Once the application has been submitted, it is processed 
and reviewed by the Safe Haven team. If approved, the Safe Haven team then 
links the required data, and uploads anonymised data to the analysis platform 
for the researchers to access and analyse. 
Data available in the NHS Greater Glasgow and Clyde (NHSGGC) Safe Haven 
includes birth and death records, inpatient, outpatient, psychiatric, general and 
maternity admissions and dispensed medicines, as well as more granular 
datasets such as disease and procedure registers.(262) The ability to connect 
these data provides an opportunity to investigate issues related to care and 
outcomes of patients with epilepsy, including use of medications, rates of 
hospitalisation and the effect of clinical and demographic characteristics on 
long-term survival. This, in turn, could be used to better understand the relative 
importance of different factors on disease management and quality of life and, 
thereby, identify ways to improve the standard of care for patients with 
epilepsy.  
The aim of this chapter is to describe a cohort of patients with epilepsy using 
linked data covering demographics, hospitalisations, deaths and prescriptions 
within NHSGGC health board, and to describe the rates of persistence to AEDs in 
this cohort. 
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4.2 Methods 
4.2.1 Data available in the Safe Haven 
The data provided by the Safe Haven were selected based on a list of CHI 
numbers identified from the NHSGGC’s SCI Gateway and TrakCare datasets. SCI 
Gateway is the system used to manage GP referrals to specialist consultants, and 
TrakCare is the system used to manage patients’ journeys through A&E and 
outpatient clinics. In total, 10,742 potential patients with epilepsy were 
identified through referrals to epilepsy outpatient clinics in SCI Gateway or 
through a record for an epilepsy ICD-10 code in TrakCare (G40.x or G41.x). 
Before being uploaded to the Safe Haven analysis platform, the individual 
datasets were linked by CHI number, and then the CHI number was replaced 
with a project-specific Safe Haven ID number which is matched across the 
different datasets. CHI numbers are not visible to researchers, as these are 
confidential patient information. 
The available datasets covered demographics, hospitalisations, accident and 
emergency visits, deaths and dispensed prescriptions. Table 11 summarises the 
number of records contained within each file before data cleaning and patient 
selection, the number of patients the data covers (based on the number of 
unique Safe Haven IDs which appear within each file), the number of records per 
patient and the date range covered by the data. 








Demographics 10,281 10,281 N/A N/A 
Deaths 2,801 2,801 N/A N/A 













75,751 9,080 5 (7) 01/12/2010 – 
01/04/2017 
Table 11 - Summary of the datasets available within the Safe Haven before data cleaning 
and participant selection 
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The demography file provided contains demographic characteristics for patients 
who were residents of the NHS GGC health board taken from the CHI, including 
date of birth, date of death (if applicable), gender, marital status, postcode 
sector and Scottish Index of Multiple Deprivation (SIMD) scores. Patients dates of 
birth were obfuscated by the Safe Haven team prior to the data being uploaded 
to the analytical platform, as they are considered identifiable patient 
information – the birth date provided contains the correct month and year, but 
the day is always set to 15. 
The Scottish Morbidity Record (SMR01) contains data on all inpatient and day 
case admissions to an acute, general hospital. The data include admission and 
discharge dates, the main condition managed or principal diagnosis, additional 
conditions or comorbidities, details on the hospital and specialty and significant 
facility the patient was admitted to, the types of admission (routine or urgent) 
and discharge (regular discharge, transfer, self-discharge or death), patient 
management category (day case or inpatient), age on admission, postcode sector 
and SIMD scores and patients’ health board of residence. The conditions or 
diagnoses associated with each admission were coded according to the 
International Classification of Diseases (ICD-10).(263) 
The Emergency Department Information System (EDIS) contains data on accident 
and emergency (A&E) attendance taken from the TrakCare system. The data 
includes admission and discharge dates and times, primary and additional 
diagnoses or conditions, information on how the patient arrived at A&E and the 
referral source (e.g. self-referral, GP referral, 999 call), the hospital and A&E 
department attended, presenting complaint (free text), ICD-10 codes and 
descriptions, age, sex and ethnicity, cause of injury (free text), information on 
waiting times within the A&E and vital measurements (e.g. pulse, respiratory 
rate, blood pressure, temperature).  
Death records are obtained from the NRS General Registers Office. The data 
contains date of death, location of death and ICD-10 codes describing the main 
and underlying or contributing causes of death.  
  136 
 
PIS contains records of prescriptions cashed at local pharmacies within the 
community in the NHSGGC health board area. The PIS extract for this project 
included prescription issue and dispensing dates, the approved name, item name 
and BNF codes for the drug dispensed, the quantity dispensed, the item strength 
and formulation (tablets, capsules, etc), the number of dispensed items per 
form, the health board, prescriber type (GP, dentist, nurse, pharmacist etc) and 
a flag indicating if the patient is a care home resident. Each prescription record 
contains a BNF code describing exactly what was prescribed. The first section of 
each BNF item code specifies where the drug appears in the BNF, and the second 
section specifies the exact product prescribed. An example is provided in Figure 
15 below. 
 
Figure 15 – Summary of the structure and content of BNF codes assigned to drugs in the 
pharmacy data using the code for generic carbamazepine 100mg tablets as an example 
 
4.2.2 Data cleaning 
4.2.2.1 Demography 
Patients not appearing in the demography file are typically patients from other 
health boards who have received care within NHSGGC. In order to minimise the 
risk of error due to incomplete data for these patients and to ensure that 
demographic summaries cover all patients, records for patients who did not 
appear in this file were removed from the other datasets. 
4.2.2.2 Death records 
Deaths were recorded in two of the files provided by the Safe Haven: the NRS 
death records file and the CHI demography file. As these datasets are taken from 
different sources there are inconsistencies between the two, including deaths 






















Carbamazepine Generic 100mg tabs Generic
Carbamazepine tablets 100mg, generic - 0408010C0AAABAB
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but on different dates. In cases where a date of death was recorded in the CHI 
demography file but not the death records file, a record was added with the 
cause of death and other information listed as unknown. In cases where patients 
had a death record but no date recorded in the demography file, or the dates in 
both files did not match the demography file was adjusted to match the date of 
death listed in the death records file. After the dates were standardised 
between the two sources, records were censored at 31/12/2016 to standardise 
the end of follow-up across all datasets. 
4.2.2.3 Hospitalisations and A&E attendances 
Duplicate records where all fields were identical were removed. Records where 
some of the fields were the same but others did not match were retained, as 
these typically represented additional information related to separate episodes 
within the same hospital stay, such as movement between different wards. 
Records were censored at 31/12/2016. Where the discharge date occurred after 
the recorded date of death, the discharge date was set to the date of death. 
Flags were added to each record to indicate whether or not an ICD-10 code for 
epilepsy was listed in the first position or in any position. 
SMR01 records represent individual episodes of care - a new record is generated 
each time a patient is moved between different specialties or significant 
facilities during a hospital admission. In order to allow for summaries on the 
number of complete admissions to be generated, an additional dataset was 
generated containing single records representing continuous inpatient stays. 
Records were arranged by Safe Haven ID, admission date and discharge date. 
Records where the admission date was before, or the same as, the previous 
discharge date were marked as being part of the same stay and records which 
represented the start of a new stay were flagged. Records were created 
representing complete stays, containing the admission and discharge dates, the 
total length of stay, the number of individual episodes that occurred during the 
stay and flags indicating whether any of the individual records contributing to a 
continuous stay had an ICD-10 code for epilepsy listed in the first or any 
position, as above. 
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4.2.2.4 Prescriptions 
Duplicated prescriptions, i.e. records where all fields were identical, were 
identified and removed from the dataset in order to avoid erroneously increasing 
the number of recorded prescriptions for these drugs and patients. Prescriptions 
prescribed or dispensed after 31/12/2016 or after a patients’ date of death were 
removed. A separate file was created containing only the AED prescriptions. 
Prescriptions for AEDs appearing under alternate BNF codes were adjusted to 
ensure all AED prescriptions were captured when these records were separated 
from the other medications. 
4.2.3 Cohort selection 
The decision was made to include only patients whose diagnosis of epilepsy 
could be validated based on the data provided. Patients were included in the 
cohort if they met both of the following criteria: 
• be a resident of the NHS GGC health board area as indicated by a 
presence in the CHI demography file 
• At least 1 hospitalisation or A&E attendance with an ICD code for epilepsy 
in any position  
• At least 1 prescription for an AED other than gabapentin 
Patients were excluded if they were prescribed gabapentin but had no other AED 
prescriptions during follow-up as gabapentin monotherapy is typically used to 
treat neuropathic pain. In order to allow for a standardised lookback period of 
one year from the start of follow-up for all patients, the start of the study 
period was defined as 01/01/2012, and patients were only included if they met 
all of the criteria after this date. Follow-up for patients who met the inclusion 
criteria started on the date of their first AED prescription or epilepsy-related 
admission during the follow-up period, whichever occurred first. End of follow-
up was defined as either date of death or 31/12/2016, whichever occurred first. 
After establishing which patients met the inclusion criteria, each of the datasets 
was filtered to remove data from patients who were excluded. Before analysis, 
each dataset was then split into two parts covering the follow-up and lookback 
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periods based on individual date of entry into the cohort and end of follow-up 
dates. If patients had at least 1 AED prescription during the lookback period, 
they were classified as existing users. The number of different AEDs prescribed 
to a patient on their index date was used to split patients into those prescribed 
monotherapy or combination therapy at baseline. 
4.2.4 Cohort summary generation 
Age at cohort entry was calculated using the date of birth provided in the 
demography data and the cohort entry date described above. In cases where the 
obfuscated date of birth resulted in a value of less than 0, age at cohort entry 
was set as 0. Weighted Charlson comorbidity scores at the start of follow-up 
were derived from SMR01 records during the 1-year period prior to the start of 
follow-up using the ‘comorbidity’ package in R, using ICD-10 codes listed in the 
primary and additional diagnosis fields.(264) The Charlson comorbidity score 
takes the following comorbidities into account: acute myocardial infarction, 
congestive heart failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic obstructive pulmonary disease, rheumatoid disease, peptic 
ulcer disease, mild liver disease, diabetes (with or without complications), 
hemiplegia or paraplegia, renal disease, cancer (any malignancy), moderate or 
severe liver disease, metastatic solid tumours and HIV/AIDS. When calculating 
the Charlson comorbidity score, each condition is assigned a score based on the 
impact it has on a patient’s chance of survival, with additional weighting given 
to more severe conditions.(265) Diabetes with complications, hemiplegia or 
paraplegia, renal disease and malignancies are assigned a score of 2, moderate 
or severe liver disease is assigned a score of 3, metastatic solid tumours and 
HIV/AIDS are assigned a score of 6 and the remaining comorbidities are assigned 
a score of 1. The total number of patients in the cohort per calendar quarter 
was calculated using the number of patients entering the cohort or ending 
follow-up (either due to death, removal or the end of the follow-up period) 
during each calendar quarter of the follow-up period. Patients were classified as 
new AED users at baseline if they had no AED prescriptions in the 1-year period 
before their index date. 
The most common causes of death were determined based on the ICD-10 codes 
most commonly listed as the primary cause of death. The frequency with which 
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these codes appeared in any position in the cohort death records was also 
determined. For each patient, the following were calculated:  
• the number of continuous inpatient stays, A&E attendances and the total 
number of admissions  
• the number continuous inpatient stays, A&E attendances and total 
admissions with an ICD-10 code for epilepsy in the first position 
• the number continuous inpatient stays, A&E attendances and total 
admissions with an ICD-10 code for epilepsy in any position 
The number of different drug classes (by BNF chapter) and number of unique 
AEDs (by approved drug name) encashed per patient during follow-up were 
counted. The most frequently prescribed drug classes (by BNF section) and most 
frequently prescribed AEDs (by approved name) were calculated, both by the 
number of prescriptions and the number of patients with at least one 
prescription during follow-up. The proportion of the total AED prescriptions 
which were for each of the top 5 AEDs was calculated by quarter across the 
follow-up period along with the proportion of patients in the cohort who had at 
least one prescription for these drugs per quarter. To avoid inflating counts for 
drugs which can be prescribed as two or more forms or doses of the same 
product at one time, only one prescription per patient per date was counted for 
each drug class or specific drug. In order to minimise the risk of accidental 
disclosure of identifying information, any results which apply to fewer than 10 
patients were censored as “<10” in line with Safe Haven requirements. 
4.2.5 Persistence to AEDs 
The number of patients prescribed each AED as their index drug was calculated 
and split according to whether patients were new or existing users and 
prescribed monotherapy or combination therapy at baseline. Where patients had 
more than 1 AED prescribed on their index date, all drugs were counted as index 
medications and information for those patients was included in more than one 
group. For patients prescribed more than 1 AED during the study period, 
prescribing order was identified based on the date of the first prescription for 
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each drug by approved name, and this was used to determine the frequency with 
which each AED was used as a second or third-line therapy (either as an 
alternative to their existing therapy or as an add-on therapy). 
Persistence to index drugs was determined using a 90-day allowable gap 
between prescriptions, with patients classified as persistent to a drug if they had 
not discontinued therapy at 365 days after their index prescription. Persistence 
was determined for AEDs as a class as well as for individual index drugs. Only 
patients’ first period of persistent use was considered, so if a patient 
discontinued treatment and was prescribed the drug of interest again after the 
end of the allowable gap they were still classified as non-persistent.  
Persistence variables were generated using the ‘refill_gap’ function from the 
prescribeR package, using the arguments displayed below. This command 
returned the first period of persistent use for each AED for each patient. In 
order to select for patients’ index medication, periods where the start date 
matched the patient’s index date were selected. 
refill_gap(df = cohort_pharmacy_aed, 
           drug = "*", 
           gap = 90, 
           threshold = 365, 
           first_period = TRUE) 
 
Rates of add-on and switching during the 365-day period of interest were 
calculated based on the total number of drugs prescribed at index and at least 
once over the 365-day follow-up period. Patients were classified as switchers if 
they were non-persistent to all of their index drugs but had a higher number of 
different AEDs prescribed overall by the end of the 365-day period compared to 
baseline. Patients were classified as having add-on therapy if they were 
persistent to at least 1 index drug and had a higher number of different AEDs 
prescribed by the end of the 365-day period compared to the number of index 
medications they were prescribed. 
All analyses were carried out in R, using R version 3.5.2 and R Studio version 
1.1.463. 
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4.3 Results 
4.3.1 Data cleaning 
4.3.1.1 Deaths 
After removing patients who did not appear in the demography data, there was a 
total of 3,094 deaths recorded in either the death records or demography files 
relating to a total of 10,281 patients. Table 12 below summarises the number of 
deaths recorded in each file. Of the 2,793 patients who had a death recorded in 
both files, 12 had two different dates recorded. After standardising the dates 
and removing 167 deaths which occurred after the censor date, a total of 2,907 
deaths remained. 
  Death in demography file 
  Yes No Total 
Death in NRS 
death records 
file 
Yes 2,793 7 2,800 
No 294 7,187 - 
Total 3,087 - - 
Table 12 - Summary of the dates of death contained in both the demography data and death 
records 
 
4.3.1.2 Hospitalisations and A&E attendances 
The SMR01 dataset contained 639 duplicate records where all fields matched, 
and no records where the admission date was after 31/12/2016. Records where 
some fields matched but not all (e.g., if the admission and/or discharge date(s) 
were the same but different ICD-10 codes were listed or if the admission date 
was the same, but the discharge dates were different) were retained. Admission 
dates were compared to the recorded dates of death, and 80 records on 78 
patients had an admission or discharge date after the date of death. After 
selecting for cohort patients and removing records which occurred before or 
after the follow-up period (described below) a second file was created which 
combined the individual SMR01 records into 30,093 continuous stays.  
The EDIS dataset contained 693 duplicated records where all fields matched and 
2,323 records where the admission date was after 31/12/2016, all of which were 
removed. There were no records where the admission date was after the date of 
death. 
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4.3.1.3 Prescriptions 
A total of 11,667 (0.4%) prescriptions for patients who were not present in the 
demography data were removed, along with 56,368 (1.8%) duplicate records, 
17,638 (0.5%) records dispensed after the end of the follow-up period and 14,410 
(0.4%) prescriptions dispensed after patients’ dates of death, leaving 3,119,010 
records. A second file containing only AED prescriptions (i.e. drugs with the BNF 
sub-section code ‘040801’) was created, containing 598,809 records. The BNF 
codes for 1,734 prescriptions for sodium valproate which were listed in the 
original data under BNF sub-section ‘040203’ (drugs for mania and hypomania) 
were adjusted to include these with the other AED prescriptions, bringing the 
total number of records for AED prescriptions to 592,543. 
4.3.1.4 Cohort selection 
In total, 5,771 patients met all of the criteria for inclusion in the cohort – Figure 
16 below gives a summary of the number of patients who met each of the 
criteria as they were applied.  
 
Figure 16 - Summary of the number of patients included and excluded at each stage of 
cohort definition 
 
Patients with a record in demography data 
(n = 10,281) 
… and at least 1 G40 admission in SMR01 or 
EDIS 
(n = 5,683) 
… and at least 1 AED prescription 
(n = 5,680) 
Patients on gabapentin 
monotherapy 
(n = 109) 
Patients included in cohort 
(n = 5,571) 
No relevant admission 
(n = 4,958) 
No relevant prescription 
(n = 3) 
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Once these patients were identified, records for ineligible patients were 
removed from the datasets, and records from before or after the follow-up 
period were removed based on individual cohort entry and end of follow-up 
dates. Table 13 below gives an overview of the contents of each dataset after 
data cleaning and patient selection – the follow-up files contain all records from 
that dataset from the patients’ cohort entry dates until the end of follow-up, 
and the lookback files contain the records for the 1 year prior to the patient’s 










Demographics 5,571 5,571 N/A N/A 
Deaths 1,026 1,026 N/A N/A 
PIS – AEDs only 








PIS – all drugs 





























Table 13 - Summary of the data available for cohort patients after data cleaning 
 
Figure 17 shows the total number of patients in the cohort over the duration of 
the follow-up period, calculated based on the number of patients entering or 
exiting the cohort during each quarter. The total number of patients being 
followed-up in a given quarter increased steadily during the first two and a half 
years of the study period, plateauing around 4,600 patients until declining during 
the final year of the study period.  
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Table 14 summarises the demographic characteristics of cohort patients. The 
cohort contained a larger number of men than women (54.4% vs. 45.6%), the 
median baseline age of included patients was 50 years and approximately half 
(51.7%) of the included patients lived in the most deprived quintile according to 
the Scottish Index of Multiple Deprivation (SIMD). The median duration of follow-
up was 4.83 years, and most patients within the cohort had at least one year of 
follow-up (93.8%). The majority of patients (82.4%) had a Charlson comorbidity 
score of 0 at baseline and 18.4% of the included patients died during follow-up. 
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  All subjects  N = 5,571 
Gender Female 2,539 (45.6) 
 Male 3,032 (54.4) 
Age 0 – 9 327 (5.9) 
 10 – 19 348 (6.2) 
 20 – 29 500 (9.0) 
 30 – 39 627 (11.3) 
 40 – 49 921 (16.5) 
 50 – 59 989 (17.8) 
 60 – 69 837 (15.0) 
 70 – 79 652 (11.7) 
 80+ 370 (6.6) 
 Median (IQR) 50 (31) 
SIMD Quintile 1 (most deprived) 2,879 (51.7) 
 2 956 (17.2) 
 3 616 (11.1) 
 4 481 (8.6) 
 5 (least deprived) 504 (9.0) 
 Unknown 135 (2.4) 
Charlson comorbidity 
score (weighted) 
0 4,593 (82.4) 
 1 508 (9.1) 
 2 231 (4.1) 
 3+ 239 (4.3) 
New AED users at 
baseline 
N (%) 1,712 (31.0) 
Died N (%) 1,026 (18.4) 
Length of follow-up Median 4.83 ( 
 IQR 1.73 
 Total 21989.29 
 Range 0.03 – 4.99 
 Patients with >180d 5,439 (97.6) 
 Patients with > 365d 5,228 (93.8) 
Table 14 - Summary of the demographic characteristics of cohort patients (n = 5,571) 
 
4.3.3 Outcomes, hospitalisations and deaths  
Over the course of follow-up, the median number of hospitalisations per patient 
was 4, and the median length of hospital stay was 11 days. The median number 
of ED visits per patient was also 4. The median number of total epilepsy-related 
admissions per patient was one for epilepsy coded as the main reason for 
admission and one when coded within the admission for any reason.  
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Hospitalisations per patient Median (IQR) 4 (5) 
Total LOS per patient (days) Median (IQR) 11 (35) 
A&E attendances per patient Median (IQR) 4 (6) 
Total hospital events per patient Median (IQR) 8 (10) 
Table 15 - Summary of the number of hospital events per patient 
 
  First position  Any position 
Epilepsy-related hospitalisations Median (IQR) 0 (1) 1 (2) 
Epilepsy-related A&E attendances Median (IQR) 0 (1) 0 (1) 
Total epilepsy-related hospital events Median (IQR) 1 (2) 2 (3) 
Table 16 - Summary of epilepsy-related hospitalisations and A&E visits for cohort patients, 
counting admissions where an ICD-10 code for epilepsy was listed in the first position or 
any position 
 
The most common causes of death amongst cohort patients are listed in Table 
17, below. Malignant neoplasm of the bronchus or lung was the most commonly 
listed primary cause of death, accounting for 5.4%. Epilepsy was the second most 
common primary cause of death as well as being listed as a contributing cause of 
death in 17.2% of the death records. The cause of death was only listed as 
unknown in the 6.6% of death records which were added based on dates of death 
listed in the demography file during data cleaning. 
Most common causes of death (ICD-10 
code and description) 
N (%) n = 1,026 
Code listed as primary 
cause of death 
Code listed in any 
position (primary or 
contributing) 
C439, Malignant neoplasm, bronchus or 
lung 
55 (5.4) 64 (6.2) 
G409, Epilepsy, unspecified 45 (4.4) 176 (17.2) 
I219, Acute myocardial infarction 43 (4.2) 52 (5.1) 
F019, Vascular Dementia 33 (3.2) 61 (5.9) 
F03, Unspecified dementia 32 (3.1) 64 (6.2) 
I698, Sequelae of other and unspecified 
cerebrovascular diseases 
32 (3.1) 58 (5.7) 
R99, Other ill-defined and unspecified 
causes of mortality 
25 (2.4) 26 (2.5) 
J690, Pneumonitis due to food and vomit 23 (2.2) 127 (12.4) 
J449, Chronic obstructive pulmonary 
disease, unspecified 
22 (2.1) 68 (6.6) 
G309, Alzheimer’s disease, unspecified 21 (2.0) 38 (3.7) 
I259, Chronic ischaemic heart disease, 
unspecified 
21 (2.0) 109 (10.6) 
Unknown 68 (6.6) N/A 
All other codes 606 (59.1) N/A 
Table 17 - Summary of the most common ICD-10 codes listed as the primary or contributing 
causes of death  
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4.3.4 Prescriptions 
AEDs accounted for 16.7% of the total number of prescriptions encashed by 
cohort patients, and as it was a requirement for entry into the cohort all 
patients had at least one prescription for an AED. Analgesics were the second 
most commonly prescribed drug class both by percentage of prescriptions (7.5% 
of the total prescriptions) and by percentage of patients (81.4% of patients were 
prescribed at least one drug from the class).  
Antibacterial drugs accounted for a smaller proportion of the total number of 
prescriptions but were prescribed at least once to over three quarters of cohort 
patients (79.1%). Drug classes which are used to manage chronic conditions as 
opposed to acute episodes, including anti-secretory drugs, anti-depressant drugs 
and lipid-regulating drugs, were amongst the most commonly prescribed classes 
both by number of patients and number of prescriptions. Topical steroids and 
emollients were prescribed to large numbers of patients (47.2% and 41.7% 
respectively) but did not appear on the list of the most commonly prescribed 
drugs by number of prescriptions, likely due to the quantity prescribed at one 
time being higher. 
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Drug class (BNF Section) 
Number of 
prescriptions (%) 
(N = 1,280,379) 
Drug class (BNF Section) 
Number of 
patients (%)  
(N = 5,571) 
Anti-epileptics 213,215 (16.7) Anti-epileptics 5,571 (100) 
Analgesics 95,613 (7.5) Analgesics 4,535 (81.4) 
Anti-secretory drugs 75,593 (5.9) Antibacterial drugs 4,405 (79.1) 
Antidepressant drugs 62,843 (4.9) Anti-secretory drugs 3,266 (58.6) 
Lipid regulating drugs 54,292 (4.2) Laxatives 2,885 (51.8) 
Vitamins 49,185 (3.8) Topical corticosteroids 2,630 (47.2) 
Antiplatelet drugs 47,383 (3.7) Antidepressant drugs 2,455 (44.1) 
Laxatives 42,759 (3.3) Hypnotics and anxiolytics 2,364 (42.4) 
Hypnotics and anxiolytics 39,518 (3.1) 
Drugs used in rheumatic 
disease and gout  
2,347 (42.1) 
Antibacterial drugs 35,598 (2.8) 
Emollient and barrier 
preparations 
2,325 (41.7) 
Table 18 - Summary of the most commonly prescribed drugs (grouped by BNF Section) 
based on total number of prescriptions (counting only 1 prescription per drug class per date 
for each patient) and number of patients who had at least 1 prescription during follow-up 
 
4.3.4.1 AED prescriptions 
Over the course of follow-up, the median number of different AEDs prescribed to 
cohort patients was 2 per patient and 11.4% of patients were prescribed at least 
4 different drugs. 
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Number of unique AEDs prescribed N (%) (total = 5,571) 
1 2,456 (44.1) 
2 1,647 (29.6) 
3 829 (14.9) 
4 359 (6.4) 
5 167 (3.0) 
6+ 113 (2.0) 
Median (IQR) 2 (2) 
Table 19 - Summary of the number of different AEDs per patient (by drug name) throughout 
follow-up 
 
Table 20 summarises the top 10 most commonly prescribed AEDs amongst cohort 
patients by number of prescriptions and by number of patients with at least one 
prescription (a complete list of AEDs appearing in the data can be found in 
Appendix 1). The top three most commonly prescribed AEDs amongst cohort 
patients were carbamazepine, sodium valproate and levetiracetam, which each 
accounted for over 15% of the total AED prescriptions and were prescribed at 
least once to more than 30% of the cohort patients.  
Drug 
Number of 
prescriptions (%)  
(N = 302,961) 
Drug 
Number of patients 
(%) 
(N = 5,571) 
Carbamazepine 55,496 (18.3) Levetiracetam 2,011 (36.1) 
Sodium valproate 54,485 (18.0) Sodium valproate 1,767 (31.7) 
Levetiracetam 48,037 (15.9) Carbamazepine 1,687 (30.3) 
Lamotrigine 46,029 (15.2) Lamotrigine 1,611 (28.9) 
Phenytoin 22,480 (7.4) Gabapentin 680 (12.2) 
Gabapentin 12,372 (4.1) Phenytoin 663 (11.9) 
Topiramate 11,073 (3.7) Pregabalin 550 (9.9) 
Pregabalin 10,860 (3.6) Topiramate 437 (7.8) 
Lacosamide 8,474 (2.8) Lacosamide 415 (7.4) 
Phenobarbital 7,390 (2.4) Clobazam 341 (6.1) 
Table 20 - List of the most commonly prescribed AEDs (by drug name) based on total 
number of prescriptions (counting 1 prescription per drug per day for each patient) and the 
number of patients who had at least 1 prescription during follow-up 
 
Figure 18 shows the changes in prescribing for the top 5 most commonly 
prescribed AEDs (carbamazepine, lamotrigine, levetiracetam, phenytoin and 
sodium valproate) across the study period. At the start of the study period, the 
most commonly prescribed drug both by proportion of total AED prescriptions 
and by proportion of patients with at least one prescription was carbamazepine. 
Over the duration of the study period, lamotrigine and levetiracetam both 
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became more frequently prescribed, with levetiracetam seeing the largest 
increase and becoming the most frequently prescribed AED during the final year 
of the study period. The proportion of prescriptions and patients per quarter 
throughout the study period decreased for both carbamazepine and phenytoin 
and remained relatively consistent for sodium valproate.  
 
Figure 18 – Summary of changes in AED prescribing during the study period, showing 
proportion of the total AED prescriptions which were for each of the top 5 most commonly 
prescribed AEDs (A) and the proportion of cohort patients with at least 1 prescription for 
each drug (B) per quarter  
 
4.3.5 Persistence to AEDs 
A summary of the number of cohort patients who were classified as new and 
existing users  of AEDs and prescribed monotherapy or combination therapy at 
baseline is shown in Table 21 - Summary of the number of new and existing users 
of AEDs at baseline and the number of patients initiating monotherapy vs 
combination therapy. At baseline, more cohort patients were existing users of 
AEDs than new users based on a 365-day look back period. AED monotherapy was 
more common than combination therapy, but combination therapy accounted for 
a larger proportion of existing users vs. new users. Existing users prescribed 
monotherapy at index made up approximately 50% of the cohort. 
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 Monotherapy Combination therapy Total 
New users 1,620 (29.1%) 92 (1.7%) 1,712 (30.7%) 
Existing users 2,780 (49.9%) 1,079 (19.4%) 3,859 (69.3%) 
Total 4,400 (79.0%) 1,171 (21.0%) 5,571 
Table 21 - Summary of the number of new and existing users of AEDs at baseline and the 
number of patients initiating monotherapy vs combination therapy 
 
4.3.5.1 Index medications 
Table 22 contains a summary of the frequency with which each AED was 
prescribed to cohort patients as their index medication or their second or third 
medication after the index date. Patients prescribed more than one drug at their 
index date were included in the totals for multiple drugs. The second or third 
prescribed drugs either represented alternative or additional drugs prescribed to 
cohort patients. The cumulative percentages for some drugs are relatively low, 
as only 26.3% of cohort patients were prescribed 3 or more AEDs during the study 
period. The AEDs most commonly prescribed to cohort patients as their index 
therapy were carbamazepine, valproate, levetiracetam, lamotrigine and 
phenytoin. The most common drugs prescribed as second-line therapies were 
levetiracetam, gabapentin, lamotrigine, sodium valproate and pregabalin, and 
the most common third-line therapies were levetiracetam, phenytoin, 
lamotrigine, lacosamide and gabapentin. Brivaracetam and permapanel were not 
prescribed to any patients as an index therapy. Stiripentol was only prescribed 
as the index drug to small number of patients and was not prescribed to any 
cohort patients as an alternative treatment. Levetiracetam, lacosamide and 
gabapentin all accounted for higher proportions of second- and third-line 
therapies than they did index therapy. Carbamazepine accounted for a lower 
proportion of second- and third line prescribing than index prescribing. 
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Drug Index drug Second drug Third drug 
N (%)  
Brivaracetam 0 0% <10 0.1% <10 0.1% 
Carbamazepine 1,446 26.0% 169 3.0% 47 0.8% 
Clobazam 113 2.0% 85 1.5% 71 1.3% 
Clonazepam 80 1.4% 68 1.2% 17 0.3% 
Eslicarbazepine <10 0.1% <10 0.2% <10 0.1% 
Ethosuximide 19 0.3% <10 0.1% <10 0.0% 
Gabapentin 243 4.4% 310 5.6% 89 1.6% 
Lacosamide 90 1.6% 150 2.7% 96 1.7% 
Lamotrigine 1,151 20.7% 301 5.4% 97 1.7% 
Levetiracetam 1,210 21.7% 605 10.9% 147 2.6% 
Oxcarbazepine 48 0.9% 29 0.5% 15 0.3% 
Perampanel 0 0% 31 0.6% 68 1.2% 
Phenobarbital 170 3.1% 28 0.5% 13 0.2% 
Phenytoin 560 10.1% 74 1.3% 113 2.0% 
Pregabalin 180 3.2% 196 3.5% <10 0.0% 
Primidone 58 1.0% 14 0.3% <10 0.1% 
Retigabine <10 0.2% <10 0.1% 15 0.3% 
Rufinamide <10 0.1% <10 0.1% <10 0.0% 
Sodium valproate 1,366 24.5% 279 5.0% 84 1.5% 
Stiripentol <10 0.0% 0 0% 0 0% 
Tiagabine <10 0.1% <10 0.1% 0 0% 
Topiramate 225 4.0% 108 1.9% 53 1.0% 
Vigabatrin 46 0.8% <10 0.1% <10 0.1% 
Zonisamide 67 1.2% 30 0.5% 31 0.6% 
Table 22 - Summary of the frequencies with which individual AEDs were prescribed as 
index, second or third drug to cohort patients 
 
Table 23 contains a summary of the number of patients prescribed each AED as 
their index drug, split according to whether patients were new or existing users 
and whether they were prescribed monotherapy or combination therapy at 
baseline. For new users prescribed monotherapy at index, the most commonly 
prescribed AEDs were levetiracetam, lamotrigine and sodium valproate. For new 
users prescribed combination therapy, the most commonly prescribed AEDs at 
index were levetiracetam, carbamazepine and phenytoin. For existing users 
being prescribed monotherapy at their index date, the most commonly 
prescribed drugs were carbamazepine, sodium valproate and lamotrigine. For 
existing users prescribed combination therapy the most commonly prescribed 
drugs were sodium valproate, carbamazepine and levetiracetam.  
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Newer AEDs including levetiracetam and lamotrigine were more commonly 
prescribed as the index medication to new users on monotherapy compared to 
existing users on monotherapy, and levetiracetam was more commonly 
prescribed in combination therapy than in monotherapy to both new and existing 
users at baseline. Older medications including carbamazepine, phenobarbital 
and phenytoin were more commonly prescribed to existing users on monotherapy 
at baseline. Phenytoin was more frequently prescribed in combination therapy 
than monotherapy. Topiramate was more frequently prescribed to existing users 
on combination therapy than the other groups. Sodium valproate was commonly 
prescribed across all patient groups but was more common amongst existing 
users compared to new users and in combination therapy compared to 
monotherapy. 
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Drug 






Carbamazepine 170 10.5% 23 25.0% 824 29.6% 429 39.8% 
Clobazam 14 0.9% <10 <11.0% 34 1.2% 56 5.2% 
Clonazepam 13 0.8% <10 <11.0% 17 0.6% 45 4.2% 
Eslicarbazepine 0 0.0% 0 0.0% <10 <0.4% <10 <0.9% 
Ethosuximide <10 <0.6% 0 0.0% <10 <0.4% <10 <0.9% 
Gabapentin 70 4.3% 11 12.0% 63 2.3% 99 9.2% 
Lacosamide <10 <0.6% <10 <11.0% 13 0.5% 63 5.8% 
Lamotrigine 341 21.0% 20 21.7% 440 15.8% 350 32.4% 
Levetiracetam 566 34.9% 54 58.7% 232 8.3% 358 33.2% 
Oxcarbazepine <10 <0.6% 0 0.0% 17 0.6% 22 2.0% 
Phenobarbital <10 <0.6% <10 <11.0% 92 3.3% 69 6.4% 
Phenytoin 41 2.5% 24 26.1% 259 9.3% 236 21.9% 
Pregabalin 50 3.1% <10 <11.0% 48 1.7% 73 6.8% 
Primidone <10 <0.6% <10 <11.0% 21 0.8% 34 3.2% 
Retigabine 0 0.0% 0 0.0% <10 <0.4% <10 <0.9% 
Rufinamide <10 <0.6% 0 0.0% 0 0.0% <10 <0.9% 
Sodium 
valproate 271 16.7% 23 25.0% 633 22.8% 439 40.7% 
Stiripentol 0 0.0% 0 0.0% 0 0.0% <10 <0.9% 
Tiagabine 0 0.0% <10 <11.0% <10 <0.4% <10 <0.9% 
Topiramate 26 1.6% <10 <11.0% 60 2.2% 135 12.5% 
Vigabatrin 20 1.2% <10 <11.0% <10 <0.4% 15 1.4% 
Zonisamide <10 <0.6% <10 <11.0% <10 <0.4% 50 4.6% 
Table 23 - Summary of AEDs prescribed as index drugs to cohort patients, split by new and 
existing users and whether patients were prescribed monotherapy or combination therapy 
at baseline, number of patients and percentage of each patient sub-group reported 
 
4.3.5.2 Persistence to AEDs 
A summary of the overall rates of persistence to AEDs at 365 days is shown in 
Table 24. The rate of persistence to AEDs as a class was 5.6% higher than 
persistence to any individual index drug. This difference represents patients who 
discontinued their index treatment but were still considered persistent when all 
AEDs were considered together and were therefore still receiving some form of 
AED treatment at the end of the 365-day period of interest. Approximately 25% 
of cohort patients had a change in their AED therapy over the 365-day period, 
having either switched to a different AED or having had another AED added to 
their treatment during the 365-day period following their index prescription. 
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 N (%) 
(N = 5,571) 
Patients persistent to AEDs as a class  3,572 (64.1%) 
Patients persistent to any index drug 3,277 (58.5%) 
Patients persistent to all index drugs  3,102 (55.7%) 
Patients with an add-on therapy 698 (12.5%) 
Patients who switched therapy  666 (12.0%) 
Table 24 - Summary of the rates of persistence to AEDs as a class and any or individual 
AEDs at 365-days after index prescription, and the rates of add-on prescribing or switching 
within the first 365 days  
 
A summary of overall persistence to index AEDs split based on whether patients 
were new or existing users and prescribed monotherapy or combination therapy 
at baseline is shown in Table 25. For patients prescribed combination therapy 
and all patients, the rate of persistence to any index AED and the rate of 
persistence to all index AEDs are reported. Persistence rates were generally 
higher amongst existing users than new users and patients on combination 
therapy rather than patients prescribed monotherapy. Persistence was highest 
among patients who were existing users and started follow-up on combination 
therapy, although rate of persistence to all index drugs was lower than to any 




Combination therapy Total 
 Any drug All drugs Any drug All drugs 
New users 661 (40.8%) 48 (52.2%) 35 (39.1%) 709 (41.4%) 696 (40.7%) 
Existing users 1707 (61.4%) 861 (79.8%) 699 (64.8%) 2568 (66.5%) 2406 (62.3%) 
Total 2368 (53.8%) 909 (77.6%) 734 (62.7%) 3277 (58.8%) 3102 (55.7%) 
Table 25 – Summary of overall persistence rates for any or all index drugs at 365 days after 
index prescription, with the number of patients persistent and the percentage of each group 
persistent to any index therapy and all index therapies reported 
 
The rates of persistence to index AEDs broken down by individual drug are 
summarised in Table 26. Persistence rates ranged from 33.3% - 100% amongst all 
drugs. The drugs which were prescribed least, including rufinamide, tiagabine 
esclicarbazepine, ethosuximide and retigabine were outliers with either 
particularly low or high rates of persistence. Amongst the more commonly 
prescribed (N>10) drugs, persistence ranged from 50.6% (gabapentin) to 71.2% 
(phenobarbital), with a median persistence rate of 61.4%.  
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Index drug Patients persistent N (%) 
Carbamazepine 933 64.5% 
Clobazam 79 69.9% 
Clonazepam 56 70.0% 
Eslicarbazepine <10 37.5% 
Ethosuximide <10 47.4% 
Gabapentin 123 50.6% 
Lacosamide 56 62.2% 
Lamotrigine 696 60.5% 
Levetiracetam 662 54.7% 
Oxcarbazepine 33 68.8% 
Phenobarbital 121 71.2% 
Phenytoin 368 65.7% 
Pregabalin 92 51.1% 
Primidone 40 69.0% 
Retigabine <10 33.3% 
Rufinamide <10 100.0% 
Sodium valproate 821 60.1% 
Tiagabine <10 100.0% 
Topiramate 131 58.2% 
Vigabatrin 24 52.2% 
Zonisamide 36 53.7% 
Table 26 –Summary of the rates of persistence to individual AEDs at 365 days after index 
prescription 
 
The rates of persistence to index AEDs by drug split by patient sub-group are 
summarised in Table 27. Persistence rates were generally higher for existing 
users than for new users, and also for individual drugs when prescribed as part of 
combination therapy as opposed to monotherapy.  
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Drug 






N % N % N % N % 
Carbamazepine 60 35.30% 11 47.80% 527 64.0% 335 78.1% 
Clobazam <10 35.70% <10 44.40% 24 70.6% 46 82.1% 
Clonazepam <10 46.20% <10 80.00% 11 64.7% 35 77.8% 
Eslicarbazepine - - - - <10 50.0% <10 25.0% 
Ethosuximide <10 25.00% - - <10 33.3% <10 75.0% 
Gabapentin 15 21.40% <10 54.50% 28 44.4% 74 74.7% 
Lacosamide <10 42.90% <10 100.00% <10 46.2% 40 63.5% 
Lamotrigine 161 47.20% <10 45.00% 276 62.7% 250 71.4% 
Levetiracetam 236 41.70% 22 40.70% 137 59.1% 267 74.6% 
Oxcarbazepine <10 55.60% - - 11 64.7% 17 77.3% 
Phenobarbital <10 50.00% <10 80.00% 59 64.1% 56 81.2% 
Phenytoin 14 34.10% 10 41.70% 174 67.2% 170 72.0% 
Pregabalin 13 26.00% <10 44.40% 29 60.4% 46 63.0% 
Primidone <10 0.00% <10 50.00% 13 61.9% 26 76.5% 
Retigabine - - - - <10 0.0% <10 50.0% 
Rufinamide <10 100.00% - - - - <10 100.0% 
Sodium 
valproate 126 46.50% <10 30.40% 368 58.1% 320 72.9% 
Stiripentol - - - - - - <10 0.0% 
Tiagabine - - <10 100.00% <10 100.0% <10 100.0% 
Topiramate <10 19.20% <10 50.00% 32 53.3% 92 68.1% 
Vigabatrin <10 30.00% <10 33.30% <10 62.5% 12 80.0% 
Zonisamide <10 12.50% <10 100.00% - - 31 62.0% 
Table 27 – Summary of rates of persistence to individual AEDs at 365 days after index 
prescription  split by new and existing users and whether patients were prescribed 




The aim of this chapter was to describe a cohort of patients with epilepsy and to 
examine the rates of persistence to AEDs. The results showed the rates of 
prescribing different AEDs as index therapies or additional therapies later in 
treatment, as well as highlighting variation in the rates of prescribing different 
AEDs and in 1-year persistence to AED therapy by drug. The results also 
demonstrate differences in both frequency of prescribing of different AEDs and 
rates of 1-year persistence to AEDs between new and existing users and patients 
prescribed the drugs as amonotherapy or in combination with other AEDs. This 
chapter also demonstrated the utility of the prescribeR package in preparing 
data for clinical research. 
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A total of 5,770 patients with epilepsy were identified using epilepsy-related 
prescriptions and hospital records representing 21,989.29 person-years of follow-
up, with a median follow-up length of 4.83 years per patient. Over the course of 
the follow-up period 18.4% of the cohort patients died. This is a relatively high 
percentage of patients, but given the number of patients over 65 in the cohort 
and the lower life expectancy for patients with epilepsy this is not entirely 
unexpected.  The level of comorbidity amongst cohort patients was assessed 
using the Charlson comorbidity score, calculated using records of hospitalisations 
in the year prior to cohort entry. Most patients (82.4%) scored 0, suggesting a 
low prevalence of serious comorbid conditions amongst cohort patients, a finding 
which is not in line with other research on patients with epilepsy.(248) This may 
be due to a number of factors, including the limited length of the lookback 
period meaning older hospitalisations are not accounted for, the use of only 
hospitalisation records to ascertain comorbidity and the specific subset of 
conditions included in the Charlson comorbidity score. Further comorbidities 
could likely be identified through the use of primary care data or other indices 
of comorbidity, but these data are not currently available for this cohort. 
Another potential method of expanding the range of comorbid conditions 
considered would be to use pharmacy data as a proxy to identify other 
conditions including conditions such as diabetes, asthma, depression and anxiety 
which often do not require hospitalisation and for which there are drugs specific 
to the condition. When using pharmacy records to define comorbidity, the use of 
medications must be specific enough in order to minimise risk of 
misclassification, particularly in cases where drugs have multiple indications. 
Prescribing of multiple AEDs per patient was common in this cohort - over the 
course of the study period, over half of the included patients were prescribed 
two or more different AEDs, and 10% were prescribed 4 or more. The most 
commonly prescribed AEDs and trends in the utilisation of the top AEDs observed 
for this cohort are in line with those observed in the literature. (122, 254-257) 
The top 5 AEDs (carbamazepine, valproate, levetiracetam, lamotrigine and 
phenytoin) accounted for almost three quarters (74.8%) of all AED prescriptions 
across the follow-up period, and around 30% of the study patients had at least 
one prescription for levetiracetam, valproate, carbamazepine or lamotrigine. 
Overall, carbamazepine was the most commonly prescribed AED across the 
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follow-up period by number of prescriptions, but the trends over time showed a 
decrease in the use of older drugs (carbamazepine and phenytoin) while the 
number of prescriptions and number of patients prescribed newer drugs 
increased, particularly levetiracetam which became the most commonly 
prescribed AED by both number of prescriptions and number of patients during 
the last year of the study. This may be due to these drugs having fewer side 
effects, and is likely in line with these newer drugs becoming available in 
generic forms; levetiracetam became available as a generic medication in 
2011(266), followed by lamotrigine’s chewable and dispersible formulations in 
2012.(267) As shown in Chapter 4, the rates of prescribing of levetiracetam and 
lamotrigine generally increased across the follow-up period for this cohort. 
There was variation in the rates of persistence across AEDs; across all cohort 
patients, 58.8% were persistent to at least 1 of their index medications, with 
persistence across individual drugs ranging from 50.6% to 71.2% for drugs 
prescribed to more than 10 patients at index. When comparing the different 
patient sub-groups investigated in this chapter, new users had lower rates of 
persistence than existing users, particularly new users on monotherapy. Existing 
users on combination therapy had the highest rates of persistence to at least 1 
index therapy, as well as to most of the individual AEDs. There are a number of 
factors which could explain these differences. Existing users may be more used 
to managing their condition and continuing to take their medications as 
prescribed, have greater disease severity and therefore a greater reliance on 
AEDs to control seizures, or be on medications which are already shown to be 
effective in controlling their seizures. New users who are non-persistent to their 
index medications, on the other hand, may be switching to other drugs on 
physician’s advice. Combination therapy users may be more likely to persist due 
to increased disease severity; combination therapy is a last resort option for 
physicians, and the recommendation is to try alternative monotherapies before 
considering adding a second medication to a patient’s regime. 
The use of the prescribeR package made the generation of the large quantity of 
persistence variables summarised in this chapter relatively simple, as the 
majority of the work was done through one function call. This allowed for 
comparison of the number of patients prescribed different drugs and the rates of 
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persistence to these drugs across a whole class with minimal additional coding. 
In this case, additional code was required to filter the drug use periods returned 
by the function to exclude non-index medications for each patient, a feature 
which could be a useful addition to the next version of the persistence functions 
in the package. 
With the required data cleaning and processing complete, the epilepsy cohort 
described in this chapter can be used to perform analyses for a range of 
different research questions related to prescribing and outcomes for patients 
with epilepsy. CHI linkage also offers potential to extend the cohort data by 
linking to additional datasets available within the Safe Haven platform including 
outpatient clinic attendance (SMR00), mental health admissions (SMR04) or 
laboratory test data. The established process for cleaning the existing datasets 
also allows for extension of the cohort to include additional patients or to 
extend the study follow-up period for the existing data as more data are 
captured and made available. For example, updating the analysis to include the 
most recently collected data would allow for assessment of the impact of 
changes made in 2018 to the guidance on the prescribing of sodium valproate to 
female patients of childbearing age.(268)  
The established cohort is not without limitations. The definition of epilepsy used 
in the inclusion criteria relies on the patient having been hospitalised or having 
attended A&E and the hospital event having been correctly recorded as epilepsy 
related. This means that there may be patients who have less severe cases of 
epilepsy or focal epilepsy syndromes where patients do not experience motor 
symptoms who are not included in the cohort as a result of not being 
hospitalised. The more severe cases are still of interest when investigating issues 
around management of epilepsy through AED prescribing and the challenges of 
managing patients with multimorbidity. Finally, studies investigating issues 
around drug utilisation typically distinguish between new and existing users of 
the drug(s) of interest. Using the current cohort definition and lookback period, 
only 31.0% of included patients were considered new users of AEDs at baseline 
(i.e. they had no prescriptions for AEDs in the one year prior to cohort entry). 
Initially, the intention was to use patients whose diagnosis of epilepsy had 
previously been validated through the use of GP records and epilepsy-related 
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referrals to neurology outpatient clinics. However, we were unable to verify that 
the data provided in the Safe Haven were for these patients exclusively, so the 
decision was made to include the requirement for an epilepsy-related hospital 
event to verify that the included patients were epileptic. 
Although there were a large number of cohort patients overall, there were 
relatively small numbers of patients prescribed certain drugs as their index 
medications, including ethosuximide, esclicarbazepine, retigabine, rufinamide 
and tiagabine, all of which were prescribed to less than 10 cohort patients at 
baseline. This means that the persistence rates reported for these drugs may not 
be a reliable estimate of persistence in a larger population, but as this is a 
population-based cohort these low prescribing rates indicate these drugs are 
infrequently used in the community.  
Additionally, while a 1-year lookback period was used to identify patients who 
were existing users of AEDs at baseline, there is potential that some patients are 
misclassified and are in fact existing users who have been previously non-
persistent. This is particularly true of new users who were prescribed 
combination therapy at baseline, as combination therapy is only usually used in 
cases where a number of different monotherapies have been tried and have 
failed to adequately manage the patient’s seizures. Additionally, for patients 
who were classified as existing users of AEDs at baseline, no adjustments were 
made for whether or not they had been taking their index drug(s) during the 
lookback period, or the length of time they had already been persistent if they 
had. For patients on combination therapy, the drugs were only investigated 
individually, so persistence to specific combinations of AEDs was not considered. 
In cases where patients were non-persistent to one drug but were found to have 
switched to a second medication during the 365-day period of interest, 
persistence to the second drug was not measured. This means there was no 
differentiation between patients who had discontinued AED therapy completely 
and patients who had persisted on a second drug beyond the initial measurement 
of persistence to AEDs as a class. Finally, although the differences in persistence 
across different patient groups were assessed, this chapter did not consider the 
impact of factors such as disease severity, comorbidity, demographic factors on 
comorbidity or the variable potential for adverse events across different drugs. 
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The results in this chapter have demonstrated the potential utility of the 
prescribeR package as a tool for generating drug exposure variables in clinical 
research using large, routinely collected prescribing databases, and have 
demonstrated variation in the levels of persistence to different AEDs in a cohort 
of patients with epilepsy. In the next chapter, this cohort will be used to test 
the prescribeR package and assess the effect that varying the definition of drug 
exposure has on the observed associations in an exemplar clinical research 
question. 
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5 Comparison of exposure quantification methods 
5.1 Introduction 
The systematic review of pharmacoepidemiological research detailed in Chapter 
2 highlighted a range of methods for quantifying drug exposure based on 
routinely collected data. These methods varied in the level of detail they 
provided, and even within the different classes of methods identified there was 
variation in the exact definition of exposure used between studies. Each of the 
assumptions required when quantifying exposure has the potential to introduce 
exposure misclassification into the study which would limit the validity and 
accuracy of the results obtained. There is evidence showing that the drug of 
interest,(209, 269) and the structure, source and potential weaknesses or 
limitations of the data being used(26, 34, 198, 227, 233) should be taken into 
account when deciding how exposure should be quantified. 
Although the systematic review highlighted some of the relative merits and 
limitations of these methods, there were a limited number of studies assessing 
the impact of altering the definition of drug exposure on the results observed in 
pharmacoepidemiological research. The aim of this chapter is to demonstrate 
the effects of varying the definition of exposure on the estimated number of 
patients exposed and the estimated duration of treatment episodes for a range 
of different AEDs and other drug classes, and to demonstrate how these changes 
impact the observed association between exposure to levetiracetam and all-
cause mortality in the previously defined cohort of epilepsy patients. 
5.2 Methods 
5.2.1 Study population 
As described in Chapter 4, in order to be eligible for Inclusion in the cohort, 
patients had to be a resident of the NHSGGC health board area, as indicated by 
a presence in the CHI demography file, have at least one epilepsy-related 
hospital admission recorded in SMR01 or A&E attendance recorded in the EDIS 
data, and have at least one prescription for an AED other than gabapentin. The 
study period started on 01/01/2012 and ended on 31/12/2016, and patients 
  165 
 
began follow-up on the date of their first epilepsy-related admission, A&E 
attendance or AED prescription during the study period, whichever occurred 
first. All data used were collected within the NHSGGC health board area. 
5.2.2 Effect of exposure definition on the estimated number of 
exposed patients 
The exposure definitions assessed in this chapter were chosen based on the 
common methods and thresholds identified in Chapter 2.  
5.2.2.1 Ever use 
Patients were defined as being exposed if they had at least the threshold 
number of prescriptions for the drug(s) of interest to assess the differences 
between the number of patients exposed as the threshold was increased from 1 
to 10 prescriptions. The following drugs/drug groups were assessed: 
• AEDs as a class (i.e. prescriptions for any drug with the BNF sub-section 
code ‘040801’) 
• The top 5 most commonly prescribed AEDs (by approved drug name); 
carbamazepine, sodium valproate, lamotrigine, levetiracetam, phenytoin 
• Other commonly prescribed drug groups (by BNF section code) – analgesics 
(0407), lipid-regulating drugs (0212), antibacterial drugs (0501) and anti-
depressants (0403) 
The structure of the R function calls used to determine which patients meet 
each definition is shown below – the ‘drug’ and ‘threshold’ values were adjusted 
to provide all of the desired exposure variables. 
ever_use(df = cohort_pharmacy_aed, 
        drug = "*", 
        threshold = 1) 
 
Some of the drugs of interest are often prescribed in multiple forms at one time 
- for example, if patients are on a higher dose, they may be prescribed two 
tablets of different strengths to make up the prescribed dose. When comparing 
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patients on different doses and prescribing across different drugs of interest, not 
accounting for these records could introduce bias by inflating some patients’ 
prescription counts, or the prescription counts for certain drugs. In the example 
shown in Figure 19, counting both the 10mg and 20mg prescriptions the third 
patient has received would increase their total prescription count, therefore 
misclassifying their exposure level. 
 
Figure 19 - Example showing how drugs prescribed in multiple doses can affect 
prescription counts 
 
In order to assess the impact of combining these records on the number of 
patients exposed at each threshold, the number of patients exposed when all 
prescriptions were taken into account was compared to the number of patients 
exposed when only counting one prescription per date. The number of patients 
who had at least one prescription for any drug was used as the baseline to 
calculate the proportion of patients who met the other thresholds to allow for 
clearer comparisons between drugs or drug classes. The structure of the function 
call used to derive these variables is shown below – the ‘drug’ and ‘threshold’ 
were adjusted to match each exposure definition. 
ever_use(df = cohort_pharmacy_aed, 
        drug = "*", 
        threshold = 1, 
        flatten = TRUE) 
 
5.2.2.2 Use at time 
Three methods of defining exposure based on use at a specific time point, or 
within a specific time frame, were investigated. The impact of using different 
lookback periods on the number of patients who were defined as new users of 
each drug of interest prescribed AEDs at baseline. To be classified as a new user 
at baseline, a patient needed to have at least one prescription for the drug 
during follow-up and no prescriptions for the drug of interest within the period 
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of interest before their index date. The proportion of patients ever prescribed 
the drug during follow-up who were classified as new users using each lookback 
duration was calculated and compared across drugs. The function below was 
used to determine patients’ exposure status, with the ‘drug’ and ‘timeframe’ 
variables were adjusted to match each exposure definition. 
new_users_var(df = cohort_pharmacy_aed,  
              df2 = cohort_follow_up,  
              drug = "*",  
              timeframe = 7) 
 
Next, the number of patients who were classified as current users of each drug 
of interest at death, was calculated using different allowable timeframes before 
their date of death - the proportion of patients who died and had ever had a 
prescription who met the exposure definition was calculated. 
uat_fixed_events(df = cohort_pharmacy_aed,  
                 df2 = cohort_deaths,  
                 drug = "*",  
                 timeframe = 7,  
                 forward = FALSE) 
 
Finally, the number of patients who met the exposure definition of two 
prescriptions for the drug of interest within a desired number of days of one 
another was determined using different allowable gaps, and the proportions of 
the number of patients who had at least 2 prescriptions on different dates and 
met each exposure definition were calculated. The ‘drug’ and ‘timeframe’ 
variables  function call below were adjusted to derive the necessary exposure 
variables 
uat_gap(df = cohort_pharmacy_aed, 
        drug = "*", 
        timeframe = 7) 
 
For each of these three methods, the allowable timeframes tested were 7, 14, 
30, 60, 90, 180, 270 and 365 days. The number of patients meeting the 
definition of exposure for AEDs as a class and each of the top 5 most commonly 
prescribed AEDs was assessed. 
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5.2.2.3 Persistence 
The effect of varying the duration of the allowable gap between prescriptions on 
rates of persistence at 180 days and 365 days after initiating treatment and the 
length of time to first discontinuation was assessed. The number of patients who 
were considered persistent to the drug of interest 180 and 365 days from their 
first prescription was determined. The rate of persistence at both time points 
was assessed for AEDs as a class and each of the top 5 most commonly 
prescribed AEDs. When considering AEDs as a class, the patient was considered 
persistent even if they switched to a different AED or started on an additional 
AED therapy. 
 
Figure 20 – Example application of the definition of 180-day persistence applied to cohort 
patients 
 
The allowable gap between prescriptions was varied, with 30, 45, 90, 120- and 
180-day allowable gaps tested. The proportion of patients who had at least 1 
prescription and had not discontinued treatment at 180 and 365 days was 
calculated. Once patients were identified as non-persistent, any further use 
within the 180- and 365-day period but after the allowable gap was ignored – an 
example of how 180-day persistence was assessed is shown in Figure 20. The 
length of time persistent until the first point of discontinuation using each 
allowable gap length was determined and summarised across the cohort. Figure 
21 shows an example of how time to discontinuation was calculated for cohort 
patients passed on individual prescriptions. 
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Figure 21 - Example of how time to discontinuation was calculated for cohort patients 
 
The function call below was used to identify patients’ first period of persistent 
use and the ‘drug’, ‘gap’ and ‘threshold’ arguments were adjusted to provide 
the measurements described above. 
refill_gap(df = cohort_pharmacy_aed, 
           drug = "*", 
           gap = 30,  
           first_period = TRUE) 
 
5.2.3 Effect of exposure definition on observed exposure-
outcome associations 
The association between levetiracetam exposure and all-cause mortality was 
calculated using a number of different exposure definitions as part of a series of 
Cox proportional hazards models. Cohort patients were classified as exposed or 
unexposed to levetiracetam based on a number of different time-fixed and time-
varying exposure definitions. The index date for all patients was their cohort 
entry date. 
The baseline characteristics (age, sex, SIMD quintile, length of follow-up and 
Charlson comorbidity scores) of the exposed and unexposed patients were 
compared to determine if any substantial differences existed between the two 
groups at baseline. For this comparison, patients were considered exposed to 
levetiracetam if they had at least 1 prescription during follow-up, as this 
included all patients who would appear in the exposed group in any of the 
definitions used for the models described below. 
In the time-fixed definitions, exposure was defined as a binary variable which 
did not change during the follow-up period. The definitions used were;  
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• 1 or more prescription (i.e. ever versus never use), 
• 2 or more prescriptions, 
• 2 prescriptions within 30 days, 
• 2 prescriptions within 90 days, 
• 2 prescriptions within 180 days.  
The necessary exposure statuses for each patient were defined using previously 
described calls to the ‘ever_use’ and ‘uat_gap’ functions. Follow-up for exposed 
patients began on the date of their first levetiracetam prescription in the first 
model and the date of their second levetiracetam prescription for the remaining 
models.  
In the time-varying definitions, prescription records were assessed across the 
follow-up period to define exposure status at multiple points. The simplest 
method used here was the legacy effect, whereby patients were considered 
unexposed until their first prescription for levetiracetam, and then exposed until 
the end of follow-up. Additional methods involved splitting the follow-up period 
into windows of equal length and defining exposure based on whether or not 
patients had at least one prescription within each window, and defining 
persistent time using different allowable gap lengths. The definitions used were; 
• Legacy effect 
• Follow-up split into 30, 90- or 180-day windows 
• Persistent time defined with a 30, 90 and 180-day allowable gap 
The exposure status and first prescription date for each patient for the legacy 
effect model were taken from a previously described call to the ever_use 
function. The following function calls were used to define the second and third 
group of exposure periods, with the ‘timeframe’ and ‘gap’ variables adjusted 
respectively. Follow-up for all patients began on their index date. 
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uat_windows(df = cohort_pharmacy_aed, 
            df2 = cohort_follow_up, 
            drug = "LEVETIRACETAM", 
            individual = TRUE, 
            timeframe = 30) 
 
refill_gap(df = cohort_pharmacy_aed, 
           drug = "LEVETIRACITAM", 
           gap = 30, 
           first_period = FALSE) 
 
In each model, the reference group consisted of patients who did not meet the 
threshold for exposure to levetiracetam – these patients all had at least 1 
prescription for another AED, as this was required for entry into the cohort. In 
addition to levetiracetam exposure, all of the models were adjusted for age, sex 
and comorbidity score at baseline. Cox proportional hazard regression models 
were used for all exposure methods to calculate hazard ratios and 95% 
confidence intervals (CI). The aim was not to establish an association between 
levetiracetam use and all-cause mortality but to highlight any systematic 
differences in observed association which occur as a result of varying exposure 
definition, so other limitations in the use of these models were not explored. As 
the same cohort and variables are used in each model, they should have the 
same degree of additional confounding. 
All analyses were carried out in R, using R version 3.5.2 and R Studio version 
1.1.463. Exposure variables were generated using the prescribeR package.  
5.3 Results 
5.3.1 Ever use 
A summary of the changes in the proportion of patients who are considered 
exposed to the drugs of interest as the threshold for exposure increases can be 
seen in Figure 22, along with the total number of patients with at least 1 
prescription for AEDs as a class or each individual drug. For all of the drugs of 
interest, at least 70% of patients were still considered exposed with a threshold 
of 10 prescriptions using both methods. When grouping all AEDs as a class and 
counting all individual prescriptions, 90.1% of the patients with 1 prescription 
are still considered exposed at the 10-prescription threshold. This value 
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decreased to 88.1% when only considering 1 prescription per patient per day. 
Amongst the individual drugs, phenytoin retained the largest number of exposed 
patients as the exposure threshold increased (86.6%/84.3% at 10 prescriptions, 
depending on method), whereas levetiracetam experienced the largest decrease 
in exposed patients (79.5%/75.6%). For all drugs the number of patients 
classified as exposed was lowered by switching from including all prescriptions 
to just one per patient per day. Using the 10-prescription threshold, the 
difference between the proportion of patients defined as exposed by the two 
methods ranged from 1.9% to 3.8%.  
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Figure 22 - Proportion of patients with 1 prescription for AEDs as a class and each of the 
top 5 AEDs who meet the threshold for exposure when including all prescriptions (A) or 1 
prescription per date (B), with the total number of patients who had at least 1 prescription 
for each shown in the table 
 
  174 
 
Figure 23 shows a summary of the changes in the proportion of patients exposed 
to different classes of drugs as the threshold number of prescriptions is 
increased, as well as the total number of patients with at least 1 prescription for 
each drug class. AEDs have the highest retention rate of patients with increasing 
threshold. There is larger variation across the different drug classes than across 
individual drugs within the same class as described above. A smaller reduction in 
the exposed patient group is seen for drugs used to treat chronic conditions or 
for long-term prevention (AEDs, lipid-regulating, anti-depressants). The largest 
reduction in the size of the exposed group was seen for antibacterials - using an 
exposure threshold of 10 prescriptions, only 24.2% of the patients who had at 
least 1 prescription would still be considered exposed. As with the individual 
drugs there is a difference between the two methods of counting prescriptions, 
but the largest difference between two points for any of the drug classes was 
2.0% for AEDs. 
  175 
 
 
Figure 23 - Proportion of patients with 1 prescription for different classes of who meet the 
threshold for exposure when including all prescriptions (A) or 1 prescription per date (B), 
with the total number of patients who had at least 1 prescription for each shown in the table 
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5.3.2 Use at time 
Figure 24 summarises changes in the proportion of patients ever exposed to AEDs 
as a class and the most commonly prescribed AEDs, who were classified as new 
users based on varying periods of lookback from their index date. There was 
variation across the drugs of interest. When using a 30-day lookback period, 89% 
of phenytoin users and over 90% of the patients exposed to the other drugs 
during follow-up were considered new users. Using a 365-day lookback period 
there is more variation in the proportion of new users – 66% of levetiracetam 
users were still classified as new users, only 19% of phenytoin users were new 
users and 31% of patients were new users when considering AEDs as a class as 
opposed to individual drugs.  
 
Figure 24 - Proportion of patients who have at least 1 prescription for drug(s) of interest 
who are classified as new users at cohort entry based on varying lengths of lookback 
period, with the total number of patients who had at least 1 prescription during follow-up 
shown in the table 
 
The proportion of patients exposed at time of death based on lookback from 
death was similar across the investigated drugs (Figure 25). Using time periods of 
less than 30 days resulted in most patients (70%-80%) being classified as past 
users but using a timeframe duration of 30 days increased the number of 
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patients classified as current users to between 50 and 60% depending on the 
drug of interest. Less than 10% of people who died and were ever prescribed 
each of the drugs were classified as past users when using a 365-day exposure 
timeframe. 
 
Figure 25 – Proportion of patients classified as current users at time of death based on 
different timeframes used to define current use, with the total number of patients who died 
and had at least 1 prescription for each separate drug shown in the table 
 
The proportion of patients exposed based on a definition of two prescriptions 
within a desired timeframe was consistent across the different drugs of interest 
except at low allowable gap values, as shown in Figure 26. Over 60% of patients 
with two or more AED prescriptions were considered exposed when requiring two 
prescriptions within 7 days of one another. Most patients with two or more 
prescriptions (>=90% for all drugs) for each drug were considered exposed when 
allowing for a gap of 30 days or more between prescriptions. 
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Figure 26 - Proportion of patients considered exposed to the drug of interest based on a 
definition of 2 prescriptions within a specified number of days, with the total number of 
patients who had at least 2 prescriptions for each drug on different dates shown in the table 
 
5.3.3 Persistence 
A summary of the proportions of patients who reached 180- and 365-day 
persistence with different AEDs using different allowable gaps between 
successive prescriptions can be found in Figure 27 below. Almost no patients 
were persistent with any of the drugs of interest at either 180 or 365 day after 
initiation of therapy when using a 30-day allowable gap between prescriptions. 
The proportion of patients persistent was relatively consistent across drugs, 
although there was more variation in the proportion of patients persistent at 365 
days after initiation with increasing gap length. Levetiracetam had the lowest 
proportion of patients persistent at 180 and 365 days after initiation. 
  179 
 
 
Figure 27 - Proportion of patients with at least 1 prescription for AEDs as a class or each of 
the top 5 AEDs who are persistent at 180 days (A) and 365 days (B) using different allowable 
gaps between prescriptions, with the total number of patients with at least 1 prescription for 
each drug shown in the table 
 
In addition to differences across drugs in the proportion of patients persistent at 
specific time points when using different refill gaps, there were also differences 
in the median time to first discontinuation. The time to discontinuation was 
similar across all drugs when using 30-, 45- and 60-day refill gaps. As the 
allowable gap length increased there was greater variation between the drugs of 
interest, although AEDs as a class, carbamazepine and phenytoin all had similar 
results. Levetiracetam had the shortest median time to discontinuation amongst 
the drugs of interest when using longer allowable gaps. 
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Figure 28 - Summary of the changes in median time to discontinuation with changes in the 
allowable gap between prescriptions for AEDs as a class and the top 5 AEDs 
 
5.3.4 Effect of exposure definition on observed associations 
Of the 5,771 patients in the epilepsy cohort, 2,011 (34.8%) had at least 1 
prescription for levetiracetam. Users and non-users had similar gender splits, 
with more men than women. Levetiracetam users tended to be younger, with a 
median age of 46 years compared to 52 years among the non-users. Over 50% of 
the patients in both groups were from the most deprived areas (SIMD quintile 1). 
A larger proportion of patients in the levetiracetam user group had one or more 
comorbid conditions than in the non-user group, and a smaller proportion of the 
levetiracetam users died during follow-up. Median length of follow-up was 
slightly higher for non-users (4.83 years vs. 4.75 years for users), but over 90% of 
the users in both groups had a follow-up duration of more than 1 year.  
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  0 levetiracetam 
prescriptions 
N = 3,560 
1+ levetiracetam  
prescriptions 
N = 2,011 
Gender Female 1,608 (45.2) 931 (46.3) 
 Male 1.952 (54.8) 1,080 (53.7) 
Age 0 – 9 162 (4.6) 165 (8.2) 
 10 – 19 166 (4.7) 182 (9.1) 
 20 – 29 244 (6.9) 256 (12.7) 
 30 – 39 395 (11.1) 232 (11.5) 
 40 – 49 620 (17.4) 301 (15.0) 
 50 – 59 645 (18.1) 344 (17.1) 
 60 – 69 583 (16.4) 254 (12.6) 
 70 – 79 480 (13.5) 172 (8.6) 
 80+ 265 (7.4) 105 (5.2) 
 Median (IQR) 52 (29) 46 (35) 
SIMD Quintile 1 1,862 (52.3) 1,017 (50.6) 
 2 624 (17.5) 332 (16.5) 
 3 408 (11.5) 208 (10.3) 
 4 289 (8.1) 192 (9.5) 
 5 299 (8.4) 205 (10.2) 
 Unknown 78 (2.2) 57 (2.8) 
Charlson comorbidity 
score  
0 2,971 (83.5) 1,604 (79.8) 
(weighted) 1 307 (8.6) 201 (10.0) 
 2 155 (4.4) 76 (3.8) 
 3+ 140 (3.9) 112 (5.6) 
Died N (%) 739 (20.8) 287 (14.3) 
Length of follow-up Median 4.83  4.75 
(years) IQR 1.43 2.16 
 Total 14,360.0 7,629.3 
 Range 0.03 – 4.99 0.05 – 4.99 
 Patients with > 
180d 
3,470 (97.5) 1,969 (97.9) 
 Patients with 
>365d 
3,351 (94.1) 1,877 (93.3) 
Table 28 - Summary of demographic characteristics of cohort patients, split according to 
whether they ever received at least 1 prescription for levetiracetam 
 
Figure 29, below, shows the hazard ratios and 95% CIs associated with exposure 
to levetiracetam based on the time-fixed definitions of exposure. There was 
little variation in the observed hazard ratio based on method. Across all models, 
the hazard ratios ranged from 1.13-1.14. None of the models showed a 
statistically significant association between levetiracetam and all-cause 
mortality (p>0.05). The hazard ratios for age, sex and comorbidity score were 
consistent across all models. 
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Figure 29 - Association of levetiracetam exposure on all-cause mortality using time-fixed 
exposure definitions 
 
As shown in Figure 30, there was larger variation in the observed associations 
when using time-varying definitions of exposure, with hazard ratios between 
0.53 and 1.14. In the models where exposure was defined in successive 30-day 
windows (HR 0.53, 95%CI 0.44 – 0.66) and 90-day windows (HR 0.76, 95%CI 0.65 – 
0.89) across follow-up there was a statistically significant reduction in all-cause 
mortality associated with exposure to levetiracetam (p<0.001). In the remaining 
models, the association between exposure and outcome was not statistically 
significant (p>0.01). As with the models using time-fixed exposure definitions, 
the observed associations between the other covariates (age, sex and 
comorbidity score) were consistent across all models. 
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The results described above demonstrate how altering the definition of drug 
exposure can impact the number of patients classified as exposed to a drug and 
the duration of treatment episodes and how these can, in turn, affect the 
association between exposure and outcome. 
5.4.1 Effect of exposure definition on the estimated number of 
exposed patients 
5.4.1.1 Ever use 
Ever use is the most simplistic definition of exposure, but it is still often used in 
pharmacoepidemiological research to define cohorts, patient sub-groups and as 
a proxy for comorbidities or outcomes. In the comparisons of the proportions of 
patients who met different thresholds, there was variation across different drugs 
within the same class, and even greater variation across the different classes. 
The drugs which were used to treat chronic or ongoing conditions such as AEDs, 
anti-depressants and lipid-regulating drugs retained a higher proportion of 
patients with increasing thresholds than antibacterials, which are typically used 
short-term. Analgesics are used for a wider variety of indications and over a 
wider range of timeframes, which is likely the reason they retain a larger 
proportion of patients with increasing exposure threshold compared to 
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antibacterials, but a smaller proportion compared to drugs which are only used 
for chronic conditions. Researchers need to account for these differences when 
setting exposure thresholds. For example, the same threshold may not be 
relevant for all drugs if defining a number of comorbidities based on pharmacy 
data. A threshold value of 1 prescription was the most common inclusion 
criterion for cohorts or sub-groups across the studies included in the systematic 
review in Chapter 2, but thresholds from 1-4 prescriptions were reported. In the 
examples tested here, a threshold of 4 prescriptions would classify 96% of the 
total users of AEDs as exposed, but only 84% of anti-depressant users, 73% of 
analgesic users and 58% of antibacterial users. These may be clinically relevant 
proportions, in cases such as for antibacterial or analgesic drugs they could be a 
way to select only patients with chronic exposure to these drugs, or certain 
conditions of interest. 
There were also differences observed between the proportions of patients 
exposed when counting one prescription per day versus all prescriptions for 
certain drug classes or individual drugs. This should be taken into consideration 
when cleaning data, as not accounting for this variation will cause systematic 
differences in the measurement of exposure across the population for different 
drugs or classes, particularly where the drugs of interest can be prescribed in 
multiple dosages or formulations at once, as can be the case with AEDs.  
5.4.1.2 Use at time  
In the results described above there was a larger difference across individual 
drugs when defining new use at baseline than when defining current use at time 
of death. This may be due to changes in the patterns of prescribing of certain 
drugs at population level around the start of follow-up, as both levetiracetam 
and lamotrigine are newer AEDs and had a smaller proportion of existing users 
than older drugs or AEDs as a class when longer lookback periods were used. The 
most commonly used timeframes for defining new use at baseline in the 
reviewed literature were 6 months and 12 months, but there were examples of 
studies using windows of varying lengths between 2 months and 3 years.  
Defining exposure before an event or categorising patients into current or past 
use of a drug of interest at the time of an event (for example, death or 
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hospitalisation) was most commonly done using 6- and 12-month windows, but 
90- and 120-day windows were also used. In both definitions, the largest 
differences in the proportions of patients exposed between different windows 
were seen when using smaller gaps; for AEDs as a class, 64% of patients were 
considered current users at death using a 30-day window compared to 94% with a 
180-day window and 97% with a 365-day window. When defining new use of AEDs 
at baseline, a 30-day window resulted in 91% of patients being classified as new 
users, compared to 33% with a 180-day lookback and 31% with a 365-day 
lookback. 
5.4.1.3 Persistence 
The variations in the proportion of patients persistent with the drugs 
investigated at 180- and 365-days were largely similar across the drugs of 
interest, although there were outliers at each of the gap values. The median 
time to discontinuation was similar across the different drugs with shorter 
allowable gap lengths. This likely indicates that these gaps are not long enough 
to account for the coverage of individual prescriptions for these drugs. 
Additionally, this may not account for database specific issues with some of the 
dates recorded within the prescribing data. In cases where the date a 
prescription was prescribed or dispensed are not available, the date that the 
pharmacist was reimbursed is imputed, and this is typically the last date of the 
month. At higher gap values, there was variation across the individual drugs. The 
median time to discontinuation for newer drugs such as levetiracetam and 
lamotrigine was lower than the older drugs. As described in Chapter 4, 
prescribing of these drugs increased over the study period, so it is possible that 
some discontinuations are due to censoring rather than exceeding the allowable 
gap. A range of allowable gaps from 14 to 365 days was common across the 
reviewed literature. In the results described here, shorter refill gaps do not 
appear to be sufficient to account for the legitimate gaps between prescriptions. 
In these analyses, no measure of the coverage for each prescription is used, so 
longer allowable gaps need to be used to account for the supply from each 
prescription. Both median time to discontinuation and the proportion of patients 
persistent at 365 days after initiation increased markedly for all drugs when 
using an allowable gap of 90 days or longer, as these gaps allow for more 
prescriptions to be included in the individual periods of persistent use. As 
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described previously, allowing for too large a gap between successive 
prescriptions introduces the potential for error by misclassifying time where 
patients legitimately had no supply of the drug of interest. 
5.4.2 Effect of exposure definition on observed exposure-
outcome associations 
The results described above highlight the potential for variation in the drug 
exposure variables generated based on routinely collected data, but it is also 
important to understand the impact this variation can have on the results of a 
clinical research study. Although most of the Cox proportional hazards models 
above did not show a statistically significant association between levetiracetam 
exposure and all-cause mortality, comparing observed hazard ratios shows the 
variation that can occur in observed association when only the definition of drug 
exposure is adjusted.  
As described above, the hazard ratios observed across the different time-fixed 
definitions of exposure were minimal, despite the size of the exposed population 
being different under each definition. The differences in the observed hazard 
ratios were larger in the models using time-varying methods of exposure, likely 
due to the fact that there is more potential for variation from patient to patient 
as exposure status changes over time. This is particularly true of the methods 
which split the follow-up into smaller windows. The statistically significant 
models were the ones with follow-up split into the smallest windows (60 and 90 
days respectively) – as with the time-fixed measures above, these were the most 
specific definitions of exposure used. When splitting follow-up into windows or 
defining persistent time, use of longer windows increased the hazard ratio 
observed.  
These results show the importance of carefully setting exposure definitions in 
pharmacoepidemiological research, as incorrectly or imprecisely defining 
exposure can potentially have a large impact on the results of a study. It is also 
important for researchers to carefully identify which method has been used to 
define exposure when reporting to maximise transparency and reproducibility. 
The models showed a wide range of both positive and negative associations 
between levetiracetam exposure and all-cause mortality driven exclusively by 
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the changes in the definition of drug exposure. These results would have 
different clinical implications if reported as the results from a real clinical 
study. Utilising a time-varying definition of exposure which takes account of the 
duration of exposure periods will help to minimise the impact of immortal time 
bias on the results. Sensitivity analysis could be implemented to assess different 
potential exposure definitions, and even different thresholds within the 
definitions of interest to identify potential biases in the methods being 
considered.  
5.4.3 Limitations 
Although these results highlight that there is a difference in the observed 
associations depending on exposure definition used, they do not confirm that 
one method is better than another per se. Researchers should aim to define 
exposure as precisely as possible based on the data available – it is more realistic 
to allow for variation in exposure status over time as this reflects reality. 
However, care needs to be taken to ensure that too many assumptions are not 
made where the data do not exist to support them. If the data only support a 
simple definition of exposure, this may still provide more valid results than an 
ill-defined complex exposure definition, as the assumptions required could result 
in larger potential for error. It can be useful to use a combination of different 
methods for different purposes within a study. For example, the study 
population could be defined as including patients who had at least 1 prescription 
for a drug of interest to include as many patients as possible, then another 
method could be used to differentiate between those who had long-term 
exposure to the drug and those who did not. As discussed in Chapter 2, it is 
important to specifically report how exposure was defined based on the data 
available when publishing research findings. This will help increase 
transparency, giving other researchers a better understanding of the limitations 
of the available data, how valid the results are and will make it easier to 
replicate results using other data sources.  
As mentioned previously, even if the exposure variable defined is able to 
perfectly represent the available data, other issues such as missing data can still 
introduce bias, and routinely collected prescribing data only represent 
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medications which were prescribed or dispensed so there is still no certainty 
that patients took the medications at all or as instructed.  
A limitation of the results is the lack of inclusion of additional methods for 
constructing treatment episodes based on individual prescriptions. The use of 
the number of days supplied on individual prescriptions was one of the most 
commonly used methods for defining exposure amongst the studies included in 
the systematic review. Assessing differences in durations of treatment episodes 
across different daily dose/duration methods and comparing current persistence 
measures to persistence with coverage would be of interest, as it is a more 
detailed method which has the potential to more accurately capture changes in 
exposure status over time whilst also providing more potential for bias if 
incorrectly applied. These methods were not included in the comparisons in this 
chapter due to the lack of individual level data on prescribed doses within the 
dataset used. While it is still possible to use the DDD or assumptions based on 
the number of tablets or units of medication per day, the decision was made to 
exclude these from this study as they are prone to misrepresent exposure time 
for drugs, such as AEDs, where there can be variation from patient to patient 
and over time in the prescribed dose, and therefore the results from these 
methods would be of limited value without the comparison to individualised 
episodes.  
5.4.4 Further work 
There are a number of opportunities for further work on this topic. As stated 
above, the lack of patient-specific dosage instructions in the data currently 
available limited the ability to look at the construction of detailed treatment 
episodes, but these would likely contribute to more precise estimates of the 
association between exposure and outcome as, if applied correctly, these 
methods have the capacity to more accurately capture the reality of how long 
the patient was exposed to the drug and how their exposure status changed over 
the period of interest. In addition to considering periods of exposure, adherence 
to treatment within these periods is also of interest as an additional covariate 
for modelling the risk associated with outcomes related to AED use. Poor 
adherence to AEDs has been shown to be associated with poor outcomes and 
increased hospitalisations, with one study demonstrating a threefold increased 
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risk of mortality associated with nonadherence.(270) The outcome investigated 
in this chapter was used simply to illustrate the potential for variation in 
observed associations, but doing a similar study using an established exposure 
outcome relationship would be an even more effective way of highlighting the 
need for accurate representation of drug exposure in pharmacoepidemiological 
research. 
5.4.5 Summary 
Defining patients’ exposure to medications of interest is a key step in 
pharmacoepidemiological research. The results described above show how 
changing the definition of exposure (either using a different method or adjusting 
the threshold for exposure) can affect the measured size of the exposed 
population and the duration of treatment episodes for exposed patients, and in 
turn how that can affect the observed association between the exposure of 
interest and an outcome. This highlights the importance of carefully planning 
data cleaning, utilising sensitivity testing and ensuring that the most precise 
definition of drug exposure possible is used based on clinically relevant 
definitions and an understanding of the limitations of the data available in order 
to minimise exposure misclassification and maximise validity of study results. 
Additionally, all of these processes must be accurately reported when publishing 
research in order to maximise transparency and reproducibility of research. 
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6 Summary and conclusions 
6.1 Summary 
The aim of this thesis was to develop and validate a set of flexible, reusable 
functions for generating common drug exposure variables based on routinely 
collected prescribing data and to demonstrate their utility in clinical research. A 
range of common methods for quantifying drug exposure were identified and 
classified based on a systematic review of literature in the field. The 
information gathered on these methods was used to provide structure to 
construct an R package, prescribeR, containing functions developed to generate 
exposure variables from individual prescriptions. This package was then tested 
by using it to generate the required exposure variables in two example clinical 
studies using data for a cohort of patients with epilepsy. In the first, the 
package was used to generate a range of variables in order to investigate the 
impact of varying drug exposure definition on the observed association between 
levetiracetam and all-cause mortality in a cohort of patients with epilepsy. In 
the second, the prescribeR package was used to measure the rates of 1-year 
persistence to different AEDs in the same cohort of patients. 
The main strength of this thesis overall is that it provides an in-depth 
examination of the role of exposure quantification in pharmacoepidemiological 
research using routinely collected data. The studies identified and reviewed in 
the Chapter 2 highlighted the variety of research being published based on 
routinely collected data, and also allowed for an examination of the potential 
strengths and limitations of the different methods being used to quantify 
exposure across these different studies. When selecting a method of quantifying 
drug exposure, it is important to consider the potential for both exposure 
misclassification and time-related bias.  
Minimising exposure misclassification requires an understanding of which 
methods are suitable for the research question being posed, as well as the 
structure and content of the database being used and the way the data are 
collected and potential for missing or incomplete data. It is important to 
balance defining exposure as precisely as possible in clinical research with 
minimising the potential for error from making assumptions without the data to 
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support them. For example, if the datasets being used do not contain 
information regarding patient specific dosage instructions, assuming the duration 
of prescriptions for certain drugs based on other measures may impact the 
accuracy of the exposure measurement. On the other hand, too broad a 
definition of exposure will introduce error by conflating different levels of 
exposure. It is also important to consider the study design in order to ensure 
that the time period for defining exposure is correctly set out in order to 
minimise the risk of immortal time bias. 
The classes of exposure quantification methods defined in the systematic review 
provided a clear outline for the development of the prescribeR package, which 
contains functions for ever use, use at time point, daily dose and persistence 
methods alongside functions for standardising data and generating data 
summaries. The benefit of using a package such as prescribeR in clinical research 
is that it provides a standardised set of tools for easily quantifying drug 
exposure, as well as a framework for clear reporting on how the data were 
processed. This, in turn, makes it easier for the results to be reproduced and 
validated with other data. 
As shown in Chapter 5, altering the method of defining exposure without 
changing any of the other study parameters can have a large impact on the 
observed associations between drug exposure and an outcome, so ensuring the 
variables generated represent the data available as accurately as possible is 
essential to ensuring that the results of the study are valid. In addition to 
minimising the risk of exposure misclassification within individual studies, it is 
important to be able to reproduce and validate the results obtained using data 
from other sources in order to ensure that database-specific limitations aren’t 
impacting the results. For this reason, it is important that published studies 
make sure to clearly describe the processes used to prepare the data, not just 
the statistical analyses. 
A paper summarising the conclusions from two studies published by a joint 
International Society of Pharmacoepidemiology and International Society for 
Pharmacoeconomics and Outcomes Research (ISPE/ISPOR) task force on real-
world evidence in healthcare decision making concluded that increased 
transparency in the planning and reporting of studies using routinely collected 
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data was an essential component in ensuring that the results of these types of 
studies had the appropriate impact on healthcare decision making. The STROBE, 
RECORD and RECORD-PE statements provide checklists for authors detailing 
items which should be included in studies reporting on observational studies, 
with RECORD focusing specifically on the reporting of studies using routinely 
collected data.(221, 271) The RECORD checklist recommends that codes and 
algorithms used to specify different variables in the study should be provided 
where possible. As discussed in Chapter 3, one of the primary benefits of using a 
package such as prescribeR during the data preparation process is that it 
standardises parts of the process, providing a structure to report the way the 
data have been used, as demonstrated in the methods section of Chapter 6. This 
then allows other researchers to understand at a glance what processes were 
applied to generate the results and then to apply the same methods to generate 
the variables of interest from different datasets. 
6.2 Limitations 
Limitations of the individual components of this thesis are discussed in the 
relevant chapters, but there are also limitations which apply to the thesis as a 
whole. The primary focus of this thesis was the methods used to quantify drug 
exposure in studies using routinely collected healthcare data. Although this is an 
essential component of preparing routinely collected data for use in research, 
there are a number of other processes involved in cleaning and enriching data. A 
number of these issues were identified throughout the thesis, and attempts were 
made to address them when preparing the data used in the analyses described in 
Chapters 4 and 5, but the potential effect that altering the decisions made or 
the impact that errors in the final datasets can have on study results was not 
assessed in this thesis. One study which investigated the impact of decisions 
made to clean missing or implausible values in the quantity dispensed, dosage 
instructions and stop dates for individual prescriptions showed that there was 
variation in the observed association between glucocorticoids or oral 
hypoglycaemic drugs and cardiovascular events based on the definitions 
used.(272) 
Similarly, a number of limitations related to the way that routinely collected 
data are handled were identified in this thesis, but again the impact of these 
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issues on study results was not assessed in depth here. Although PIS contains 
most of the prescriptions prescribed and dispensed in Scotland, it does not 
account for medications administered or dispensed within hospitals, which may 
impact studies where the drug of interest is often prescribed during 
hospitalisations or on discharge. As described previously in Chapter 1, PIS does 
not contain data regarding diagnoses or indication for prescribing. Diagnoses can 
be inferred from other data such as hospitalisations or primary care data, but 
the completeness and accuracy of these data should also be considered. Where 
these data sources are not available, surrogate markers can be used, as was the 
case in the definition of epilepsy in this thesis. Without additional data, it is not 
possible to quantify the impact of these assumptions on case definition and 
study results. Finally, the prescribeR package was developed and tested using 
prescribing data from a single source (PIS), and the development of the 
processes used within the functions were based on experience using this data. 
Therefore, there may be steps required in handling data from other sources 
which are not currently included in the prescribeR functions. However, one of 
the benefits of hosting the package on GitHub is that it is possible for users to 
report issues or suggest improvements to the package, providing the opportunity 
to resolve any issues or limitations that are raised and therefore improve the 
package’s utility.  
6.3 Future work 
There are a number of opportunities for further work based on the research 
described in this thesis. At present, the prescribeR package is primarily focused 
on the generation of individual-level drug exposure variables based on the 
common methods identified in the systematic review in Chapter 2, but it is not 
necessarily comprehensive. The structure of packages in R means it is easy to 
iterate on the current version to include expansions to existing functions or to 
add new functions as required. Potential additions to the package could include 
additional functions for examining population-level prescribing trends or 
functions for constructing variables based on more complex prescribing 
behaviours such as co-prescribing, polypharmacy and medication switching. 
Beyond exposure quantification, functions could be added for other common 
data preparation or data enrichment tasks, such as adding variables from other 
datasets or standardising field syntax. 
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There are also a number of opportunities for further work assessing the impact 
of varying drug exposure definition on the results obtained in clinical studies. As 
stated in Chapter 5, the lack of patient-specific dosage instructions in the data 
currently available limited the ability to compare different methods of 
generating individual treatment episodes. Treatment episodes based on patient-
specific dosage information would likely provide more precise estimates of the 
association between exposure and outcome, as these methods have the capacity 
to more accurately capture the reality of how long the patient was exposed to 
the drug and how this changed over the period of interest. Additionally, the 
outcome investigated in this thesis was used simply to illustrate the potential for 
variation in observed associations, but a similar study using an established, 
clinically relevant exposure outcome relationship would be an even more 
effective way of highlighting the need for accurate representation of drug 
exposure in pharmacoepidemiological research. 
6.4 Final conclusions  
Routinely collected data have the potential to be a vital resource for 
pharmacoepidemiology research and, in turn, for generating evidence for clinical 
decision making. However, the data are not without limitations, so it is 
important that researchers address these during data preparation and analysis. 
Quantifying drug exposure is an essential step in research using routinely 
collected data, as bias introduced in this step has an impact on the results 
obtained and therefore impacts the validity of the evidence generated. The 
prescribeR package provides researchers with a set of straightforward, reusable 
functions for generating drug exposure variables using a number of common 
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